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Background: Continued Dispensing (CD) is a new mechanism of medication supply in urgent 
situations for eligible patients. Currently, Statin and Oral Contraceptive (OC) users are the 
only eligible patients. In all Australian states and territories (except Queensland), pharmacists 
are allowed to supply, without a valid prescription, one additional supply of a Statin or an OC 
to patients who were prescribed these medications for a period of six months or more. 
Pharmacists must ensure that this supply is safe and appropriate. This method was initiated to 
minimise treatment interruption that may result from patients’ inability to obtain a renewed 
prescription. Patients can utilise the CD once in any 12 months period. While there were mixed 
announced views about the CD by consumer and health organisations, attitudes of the eligible 
users, pharmacists and general practitioners (GPs) had not been explored.   
Aims and Methods: This research project sought to explore stakeholders’ attitudes towards 
the CD. Three surveys and a case vignette were employed to collect data before and after CD 
implementation. (a) A nation-wide survey using Computer Assisted Telephone Interviews 
(CATI) was used to obtain views of patients (i.e. Statin and OC users), with emphasis on their 
acceptance, and their concerns about the CD. Patient support to include other medications 
into CD eligible drugs (i.e. CD expansion) and more flexible CD (i.e. CD extension) was also 
explored. The study also identified how often patients run out of medications and what actions 
they usually take to obtain their medications. (b) A self-administered questionnaire was posted 
to a random sample of 1490 community pharmacists in Australia, nation-wide. Data regarding 
their agreement with CD, its advantages, CD expansion, and CD extension were collected. In 
addition, the questionnaire asked them to estimate how often and why they usually face 
medication requests without a valid prescription from their customers (i.e. regular and non-
regular customers), and what is their usual practice (i.e. when do they supply and what method 
do they use, and why they refuse to supply). The participant pharmacists also provided 
recommendations on how to modify the current urgent medication supply arrangements to 
improve patients’ access to their medications in a timely and cost-effective manner. (c) A case 
vignette method was used to investigate how appropriately pharmacists would conduct the 
CD. Six written scenarios were used with 30 pharmacists who attended an annual conference 
in Perth, Western Australia. This method also allowed for collection of additional and updated 
data about pharmacists’ views of CD post its implementation. (d) The postal survey method 
was also used to gather GPs’ views on CD post implementation. Seventy-five open-
ended questionnaires were posted to a random sample of GPs working in Western Australia. 




improved, CD expansion and CD extension. 
Results: Firstly, 151 Statin and 150 OC users were recruited in the patient survey. The majority 
of them strongly supported the CD. They did not have concerns about CD nor did they perceive 
CD as a risky method. They also supported CD expansion and CD extension. Statin and OC 
users trusted their pharmacists to supply when it is safe and refer them to their doctor when it 
was deemed necessary. Atorvastatin (e.g. Lipitor®) among the Statins and Ethinylestradiol 30 
μg + levonorgestrel 150 μg (e.g., Levlen®) among the OCs were the most commonly used 
drugs. More than one-third of participants had run out of their medication as least on one 
occasion. Among those who ran out, there were 35.4% and 33.6% who stopped treatment or 
asked a pharmacist for an urgent supply, respectively. Statin users were less likely to run out 
of medications than OC users (P=0.021). The majority (86%) of the participants had a regular 
pharmacy, although more so for Statin users (97.4% versus 74.9%, respectively; P<0.0001). 
Secondly, a total of 385 community pharmacists participated in the postal survey, yielding a 
response rate of 27.9%. The participants’ supported CD for the currently eligible medications. 
They were more supportive in case of their regular customers than for non-regular customer 
(p< 0.0001). However, they were also in favour of more medications being eligible for supply 
under CD. Medication type and prescription type affected their support for CD expansion. 
They were more supportive in the case of drugs without abuse potential and in the case of 
prescriptions with less administrative burden. They were less supportive of CD extension than 
the patients. Just over the half of the participants agreed with current CD utilisation frequency 
(i.e. once in any 12 months). Those who supported more frequent CD cited prescription life 
span or difficulty to obtain urgent appointments. In this regard, the participants reported being 
faced continually with requests for medication supply from their regular and non-regular 
customers when they ran out of medications and were unable to obtain a renewed prescription. 
Inability to obtain an urgent appointment, interstate traveling without medication, and 
expired prescriptions were amongst the most common reasons reported for medication 
requests without a valid prescription. The participants usually were more agreeable to supply 
the requested medication for their regular customers than non-regular customers. Medication 
with abuse potential, authority prescriptions, and a second request for the medication were 
generally associated with ‘No supply’ practice, particularly if the customer was not a regular 
pharmacy client. Participants also suggested some modifications to the currently available 
urgent medication supply arrangements. They suggested increasing the amount of the 
emergency supply and legalisation to allow fax and email prescriptions. Use of technology to 




highly promoted by the participants as potential solutions to the issue of patient requesting 
medication without a valid prescription.  
Thirdly, pharmacists participated in the case vignettes study. The majority of pharmacists’ 
decisions to use CD with the provided scenarios were appropriate decisions. The pharmacists 
also reported their reasons for not using CD. Here, the need for a medical review, clinical 
instability on the medication and absence of the patient’s history were the most commonly 
reported reasons for not using the CD method. The participants reported low use of CD, and 
cited the presence of other alternatives to supply in urgent cases and CD paperwork as reasons 
to avoid the CD.   
Finally, responses to the GP survey were low with only six GPs working in Perth, Western 
Australia providing their views and suggestions. The GP participants supported the current 
CD. However, they suggested CD should be used for more urgent medications than Statins 
such antihypertensives and antidepressants. They disagreed with CD extension as this may 
be used to avoid doctor visits. They suggested post-CD patients should visit their GP within a 
week to ensure they have the necessary medical review.   
Conclusions: Whilst the stakeholders (patients, pharmacist and doctors) who participated in 
this research project supported the current CD as the first step towards improving patient 
access to medications in urgent situations, they supported CD expansion to include other and 
more urgently needed drugs. Patients were also supportive to a more flexible CD frequency, 
whilst pharmacists and GPs supported the current status quo. Participants identified areas in 
the current CD that need improvement. If their suggested solutions were taken into 
consideration by health policy makers, they would enhance CD uptake and its ability to 
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As far as we know this is the first research study about stakeholders’ (patients, pharmacists 
and GPs) attitudes towards Continued Dispensing (CD). CD is a recently implemented method 
to supply medication in urgent situations (commenced September 1, 2013). The eligible 
patients are Statin and Oral Contraceptive (OC) users who request these medications without 
a valid prescription because of inability to obtain an appointment with a prescriber to renew 
their prescription.[1] In this case, CD allows pharmacists to re-dispense one additional supply 
without a valid prescription. In other words, regular users (i.e. those who have used the 
medication for six months or more) can obtain one additional monthly supply (i.e. same 
amount as the last supplied quantity) without the need to see a doctor. Currently, CD has been 
legalised in all Australian states except Queensland.[2]   
The Australian Medical Association (AMA) has condemned CD because it is a medication 
supply without a medical assessment by a General Practitioner (GP), and it involves only one 
healthcare professional (i.e. the pharmacist).[3] According to the AMA, this may compromise 
patient safety, and it involves a conflict of interest for pharmacists. On the other hand, the 
Pharmacy Guild of Australia (PGA) has supported CD because it is a convenient way to obtain 
medications in urgent circumstances.[4] In this regard, patient organisations have strongly 
supported CD and highlighted CD’s convenience.[5, 6]  
Currently, CD is limited to only two medication classes (i.e. Statins and OCs) and it is only 
allowable once in any 12 months period for each drug. Consequently, the patient health 
organization Services for Australian Rural and Remote Allied Health (SARRAH) has 
criticized these constraints on CD.[5] Moreover, the AMA has stated that Statins are not 
urgently needed medications and that the patients can safely wait for an appointment if it is 
not instantly available.[3]  
1.2 Research Questions  
It is unclear how patients (Statin and OC users), pharmacists and GPs will see CD, to what 
extent they may agree or disagree with CD, and how CD limitations will affect stakeholders’ 
views. Moreover, what can be done to improve CD, particularly what other medications can 
be included within CD eligible drugs, and how the presence of other arrangements for urgent 
medication supply may affect pharmacists’ utilisation of this new supply method? Finally, to 




1.3 Focus of dissertation  
This project collected data before and after CD implementation. This project explored 
stakeholders’ attitudes towards the current CD method and a modified version (i.e. one that 
would contain more medications and can be used more frequently). 
1.4 Aims  
This project had four main aims: 
1) To explore patients’, pharmacists’ and doctors’ attitudes towards the current CD to 
identify the pros and cons of CD. 
2) To identify the disadvantages of current urgent supply mechanisms from the 
stakeholders’ points of view, and how these can addressed through CD or other suggested 
systems.  
3) To evaluate the possibility of expanding CD to other therapeutic classes of medication 
based on the opinions of patients, pharmacists and doctors (i.e. their views about a modified 
version of the CD). 
4) To assess pharmacists knowledge of the appropriate use of CD using a series of case 
vignettes.  
1.5 Methods  
To achieve the project aims four methods were used: 
1) Computer Assisted Telephone Interviews (CATI) were used to obtain patients 
views (nationwide). 
2) Postal Survey of pharmacists was utilised to obtain their views on CD 
(nationwide). 
3) Case vignette study involving pharmacists from Western Australia to assess 
how appropriately they conduct CD, and also to obtain updated views on CD 
through a self-administered questionnaire.  




their views on the current CD and how it might be modified.  
1.6 Basis of methods selection 
To examine the first three aims a range of questionnaires were used, whilst case vignettes were 
used to examine the fourth aim. The idea was to use similar (thus comparable) questions with 
all stakeholder groups. The project approach was to collect qualitative and quantitative data. 
The method of questionnaire administration was either by trained staff from a telemarketing 
company, CDM Direct Communication Services in the case of Statin and/or OC users (i.e. 
Computer Assisted Telephone Interview, [CATI] survey) , or self-administered for pharmacists 
and GPs using a postal survey. Participants’ identities were not collected to ensure the 
anonymity of the respondents, in the hope that their responses would be more reflective of 
their actual attitudes.[7, 8] In the case of the questionnaires administered to patients and 
pharmacists, in addition to questions about demographic information, each questionnaire 
contained two essential parts; questions about participants’ attitudes towards the current CD 
and additional questions about potential modifications to the CD model. The pharmacists’ 
questionnaire also contained another part about their usual practice when dealing with 
medication requests without a valid prescription. A literature review and experience from a 
previous study,[9] assisted in developing the questionnaires. The questionnaires were assessed 
for face and content validity by staff members within the pharmacy practice group at Curtin 
University. The questionnaires used with patients and pharmacists contained mainly 
closed-ended questions. In the case of GPs, the questionnaire contained only open-ended 
questions, which covered the similar topics as those in the patient and pharmacist surveys.  
Participants were selected at random from publicly available resources on the internet in the 
case of the pharmacists and GPs surveys, and the phone directory for CATI participants. The 
plan was to obtain a representative sample size for each study: a total of 300 Statin and OC 
users for the CATI, pharmacists from 20% of the community pharmacies in Australia for the 
pharmacists’ survey (stratified sample), and 24 GPs for doctors’ survey.  
In order to achieve the fourth aim of the project, a case vignette method was used. This method 
was considered a reliable method to investigate the appropriateness of community pharmacists 
conducting the CD method compared to published guidelines. The Pharmaceutical Society of 
Australia (PSA) published six case scenarios[10] related to CD which were used as the basis 
to develop the case vignettes for the current study. These scenarios were used to assess 




1.7 Research hypotheses 
The following hypotheses were tested through this research. The information in brackets 
identifies in which part of the research project they were tested:  
H1 (Patient survey): Patients’ concerns regarding CD are affected by their perception of risks. 
H2 (Patient survey): Disease sufferers will be more supportive of the inclusion of their 
medications in an expanded CD than those without the disease.  
H3 (Pharmacist postal survey): Pharmacists’ decision to supply (regardless of the method of 
supply) will differ according to customer type (i.e. regular versus non-regular). 
H4 (Pharmacist postal survey): Pharmacists’ usual practice (before CD) will not be associated 
with their demographic variables (i.e. age, gender, pharmacy location). 
H5 (Pharmacist postal survey): Pharmacists’ support for the use CD will differ according to 
customer type (i.e. regular versus non-regular). 
H6 (Pharmacist postal survey): Pharmacists’ support to include more medications into eligible 
CD list will be associated with their demographic variables (i.e. age, gender, pharmacy 
location).  
H7 (Case vignettes): Pharmacists decisions to use CD will differ according to their 
demographic variables (i.e. age, gender, years of experience). 
H8 (GP survey): GP’s will not support CD based on the arguments raised by the AMA. 
1.8 Research significance 
CD was implemented without a trial. Therefore, results of this research study will help health 
policy makers enhance CD through providing more insight in terms of eligible medications 
and utilisation frequency. This project provides a perspective on what additional medication 
classes could be included in an expanded CD system and what might be an appropriate CD 
utilisation frequency. Further, this project has obtained recommendations from healthcare 
professionals on what measures should be considered in enhancing CD safety and what 




1.9 Thesis outline 
This dissertation is divided into eight chapters, starting with a general introduction and ending 
with overall bibliography. References used for each chapter are presented chronologically at 
the end of the chapter. All references are displayed again in alphabetical order at the end of the 
thesis under bibliography section. Since some results of this project have been already 
published (two papers, and an additional one is under consideration for publication), a decision 
was made to display Chapters 3,4,5 and 6 using a standardised format (i.e. each has an 
introduction, aims, methods, results, discussion, conclusions and references). Overall findings 
are discussed in relation to the overall aims of the project in Chapter 7, whilst general 
conclusions and research recommendations are presented in Chapter 8. Each abbreviated item 
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2.1 General introduction  
Continued Dispensing (CD) is a recently implemented method to supply medication in urgent 
situations, to eligible patients who meet specific criteria. Further, a Pharmaceutical Benefit 
Scheme (PBS) payment is available for CD supplies that meet the criteria. (Box 2.1).[1]. The 
PBS is part of the Australian Government’s broader National Medicines Policy (Medicare 
Australia). It provides affordable access to essential medications for all Australian permanent 
residents, and visitors from selected countries.[2] CD allows pharmacists to claim 
reimbursement using a “consumer’s signed acknowledgement of receipt” instead of a 
prescription.[1]  
 
 Box 2.1 CD Principles for eligibility 
 The requested medication is eligible (Statin or OC) . 
 They have been using (prescribed) these medications for 
six months or more. 
 They did not utilise CD method to obtain the same medication 
during the last 12 months. 
 Their health condition is stable, and continuation of the medication 
is supported by a prior clinical review (i.e. the last prescription was 
provided after consultation). 
 There was a recent (less than 12 months) consultation between the 
consumer and the prescriber.  
 They were unable to obtain a prescription.  
 The pharmacist judges that there is an immediate and ongoing need 
for the supply.  
 The medicine is safe and appropriate.  
Currently, the CD method is restricted to only two classes of medication. Also, it is only usable 
once in any 12 months period. This method allows community pharmacists to supply one 




regular users. Currently, they are the only patients eligible to utilise the CD method when they 
request these medications without a valid prescription and are unable to obtain an appointment 
to get a renewed prescription. No additional training is required for pharmacists to conduct the 
CD method.[3]  
CD provides patients with an additional way to obtain their Prescription Only Medications 
(POMs) when they do not have a valid prescription.[4] In this research project, the phrase 
‘without valid prescription’ means the requested medication has been prescribed by an 
approved practitioner, however; the consumer (or a carer) requests the medication with an 
expired prescription (usually after one year of the issued date), with a prescription without any 
remaining repeats, or the consumer/carer requests the medication from a new pharmacy (no 
dispensing history) without a paper prescription (in which case the consumer/carer may use 
an empty pack of the medication as proof of a previous supply). The CD method does not 
apply to new users of the drug (i.e. those who have been on the medication for less than six 
months).  
CD was considered to be a convenient way to obtain medications in urgent cases because it 
does not require a valid prescription and urgent access to pharmacists is easier than to doctors. 
In general, pharmacies are located in most Australian communities.[5] Furthermore, 
pharmacies opening hours are generally longer than those of doctors’ surgeries.[6] Therefore 
when patients need medication urgently, it is often more convenient for them to visit a 
pharmacy than to obtain an immediate appointment with their regular prescriber.  
Another factor that makes pharmacies more convenient is the tendency of most patients to visit 
a specific prescriber (usually their regular doctor).[7, 8] Even though patients particularly with 
chronic diseases tend to use a regular pharmacy, they may use any pharmacy (or pharmacist). 
In a previous Australian study, the majority (84·8%) of the respondents had a regular 
pharmacy.[9] Pharmacy location was the main reason for the selection of the regular 
pharmacy.[9, 10] Opening hours and accessibility were also reported as important.[11, 12] 
However, some consumers may obtain their medication from the most accessible pharmacy, 
particularly if they are travelling, move to a new place of residence, or their regular pharmacy 
is closed. 
Lessening of doctors’ work overload was another reason behind the establishment of CD.[13] 
There are several factors that led, and continue to lead, to increase doctor workload. General 
life expectancy has increased (Figure 2.1). Patients tend to be live longer,[14] and be diagnosed 




Authority about public GP attendance stated that there was increase in the average number of 
GP visits per annum during the last 25 years from 4.5 per person in 1987-88 to 5.6 per person 
2012-13, with more than 22% of all Australians having had 6-11 visits (Table 2.1).[17] The 
report has also described those who had ≥20 visits as “high GP attenders” with an average 
cost of $3,202 per person. Those attendees represented 3.8% of all Australians.[17] 
 
Figure 2.1 Proportion of the Australian population aged 65 years or older 













Table 2.1 Non-Hospital Medicare expenditure by GP attendance; 2012-13 
Source: National Health Performance Authority.[17] (No special permission was needed to 
reproduce) 
The increased life expectancy and co-morbidities of the population have resulted in patients 
potentially requiring more frequent and longer visits with their doctor.[18] Such visits will 
include some which are solely so patients can obtain new prescriptions for their chronic 
medications. It was estimated that in 2012-13, there were approximately 4 million visits to 
GPs just for renewing of prescriptions for ongoing regular medications, which represents 3.2% 
of the annual visits.[5] This stretches the already busy doctors’ schedules. Garth et al. reported 
that if the patient did not plan in advance to obtain an appointment, it is often difficult or even 
impossible to obtain one urgently.[19] Also, doctors may squeeze other appointments to see 
those requesting prescription renewal.[19] Doctor shortages in general, and in rural and remote 
areas specifically, is another contributing factor,[5] which may increase doctors’ workload.  
CD may provide better use of pharmacists and efficient use of new pharmacy graduates.[20] 
Pharmacists are not only medication experts,[5, 21] they also have other skills, which are either 
unrecognised or unused by patients and/or the health system.[5, 13] Pharmacists are trained in 
pharmacology and other health related subjects. In practice, these skills have often been 





diagnosis and clinical review and prescribing. CD does not undermine the role of doctors.[4] 
In cases of stable chronic disease, where the diagnosis has already made by a doctor, these 
patients may be managed by pharmacists. Hoti et al. in their study found pharmacy clients who 
supported an expanded role for pharmacists (prescribing), supported the form of pharmacist 
prescribing that does not involve diagnosis (i.e. Supplementary Prescribing).[24] Similarly, in 
the case of CD when the original prescriber is not available, pharmacists are capable of 
following up with these patients either by continuing the medication, or referring them to 
another doctor or emergency departments.[5] Through counselling of patients requesting a 
repeat supply, pharmacists may identify cases of unnecessary medication use, medication 
being used incorrectly, and where patients require immediate review by their doctor. For 
example, Morecroft et al. described how a pharmacist who was counselling a patient for an 
urgent supply of antidepressant found that the patient was still using a high dose of the drug 
even though the prescriber had reduced the dose.[6] A respondent in the Morecroft et al. study 
argued that in some instances of urgent visits to after-hours GP services the regular pharmacist 
may be in a better position to deal with such requests than an on duty doctor.[6]  
Moreover, it has been reported that the inability of doctors in emergency departments to access 
a patient’s regular pharmacy dispensing record may place the patient at increased risk of drug-
drug interactions.[25, 26] Not all patients who request a medication (as a repeat supply or a 
self-medication) from a pharmacist are provided with the medication. Where appropriate the 
pharmacist may refer the patient to a GP or another appropriate health service. Pharmacist 
referrals may benefit patients and doctors in different ways. For example, the pharmacist may 
write a referral letter with all medications used by the patient including Over-the-Counter 
(OTC) medications. This additional information may expedite the patient seeing the doctor 
and save time for the doctor in their review.[27] The optimal use of pharmacists’ knowledge 
and skills benefits not only the patients, for whom it was impractical to see their regular doctor, 
but also the health system.[5, 13] 
Another indirect aim of CD is economic savings by the government. This may be achieved 
through the efficient use of pharmacists’ skills, particularly to avoid unnecessary visits to 
doctors, such for “just” prescription renewal.[20] In 2011-12 over $140 billion was spent on 
the health care system in Australia.[28] Suboptimal use of resources, such as the pharmacists, 
may add avoidable pressure to health expenditure. By removing the prescription requirement 
for an additional supply of a regular medication, as in the case of the CD, pharmacists are able 
to continue the medication, if appropriate, without the need for a doctor’s visit solely to renew 




pharmacists (often pharmacist prescribers) are often tasked with prescription renewals.[29, 30] 
The introduction of pharmacists into GP surgeries was proposed to address GP shortages in 
the UK. In addition, this step may save some resources by moving unnecessary workload from 
doctors to pharmacists.[5] Easier access to medications may minimise short and long term 
treatment interruptions.[30, 31] Treatment discontinuation may lead to more hospitalisation 
and an associated increase in health expenditure. 
2.2 Literature Review 
2.2.1 Background 
Ensuring timely access to treatment, including medication, is the ultimate goal of any health 
system. Whilst a medical review and a subsequent prescription from an authorised prescriber 
are essential to ensure patient safety and the need for the medication, this may result in a delay 
to obtain the medication if an appointment with the prescriber and thus a prescription cannot 
be obtained in a timely manner. Patients need a prescription to obtain their POMs. Such 
prescriptions in Australia are generally valid for 12 months (from the date of writing), after 
which a new prescription is required. Complicating the issue for patients prescribed multiple 
chronic medications is the fact that differences in quantity of supply and daily dosages can 
mean that medications run out at different times, and hence the prescription renewal cycles are 
often different.[6] In short, there are situations when patients need their medications before the 
next available appointment with the prescriber.[6, 19] In cases where an urgent appointment 
with the prescriber and a new valid prescription cannot be achieved, there is a risk of treatment 
interruption.  
Treatment interruption and medication non-adherence are avoidable complications of patients’ 
inability to obtain a new prescription for their ongoing medical care. When patients run out of 
their medications, they may seek an urgent appointment with the original prescriber to renew 
their prescription. However, this option is not always available. Consequently, they may 
request an appointment with another prescriber, or after hour’s doctor. However, there are 
some patients who do not want to change their prescriber, and hence do not avail themselves 
of these options.[7] Another option is to attend an Emergency Department. The drawbacks of 
this option are long waiting times, in addition to the delay that such presentations may cause 
to other more urgent cases.[32] If the patient does not utilise any of the above options, this 
might result in the patient stopping treatment for a short period. This period may be extended 
if there is no significant symptoms or acute reaction as a result of medication discontinuance. 




Treatment regimens may be affected by short or longer period of interruption. For example, 
unwanted pregnancy from the temporary discontinuation of OCs or complications resulting 
from a premature discontinuation of antidepressants.[33] Patients’ non-adherence to their 
chronic medications is a significant health issue.[34] Patients who have a tendency not to 
adhere to their medications may find the inability to obtain a new prescription as an excuse for 
their actions. 
On the other hand, patients who want to adhere to their medication may consider other options 
to avoid treatment interruptions. For example, some may decrease the daily dose in order to 
not consume all the medication before the next appointment with the prescriber. Others may 
borrow the medication from a partner or housemate.[6, 35] All of these options are not 
recommended and may result in under-treatment, or the potential use of the wrong 
medication.[35]  
A further option which patients may consider, is to request an emergency supply of their 
medication from their regular pharmacy (or any other pharmacy). Pharmacists regularly face 
requests for medication supply without a valid prescription from customers who have run out 
of medication and unable to obtain a new prescription.[6, 36] Patients also may find requesting 
the urgent supply from their regular pharmacy more convenient and less expensive. For 
example, in the UK pharmacists may provide their regular customers with a “loan” supply 
with an anticipated prescription to follow.[6] In this case, the patient will not have to pay any 
out of pocket expenses. 
2.2.2 Urgent medication supply within Australia  
In accordance with the Poisons Act, a POM must not be supplied without a prescription. 
However, pharmacists are legally allowed to supply in the absence of the prescription in the 
case of an emergency. For example, when patients run out of medications, and it is not practical 
to obtain a prescription without undue delay, which may affect the patient. When pharmacists 
face such a situation, it is not always safe to not supply, such as illustrated by a case in America 
where refusal to supply insulin resulted in a young man’s death.[37] However, the pharmacist 
must be confident that it is safe to supply as well. For example, in cases where the last 
prescriber had prescribed fewer than usual number of repeats, the patient has been admitted to 






Three methods for urgent supply in Australia have been identified from the literature:  
1) Emergency Supply 
2) Owing Prescription 
3) Continued Dispensing 
In each method, the pharmacist must be satisfied with the urgency of the request and make the 
safest decision. All the urgent supply methods share the same set of basic principles as outlined 
in Box 2.2.[35, 39-44] 
Box 2.2 Basic principles of urgent supply methods 
 The request for medication is urgent. 
 The original prescriber either unavailable or unable to provide a 
paper prescription. 
 The patient is stable on the medication. 
 The medication was prescribed by a registered practitioner. 
 The urgent supply is safe. 
 
The primary differences between these methods relate to the supply quantity, prescriber 
involvement, and funding.  
 
2.2.2.1 Emergency Supply (ES) 
This method allows pharmacists to supply a three days quantity of the requested medication 
or the minimum quantity of unbreakable containers such as inhalers. To fulfil this condition 
pharmacists may need to break an original pack that cannot subsequently be sold; hence this 
may lead to medication wastage and increased charges by the pharmacy to cover the loss on 
the broken pack. This method does not require a follow-up prescription (i.e. a prescription 
after the supply has taken place) or prior contact with the original prescriber.[35] However, 
this method is not funded by the PBS; the patient must pay the full price for the medication 




2.2.2.2 Owing Prescription (OP) 
This method involves the supply of one additional repeat of the last valid prescription, thus 
does not require breakage of the original pack. It is also covered by the PBS system, in the 
case where an owing prescription is presented to the dispensing pharmacy. Therefore, the 
patient has no additional out of pocket expenses other than the usual co-payments. However, 
it involves prior contact with the original prescriber. If the original prescriber authorises the 
supply, then a paper prescription (a follow-up prescription) must be sent by mail within seven 
days to the supplying pharmacy. The pharmacy will then use this prescription to claim 
reimbursement from the PBS. Faxed or emailed prescriptions are not accepted.[42]  In the case 
of some Authority items, the prescriber must obtain permission from Medicare, before they 
can authorise supply over the telephone. Doctors complain about their efforts in writing 
prescriptions without reimbursement.[2, 45]. In practice, the pharmacist may conduct the OP 
supply without prior contact with the prescriber.[43] This practice may lead to a financial loss 
if the doctor decides not to renew the prescription at the patient’s next appointment.[39]  
2.2.2.3 Continued Dispensing (CD)  
This is the most recent method to supply medications in urgent situations. It was implemented 
in all Australian states and territories from September 1, 2013, except Queensland. It was 
implemented to complement the ES and OP methods, and to supply certain medication in 
specific circumstances.[44] 
Like the ES method, CD does not involve prior contact with the prescriber. In addition, it 
shares the OP method regarding the supplied quantity. It is also covered by the PBS system. 
Pharmacists can claim the cost of the medication and dispensing fees from the PBS. Therefore, 
there are no additional out of pocket expenses for patients. Whilst this is convenient for 
patients, it involves extra work for pharmacists to record all the required details to allow 
claiming from the PBS. Also, the method is restricted to two medication classes only, and it 
has a limited utilisation frequency. It can be used to supply the same medication (Statin or OC) 
for the same patient only once in a 12 month period.[46] These restrictions may limit the 
achievement of CD stated targets.[47] The CD method was originally proposed by Bessell et 
al. in 2005, under the term “Medication Maintenance” (MM).[35] Bessell et al. conducted a 
study to propose models to improve Australians’ access to their medications. They proposed 
four models including MM. The MM model was the originally proposed version of the CD 
method of supply. However, there are some differences between the proposed and the 




Controlled medications were the only medications excluded from the MM model. However, it 
was initially proposed to provide medications for patients in Residential Aged Care Facilities. 
The CD method is useable in the community pharmacy setting, which services a broader range 
of customers.  
The current CD came to fruition after the Fifth Pharmacy Community Agreement between the 
Australian Government and the Pharmacy Guild of Australia (PGA). The latter represents 
pharmacy owners in Australia. Other (former) names for CD were Medication Continuance or 
Repeat Prescribing.[20, 48]  
2.2.2.3.1 CD and other PBS arrangements  
When CD is used, other  existing PBS arrangement will apply such as the Medicare Safety 
Net and the 20 day rule.[20] The Safety Net reduces the cost of medications when the 
consumer co-payments reaches the Safety Net threshold.[49] The threshold is $1453.90 for 
General consumers and $366 for Concessional card holders.[50] After consumers co-payments 
reach the threshold, there is no longer a co-payment for Concessional consumers, and the 
amount of co-payments for General consumers is reduced to the Concessional co-payment. 
For example, the usual co-payment (for 2015) by General consumer for Pregabalin Capsule 
75 mg is $ 37.70 before Safety Net threshold, and it is $6.10 once the threshold is met. 
Concessional consumers co-payment for the same medication is $6.10 before the Safety Net 
threshold, and they are exempted from co-payment when the threshold has been reached.[51]   
The 20-day Rule was initiated in 2006 to prevent overuse/misuse of the Medicare Safety Net. 
According to this rule, any resupply for the same medication within 20 days from the last 
supply will not be counted towards the safety net. In this case, even though the Safety Net 
threshold has been reached, the co-payments will be the usual unreduced co-payments. As an 
example for the medication above, the co-payments (for 2015) would be $37.70 for General 
consumers and $6.10 for Concessional consumers.[52]  
2.2.2.3.2 CD eligible medications 
Currently, Statins and OCs are the only eligible medications that can be supplied using the CD 
method. The permitted Statins are atorvastatin, fluvastatin, pravastatin, rosuvastatin, and 
simvastatin. The allowed OCs are levonorgestrel, levonorgestrel with ethinyloestradiol, 




Their relative safety was the reason for selection of these medication classes.[4, 54] It has been 
suggested that other medications may be added after the complete implementation of e-Health 
records and electronic prescriptions.[20] 
2.2.2.3.3 Statins safety risk ratio  
Statins are among the most widely prescribed medication for patients at risk of coronary heart 
disease and other atherosclerotic vascular disorders. The most commonly reported adverse 
effects of Statins are the asymptomatic increase in hepatic enzymes and musculoskeletal 
disorders (myalgia in 5% of users, myopathy in 0.2% or less, and rhabdomyolysis in 0.01% of 
Statin users).[55] According to Brown, adverse effects are rare, and the benefit to risk ratio is 
very high.[56] In addition, a large cohort study reported mixed benefits and adverse effects of 
the Statins, such as a reduction in oesophageal cancer and increase in liver dysfunction and 
acute renal failure.[57] The relative safety of Statins prompted the availability of low dose 
preparations without a prescription under pharmacist supervision in the UK.[58] Gotto stated 
that “After a median of 5.2 years, lovastatin therapy yielded a statistically significant 37% 
reduction in the rate of first acute major coronary events defined as fatal or nonfatal myocardial 
infarction, unstable angina, and sudden cardiac death (P<0.001).”[59] According to 
Therapeutic Goods Administration (TGA) website (last updated 26 October 2015), the most 
recent concerns about Statin side effects are memory loss and cognitive impairment, which is 
reversible upon medication withdraw, the risk of type 2 diabetes mellitus, and an increase in 
liver enzymes. In addition, the TGA mentioned that it “will review the evidence 
associated with the use of Statins and Protease inhibitors.”[60] 
2.2.2.3.4 OCs safety risk ratio  
The use of OCs is the most common method of contraception and is used by millions of women 
around the world. OCs are a safe and effective method of contraception (if properly used). 
Besides their effect in preventing unwanted pregnancies, they have other health beneficial 
effects. For example, users of combined OCs have lower death rates overall, and lower death 
rates from cancer, cardiovascular disorders and other disorders.[61]    
The decision to include OCs as an eligible medication class for the CD was based on safety 
grounds. Their inclusion also supports the recommendations by the World Health Organisation 
(WHO) to update medication supply policies to allow more convenient access to OCs, and 
greater consideration of users preferences.[62] According to the WHO, OC users fall into four 




the use of the contraceptive method,” Category B: “A condition where the advantages of using 
the method generally outweigh the theoretical or proven risks,” Category C: “A condition 
where the theoretical or proven risks usually, outweigh the advantages of using the method,” 
and Category D: “A condition which represents an unacceptable health risk.”[63] 
Females who fall in Category A and B can used OC without significant clinical review.[62] 
This suggests that pharmacists would safely be able to supply OCs in such cases.   
2.2.2.3.5 Non-adherence to Statins and OCs 
Non-adherence to chronic disease medications is a global challenge. Non-adherence is not 
uncommon in older Australians with chronic diseases. It is estimated that on average only 50% 
of the users are adherent to their chronic medications.[64, 65]  
For Statins, non-adherence is not an uncommon phenomenon.[66] Bates et al. have defined 
two types of non-adherence. Non-adherence could be primary and result in “the failure to 
initiate therapy” or secondary where there is “failure to continue the therapy.”[66] According 
to Bates et al. secondary non-adherence included “premature discontinuation”.[66] It is worth 
emphasising that secondary non-adherence was defined by Solomon and, Majumdar as “when 
prescriptions are filled, but the medication is not taken as prescribed.”[67] These authors have 
used the term lack of persistence to define “self-discontinue therapy by not refilling their 
prescriptions.”[67] Moreover, non-adherence can be classified as intentional or unintentional. 
If the patients decided not to use or not to continue a medication, this is intentional non-
adherence. However, unintentional non-adherence results from reasons outside the control of 
the patient such as forgetfulness, traveling without medication, or being unable to access the 
medication.[34] Therefore, patients who do not have a valid prescription may become 
unintentionally non-adherent.  
In such cases, the discontinuation period may be short until the medication is obtained, or for 
longer periods. Brookhart et al. reported that 53.8% of new Statin users had a period of Statin 
discontinuation of 90 days or more, although 60% of patients resumed the treatment within 2 
years.[68] Increased patient co-payments are amongst other causes of non-adherence to 
Statins.[69] Ellis et al. stated that “patients whose average monthly Statin prescription co-
payment equalled or exceeded $20 were more than 4 times as likely to discontinue Statin 
therapy than those patients who paid less than $10.”[69]  This suggests that cost may be a 
deterrent factor to patients offered an emergency supply of their Statin which involves full cost 




Non-adherence to OCs or OC discontinuation may occur when OC users had no access to 
their medication. The latter may be due to the patient’s inability to obtain a new prescription, 
being away from home and not having the OCP with them, and being unable to obtain a new 
pack. These were the most cited reasons for OC discontinuation reported by 141 women who 
participated in a study in North Carolina.[70] The study authors recommend removing barriers 
to obtain a new pack of OC as this would lead to lower discontinuation rates. This was 
confirmed by another USA study, which found lower discontinuation rates among women who 
obtain OC without a prescription in Mexico compared to women who need a prescription to 
obtain OC from El Paso US clinics.[71] Other factors which may contribute to OC 
discontinuation include financial difficulty and lack of time for medical visits.[72]  
2.2.2.3.6 Statin prescription status 
Statins are prescription only medications in Australia. However, in the UK in 2004 a Statin 
(simvastatin 10 mg) was made available without a prescription, but its supply requires 
pharmacist supervision; i.e. “Pharmacy P” medication.[73] This ensures convenient access as 
well as, providing necessary consultation with a health care professional. In Australia, the 
equivalent term for Pharmacy P medicine is Pharmacist Only Medication.[74] In the USA, 
there have been several attempts to switch Statins to be available without a prescription. 
However, the US Food and Drug Administration (FDA) has so far rejected those proposals. 
The lack of availability of Pharmacist Only Medication provisions in the US may have affected 
the FDA decision to grant over the counter status to Statins.[75]  
Switching medication to non-prescription status in Australia may be followed by their removal 
from the PBS list of medications. This means that the patients would need to pay in full. The 
financial burden to the patient may, however, be offset by less expensive generic products 
driven down by market forces.[76] 
2.2.2.3.7 Research about non-prescription Statin 
The availability of Statins without a prescription was not supported by GPs in a study 
conducted in Scotland.[77] Although this study was limited by low response rate, its result was 
not surprising because of doctors’ tendency to oppose down-scheduling medication.[78]  
On the other hand, UK pharmacists expressed a strong self-confidence to supply Statins 
without a prescription.[79] Moreover, pharmacist interventions have proven to be effective in 




2.2.2.3.8 OC prescription status  
High dose OCs known as the Emergency Contraceptive Pill (ECP) have been available without 
a prescription since 2004, as a Pharmacist Only Medication in Australia. Given the time-
sensitive nature of emergency contraception, access without delay increases the efficacy of 
ECP.[40]. The PBS does not fund this method.[41] Several countries have made ECP available 
without prescriptions such as France, the UK and the USA.[81] However, normal OCs are 
POMs in Australia. In a study by Dixon et al.[82] participants complained about access 
difficulties and the cost of GP visits, with some reporting these issues had deterred them from 
taking OCs.  
The consequence of not using an OC, or other effective forms of contraception, may be an 
unintended pregnancy. In Australia, unintended pregnancies are a major issue with 
approximately half of all pregnancies being unintended (which equates to ~ 200,000 unplanned 
pregnancies annually).[83] Unplanned pregnancy is not the only complication of failure to use 
effective contraception, with one in three cases of unintended pregnancy leading to 
abortion.[84]   
In 2014, a proposal was submitted by Green Cross Health (a New Zealand pharmacy banner 
group) to the TGA to down schedule OCs to Pharmacist Only Medication (i.e. Schedule S3). 
This proposal required “patients to fill in a simple questionnaire on any family history of 
hypertension, heart problems or stroke. The pharmacist would also need to conduct a blood 
pressure test on the patients to make sure they are suitable for the medication.”[85] The AMA 
opposed the proposal because of patient-related factors, namely safety and privacy, whilst 
questioning pharmacists’ ability to interpret patient information.[85] This attempt failed with 
the TGA in 2015 rejecting the proposal and confirming the need for a prescription to obtain an 
OC.[86]  
Removal of a prescription requirement may increase access to OCs.[87] Grindlay and 
colleagues,[88] analysed data from 147 countries around the world. They found that, in the 
majority of these countries, OCs were available without a prescription either legally or 
informally. The authors concluded that this availability may support the safety of non-
prescription OCs. Travelling without OCs or the inability to obtain an OC product when a new 
menstrual cycle started have been cited as reasons for OCs discontinuation, and the use of a 
less efficient method or non-use of contraception.[62] Moreover, unintentional pregnancy has 
health risks on women with other diseases. According to the WHO, there are a 17 medical 





Easy access to OCs would be preferred by OC users. In a study by Landau and colleagues,[12] 
exploring women’s views about pharmacy access to hormonal contraception in the United 
States, approximately two-thirds (63%) of the participants supported non-prescription status 
for OCs under a pharmacist supervision.[62] It is worth emphasising that results of the Landau 
and colleagues study may be affected by views of women without insurance cover. In 
Australia, normal supply of OC in the presence of a prescription is covered by the PBS. 
However, an emergency supply of the OC without a prescription for women who have run out 
of their regular OCs is not covered by the PBS. Therefore, removing the prescription 
requirement to obtain the OC, such as in the case of CD, should improve access and minimise 
treatment interruption. In the case of CD, women can obtain one supply, in any 12 months 
period, in cases where it is not practical to obtain a new prescription.  
2.2.2.3.9 Pronounced opinions about CD  
2.2.2.3.9.1 The Australia Medical Association (AMA) 
The AMA announced in 2011 that it “is strongly opposed to a proposal to allow pharmacists 
to supply prescription medicine without a valid prescription and without referring to the 
medical practitioner treating the patient.”[90] According to the AMA, pharmacists are not 
trained to make decisions to continue or cease the medication. The AMA also claimed that OC 
are not a chronic disease therapy, and Statins are not urgent medications. The AMA added that 
the vast majority of GPs can provide immediate prescriptions with or without a consultation if 
clinically appropriate.[90] Conflict of interest that may arise from pharmacists being a 
prescriber and dispenser was also cited by the AMA.[91]  
2.2.2.3.9.2 Pharmacy Guild of Australia (PGA) 
The PGA supported the introduction of CD.[4, 48] The PGA thought CD would benefit the 
health system through decreasing costs associated with prescription renewal and enhance 
utilisation of pharmacist skills. The PGA also claimed that CD would benefit patients through 
minimising treatment interruption that results from running out of medication between 
appointments, and also offering a financial benefit for consumers through PBS covering of the 
CD supply. Further, the PGA stated that CD would help minimise the disadvantages of other 
emergency supply methods such as the administrative burden of the OP and waste production 




2.2.2.3.9.3 Consumer Organisations  
The Consumers Health Forum of Australia (CHF), representing Australian healthcare 
consumers, supported CD as a method to improve patient adherence to medications and to 
prevent treatment interruption that may result from inability to renew a prescription.[92] The 
CHF also emphasised that consumers must be consulted about what medications they believe 
should be included in the CD method. The CHF also announced its support for consumer 
satisfaction surveys that would improve the CD method.[92, 93]  
The Health Care Consumers’ Association (HCCA),[94] also supported the CD through its 
input on a CD consultation paper in the Australian Capital Territory (ACT), and valued its role 
to improve access to medications. It also called for CD expansion to include more medications 
such as diabetes, arthritis and asthma medications. The HCCA also urged the inclusion of 
opiates and argued that chronic pain has major impacts on consumers. It expressed consumers’ 
concerns about being “forced to pay to visit the doctor every few months to renew their 
prescription”. Furthermore, the HCCA has described this situation as frustrating particularly 
for consumers who know they have to use these medications continuously for life. It also stated 
that this may be an expensive and time-consuming process.[94]  
The Services for Australian Rural and Remote Allied Health (SARRAH) also supported CD 
and called for both CD expansion and extension (i.e. more frequent access).[47] SARRAH 
commented on the CD consultation paper and its response was assisted by Lindy Swain, 
Pharmacist Academic and a member of SARRAH Advisory Committee. SARRAH provided 
reasons why CD should be expanded. It claimed that the vast majority of patients prescribed a 
Statin are using other medication for co-morbidities such as diabetes and hypertension. 
According to SARRAH, patients and doctors may not understand why a prescription is needed 
for some medications but not for others. The difficulty in retaining physicians in these areas 
was also cited as a reason for CD extension, where obtaining an appointment with the doctor 
is problematic. SARRAH, also valued CD’s role in the continuity of care for patients who are 
travelling without their medication.[47] It is worth mentioning that SARRAH’s position on 
CD may be biased by the assistance they obtained from its pharmacist member.    
2.2.2.3.9.4 Public views 
Customers’ comments about the CD bill (Medication Continuance) showed public support for 
CD.[95] The reasons provided related to the cost associated with a doctor’s visit just to renew 




$30-60 for a consultation with a doctor that only included writing a prescription.    
Further, some consumers acknowledged pharmacists’ expertise, and they particularly 
appreciated the way the pharmacist handled repeat prescriptions. A comment read: “From my 
experience at least the pharmacist asks questions before giving medication”. This comment is 
probably referring to the difference between prescription renewal (without consultation) by 
doctors and obtaining a repeat supply from pharmacists.[95]   
2.2.3 Urgent medication supply: International Aspects   
Worldwide there are urgent medication supply methods. These methods are quite diverse; 
however, they either involve urgent supply upon request of a prescriber or a patient. Also, they 
all share fundamental principles with the Australian urgent methods (Box 1.2).  
2.2.3.1 Urgent supply in Canada 
The Canadian health system allows pharmacists to exercise significant control over 
medication supply in urgent situations.[96, 97] The quantity of supply may be limited to be 
enough until the next appointment with the original prescriber or up to one month’s supply. In 
most cases, the prescription must be renewed at the original pharmacy (where a previous 
normal supply was obtained), however some provinces permit the renewal at any 
pharmacy.[98] The other general rule is the exclusion of controlled drugs except the use of 
benzodiazepines in the case of convulsive disorders. Notification of the original prescriber 
ranged from mandatory to recommended.[98]  
In several Canadian Provinces, the pharmacist may adapt the ongoing prescription or 
even prescribe in the emergency cases when another prescriber is not available and 
the treatment is needed urgently. For example, in the Province of New Brunswick, pharmacists 
may legally adjust the dose, or change the dosage form of prescribed medication. They can 
also renew prescriptions, prescribe independently in case of an emergency, or 
collaboratively with an authorised practitioner. In the Northwest Territories, pharmacists 
can continue dispensing for up to 30 days for patients with chronic diseases except for 
controlled medications. In certain circumstances, pharmacists are also allowed to substitute 
the prescribed medication with less costly equivalent. It is worth mentioning that in the 
province of Alberta, pharmacists, who have been acquired an additional prescribing 




2.2.3.2 Urgent supply in the United Kingdom (UK) 
 In the UK, patients who need an urgent supply of their regular medication can request an 
emergency supply from a pharmacy. The quantity supplied may be up to 30 days’ supply, up 
to five days’ supply of permitted controlled medication, a full treatment cycle for OC, and the 
smallest pack size for special containers such as inhalers. The patient must pay the cost.[99] 
According to NHS Direct Wales website, most of the pharmacies would refund the patient if 
a “follow prescription” was obtained.[100] The latter is called “loan” supply in the UK, and it 
is identical with some forms of OP supply without prior contact with the prescriber in 
Australia.[35]  
On the other side, the request may be made by a prescriber because of the inability to provide 
an immediate prescription. In this case, the supplied quantity is at the instruction of the 
prescriber, and it is a funded method, hence incurs no  additional cost to the patient. Controlled 
medications cannot be supplied by this provision except for treatment of epilepsy.[101] 
Pharmacists and nurses in the UK can renew prescriptions in urgent cases through Patient 
Group Direction (PGD). The PGD is defined as “written instructions for the supply or 
administration of medicines to groups of patients who may not be individually identified 
before presentation for prescribing treatment.”[102] This is a funded program, therefore the 
pharmacist will be remunerated for this service. The quantity supplied usually is the same as 
for the normal repeat supply or up to one month’s supply if that was not known. However, 
PGD can only be used to supply a limited range of medications such OCs, emergency 
contraception, antibiotic and anti-histamines.[33] The supply can be made upon request from 
a patient, patient representative or a registered prescriber.[103] While, there were no major 
safety concerns about the PGD, inflexibility of the PGD does not support pharmacists’ 
professional input.[104] For example, the strict inclusion criteria minimises their independent 
clinical judgment. Therefore, the PGD would be less helpful to experienced pharmacists 
because it does not add much more experience to skilful practitioners.[104] Similarly, CD 
restrictions, particularly in terms of its eligible medications, may result in CD avoidance by 
pharmacists who find difficulty explaining to patients why they can obtain some medication 
without prescription but still need a prescription for other medications. 
In a recently published UK study,[105] Nazar et al. evaluated a new service (NHS Community 
Pharmacy Emergency Repeat Medication Supply Service (PERMSS). This service is designed 




where they are unable to obtain a prescription before they need to take their next dose. The 
authors collected feedback from 1511 patients (response rate 60.8%) and 211 pharmacists 
(response rate 70%) regards the service. The majority (93%) of the patients found the service 
was easier or much easier to access than other NHS services. Furthermore, 50% of the patients 
reported that they would have missed doses of their medication had they had to get a new 
prescription. Even though 66% of the pharmacists reported the service had increased 
consultation times and the workload, the majority (92%), were happy or very happy to provide 
the service. Nazar et al. concluded that community pharmacists were able to manage 
emergency requests for medication repeats and patients were satisfied with the service. 
2.2.3.3 Urgent supply in Ireland 
In Ireland, an emergency supply request can be made either by a patient or a prescriber.[106] 
In both cases, the pharmacists must consider the potential risk of supply or non-supply. The 
supplied quantity is either as instructed by the prescriber (in the case of request made by a 
medical practitioner) and no more than five days’ supply in the case of requests made by 
patients, full cycle of OC, or the minimum quantity in case of special containers. Controlled 
medication cannot be supplied under these provisions.    
2.2.3.4 Urgent supply in the United States of America (USA) 
There are diverse emergency supply rules in the USA.[107] For example, the quantity of 
emergency supply varies from no emergency supply to a reasonable amount. The majority of 
states allow a three days’ supply followed by a 30 days’ supply. Controlled medication cannot 
be supplied under these provision.[108] 
2.2.3.5 Summary of urgent supply methods 
It can be summarised from the above that there are two types of urgent supply in Australia and 
worldwide. The first type involves a doctor intervention to request or to authorise the urgent 
supply (e.g. ES under request from a doctor in the UK, and OP in Australia). This type of 
urgent supply is characterised by a usual amount of the medication (i.e. one month supply or 
according to the doctor’s instruction). This system is usually a funded supply, thus patients 
pay the standard co-payments without any additional cost.  
The second type does not involve a doctor intervention or authorisation (e.g. ES in Australia 
and ES in the UK upon patient request). The amount of supply often ranges from a three days’ 




full price because this supply is not nationally funded. Consequently, some pharmacists 
may help the patient through by supplying the medication before a prescription is obtained 
(such as loan supply in the UK).  
It is worth mentioning that regardless of doctors’ involvement or not, these urgent methods 
can be done without the doctor consulting the patient face to face. This may imply that the 
prescriptions in these cases are only as a legal requirement, not a safety measure. CD has been 
implemented to ease patients’ access to medications through removing this legal requirement 
for selected medications and specified conditions. However, the stakeholders’ views of its 
value and utility remain largely unknown. For that reason this research was undertaken. 
Presented below (Section 2.2.5) is a review of the methodologies used in this research for the 
purpose of ascertaining views of patients, pharmacists and GPs. 
2.2.4 Association between pharmacists’ demographics and their 
decisions  
The urgent supply of medication involves a decision-making process by the pharmacist to 
either supply or refuse to supply the medication for the patient requesting a medication without 
a valid prescription.  
The association between healthcare professionals’ demographics and their decision-
making process has been described in the literature. Weisse et al. studied the effect of 
physicians’ gender and race on pain management using case vignettes.[109] They found that 
male and female physicians exhibited different treatment patterns. For example, male 
physicians prescribed higher doses of Hydrocodone to male patients than female patients, 
while female physicians prescribed higher doses to female patients.[109] Similarly, Hamberg 
et al. found that male and female physicians managed neck pain differently.[110] Other studies 
have investigated pharmacy location influences on pharmacies stocks of opioids 
analgesics.[111, 112] Morrison et al. reported that pharmacies in minority areas 
were significantly less likely to stock opioids compared with non-white pharmacies: “those in 
which less than 40 percent of residents were white.”[111] Greet et al. has also confirmed the 
influence of pharmacy location.[112] Moreover, Kahan et al. explored relationships between 
pharmacist demographics (age and years of practice) and their survey items (number of total 
daily prescriptions in the pharmacy, number of opioid prescriptions, and number of opioid 
patients for whom the pharmacist had concerns).[113] In another study about attitudes of 




patients, the authors found numerous associations between pharmacists demographics 
(gender, age, and years of practice). For example, males had more positive attitudes than 
female pharmacists, and older and more experienced pharmacists had more positive attitudes 
than their younger and less experienced counterparts.[114]   
2.2.5 Data collection methods 
Four techniques of data collection used in this research project. Each method was selected to 
obtain answers to the study questions.[115] Besides validity and reliability of each method, 
the method selection criteria were based on two factors: convenient and cost-effectiveness. All 
techniques used in this project assumed that the participants provided unbiased answers. 
Certain steps were taken to minimise any potential bias including ethical review and validation 
processes to detect any biased questions or biased information in the information sheets. 
Selection of participant samples on a random basis, use of independent interviewers in the 
patient survey, and all data collected anonymously. Nonetheless, in any study with humans, 
bias cannot be eliminated completely.  Data collection methods are described below: 
2.2.5.1 Computer-Assisted Telephone Interviews (CATI)  
This method was used to collect data from Statin and OC users from around Australia. This 
method has several advantages that make it meet the selection criteria for this project. 
Collecting data from the public must consider that there would be variation in the sample 
regarding the level of education and thus ability to understand the questions. This method 
allows the participants to ask questions; it also enables supervision of questionnaire 
administration by the interviewer.[116] Also, it has been reported that the phone interviews 
take less time, and are more interesting than the self-administrated method.[117, 118] 
Participants questioned by telephone are reported to be relaxed and able to talk freely. Also, 
telephone interviews provide more anonymity than face to face meetings.[119]  
In addition, with the geographical expanse of a country like Australia, CATI is a cost-effective 
method.[24] It would be very difficult, expensive, and time-consuming to obtain a 
representative sample without using CATI. 
In this method, a computer is used to assist the interviewer. The computer enables the 
interviewer to view the question on the screen, skip irrelevant questions and enter the data 
instantly.[120]   




phones or coverage issues.[121] Some groups of the population are not contactable by this 
method such as mobile phone only users, persons with hearing difficulties, and individuals 
who have communication problems including difficulty in understanding the interview 
language.[122] It also suffers the disadvantage of the absence of visual cues and gestures from 
the interviewer that may be seen during the face to face interviews. However, such nonverbal 
data has a risk of misinterpretation.[119] Finally, although “telephone interviews are less 
vulnerable to interviewer and respondent bias than face to face interviews,”[123] these types 
of bias are still possible.  
2.2.5.2 Self-administered questionnaires 
This method was used to collect data from community pharmacists from around Australia. 
Again, this process meets the selection criteria for this project (convenient and cost-effective). 
Data collection from workplaces needs to take into consideration how convenient the method 
is for potential participants.[116] The self-administered method allows the participants to 
choose the most appropriate time to complete the questionnaire, and it is a less distractive 
process.[116] Besides, this technique may use both open-ended and/or closed-ended questions. 
While the open type allows participants to express their opinions, the closed type takes less 
time.[124]  
This method meets the second factor of the selection criteria (cost-effective). Again, the large 
geographical size of Australia has its effect on data collection process. Sending a questionnaire 
by mail to a demonstrative sample of Australian community pharmacists (via pharmacies) has 
the advantage of low cost. In addition, a reminder may be sent according to the response rate 
without significantly affecting the study budget. It is has been estimated that the cost of the 
self-administered questionnaire is far less than other methods (50% and 75 % less than 
telephone and face-face interviews, respectively.[116] Compared to the CATI method, the self-
administered questionnaire does not require special training and can be done by one 
person.[116] This decreases the cost and time.  
The self-administered questionnaires can be sent by email. This would be a less costly method, 
and it may be more convenient for some participants. However, there are technical issues such 
as the email may be redirected to junk file.[125] Moreover, low response rates may arise due 
restricted access to computers (other than for usual work) or the internet because of workplace 
policy.[126]  




researchers. This allows for greater flexibility, confidentiality and anonymity but researchers 
have no control on who completed the questionnaire. Moreover, the questionnaire needs to be 
stand-alone (self- explanatory).[116] Pre-testing the questionnaire through a pilot study will 
enhance its understandability by the potential respondents.[127]  
The response rate is an issue in mailed surveys.[116] However, this can be improved by 
sending reminders to all those surveyed or the non-respondents.[127]    
2.2.5.3 Case vignettes  
A case vignette is “a written case history of a fictitious patient based on a realistic clinical 
situation.”[128] This method can utilise written or video vignettes. In this project, the written 
type was used because they were convenient and inexpensive to produce and distribute. They 
were designed so that participants would find it is convenient to read through the case study 
and then provide their answers.[129]  
Regarding the second factor of the selection criteria, the cost-effectiveness, the written 
vignettes are less expensive than video vignettes. The latter would involve recruiting actors 
and recording facility. Also, actors’ performance, and the ability of the participants to 
understand the unspoken gestures may affect the results.[129, 130]   
The main disadvantage of case vignettes is the fact that the respondents are aware that they are 
under evaluation (Hawthorne effect).[131] This may affect their responses.[128]  
There are other alternatives to case vignettes. For examples, using mystery shoppers or trained 
customers. However, they are expensive or may not be applicable.[128] While mystery 
shoppers may have been used to investigate how the pharmacist deals with non-regular 
customers, they could not be used to assess how regular customers would be treated.     
2.2.5.4 Informal interviews 
At one stage of this project, the GPs study, the informal interview was used as a personal 
communications interview one GP and three pharmacists. This method was used as an 
additional technique to collect information about concerns by the research team about GP 
awareness of CD. This method has advantages that may be not fully utilised during this 
research project. For example, the collection of in-depth data about previous data or to obtain 
answers to questions that arose during the data collection.[115] This method has some 




audiotaping may not possible.[115]  
2.2.6 Questionnaire construction 
Appropriate questionnaire construction and design are necessary to maximise the number 
of participants and to obtain accurate and relevant information. Potential participants must be 
informed about the study aims and why their participation is important. The questionnaire 
should be easy to understand. It must contain questions about dependent variables and about 
independent variables that can be used to explain the dependent variables. It is good practice 
to included additional questions to detect inconsistency of answers and/or tendency to tick 
either “agree” or “disagree” to all the questions.[132] Avoiding long and confusing questions 
is essential for the questionnaire to obtain answers from the respondents.[133] In other words, 
the question must be about one piece of information. Moreover, terms of different meaning 
must not be used or clearly defined if used. Time frame references must be used when it is 
applicable for example, in the past six months. It is also important the question asks the exact 
level of details.[132] 
The response format is another important area in questionnaire construction and designing 
process.  In this regard, open-ended or closed questions may be used. While closed questions 
are easy and less time to answer they must be carefully constructed to contain all relevant 
answers.[134] Answer options such as “I do not know” or “not applicable” may be included 
when it is appropriate.[133] Closed question does not allow participants to express their views. 
This can be overcome by using additional option “other; please specify”. Open-ended 
questions allow for the collection of more details and in-depth data. Nevertheless, they take a 
longer time to answer and more memory efforts than closed question.[132, 133]  
The order of the questions is another factor that needs to be considered. According to Ching, 
there are some general rules to guide in questions arrangement: “Go from general to particular. 
Go from easy to difficult. Go from factual to abstract. Start with closed format questions. Start 
with questions relevant to the main subject. Do not start with demographic and personal 
questions.”[132] It is worth mentioning that demographic questions could be placed at the 
beginning of the questionnaire, as they the easiest to answer.[134] In general, there is no right 
or wrong answer to the question where to put demographic questions? Green et al. studied the 
effect of place of demographic information at the beginning and at the end of the questionnaire. 
They could not find any significance differences between the place of demographic questions 




Reliability of the questionnaire is important to produce a satisfactory survey. 
Reliability reflects the extent to which “questions lead to reproducible responses that are 
internally consistent.”[136] In this regard, questionnaires that contain ambiguous questions or 
difficult to answer are not reliable. The validity of the questionnaire, or the “extent to which 
the questions provides a true measure of what they are designed to measure”,[137] is another 
important factor that must be taken into the account when the questionnaire development 
process started. According to Hoti,[33] there are four main types of validity: face validity- 
whether the responses produce accurate information, criterion validity - if questions correlate 
with the variable, construct validity – if questions present the concept precisely, and content 
validity – if data is relevant to study aims.” Among the ways to validated a questionnaire are 
piloting within a small group of the potential respondents, and/ or using a panel of experts. 
This should be supported by literature review to identify issues which are relevant to study 
aims and hence provide content validity.[33, 136]     
2.2.7 Strategies to increase response rate 
Several strategies to increase response rate have been described in the literature.  
1) Data collection method: 
Using telephone interviews usually yields higher response rates than mail surveys, and they 
can cover more geographical areas.[138] Nevertheless, mail surveys cost less, and they are 
more convenient for participants at work-stations, such as pharmacies A mixed approach such 
telephone plus in-person may improve response rates from hard-to-reach participants such as 
physicians.[139]  
2) Motivations: 
Incentives have been proven to increase the response rate.[140] According to Cho et al. even 
very small incentives, as small as US$1, are enough to increase the response rate.[141] 
However, incentives may lead to study bias (some may participate just to obtain the 
incentives), and untruthful answers if the participant’s identity is collected. Further, in some 
cases incentives may be not ethically acceptable.[138, 142]  
3) Participants’ anonymity:  
Assuring anonymity of the respondents is critical to encourage participation and obtaining 




4) Questionnaire delivery (how the questionnaires are received and/or returned): 
 It is important to use stamps on outgoing envelopes and pre-paid stamped addressed return 
envelopes. In addition to, using a single-sided questionnaire, it is important to have a logo 
printed on both the information sheet and the questionnaire. According to Edwards et al. “The 
odds of response were increased by more than a quarter when questionnaires originated from 
a university rather than an alternative source.”[140] Moreover, some questions were shorted 
to decrease the length of the questionnaire. Shorter questionnaires yield higher response rates 
than longer ones. However, the shorter ones may put the internal validity of the questionnaire 
at risk.[142]  
5) Follow-up reminders with the potential participants: 
A second reminder has been proven an effective tool to enhance response rates. Second mail 
reminders, particularly those containing another copy of the questionnaire, yield higher 
response rates.[140, 144] Follow-up phone calls may also be used as they are less 
expensive.[145] However, according to Brick et al. follow up by mail reminders yield 
considerably higher response rates than follow up done by telephone.[146]  
6) The length of the interviews or the time needed to answer the questionnaire: 
Interviews lengths of 15 minutes or less are associated with better response rates.[139] 
Regarding self-administered questionnaires, every reasonable effort should be made (such 
as using closed-ended questions rather than open-ended questions) to decrease the time needed 
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3 Chapter 3: Patient Attitudes towards Continuing 












This chapter is an amalgam of published papers: the Introduction, Aims, and Methods and the 
Conclusions have been combined, however the Results (except Demographic data) and 
Discussion sections have been retained as separate sections. 
Paper1: Abukres SH, Hoti K, and Hughes JD. Patient attitudes towards a new role for 
pharmacists: Continued dispensing. Patient Preference and Adherence. 2014; 8: 1143-1151  
DOI: http://dx.doi.org/10.2147/PPA.S66719  
Paper 2: Abukres SH, Hoti K, and Hughes JD. Continued dispensing: What medications do 
patients believe should be available? PeerJ. 2015; 3: p.:e924  
DOI: https://dx.doi.org/10.7717/peerj.924  
3.2 Note: Manuscript changes from the submitted papers 
The published Papers 1 and 2 have been reproduced in Sections 3.4.1 (Combined 
Introduction), 3.4.2 (Combined Aims), 3.4.3 (Combined Methods), 3.4.4.1 (Combined 
Demographic Information and Response Rate), 3.4.4.2- 3.4.4.8 (Other results: Paper 1), 
3.4.4.9 (Other results: Paper 2), 3.4.5. (Paper 1 Discussion and Paper 2 Discussion), and 3.4.6 
(Combined Conclusions). In the combined sections, some text from both papers was removed 
to avoid duplication (repeating of same ideas). The Abstracts and Reference lists have been 
removed, and this is within the terms of the Creative Commons Attribution Non-Commercial 
2.0 Generic License,[1], Dove Medical Press Copyright’s Notice, [2] and Peer J Copyright’s 
Notice,[3]. Permission from co-authors has been obtained (Appendix 3.1). No significant 
changes (except spelling) from the original publication have been made regarding content, 
grammar and headings. While the References used in these published articles are unchanged 
from the original publication, the References have been renumbered in line with the single 
reference list in the thesis. The numbers and style of the Appendix, Figure, and Tables have 
also been aligned with the format of this thesis. 
Additional changes requested by thesis examiners 
There are two types of changes as result of the examination process: 




Please note that the addition data were not part of the already published papers.   
2. Some terms were changed, this include: the term ‘affected’ replaced with ‘associated 
with’, the term ‘influence of’ replaced with ‘associated with’ the term ‘dispensed’ 
replaced with ‘supplied’, the term ‘asthmatic patients’ replaced with ‘patients with 
asthma’. 
Important note: Paper 1 was published first and it has been cited in Paper 2. The IC (Indirect 


















3.3 Unpublished data and more details of already published 
data 
Table 3.1 displays demographic information of each group of users separately. These data were 
not published in any of the papers.   
Table 3.1 Comparison between Statin and OC users according to their demographic data 
Varibles  Variable items  Users 
Statin  OC  
Age (p=0.0001) 18-20 0 14 
21-30 0 43 
31-40 1 51 
41-50 8 38 
51-60 25 1 
61-70 49 2 
71-80 40 1 
>80 28 0 
Gender (p=0.001) Male 60 0 
Female 91 150 
State/territory (p=0.0001) ACT (Australian Capital Territory) 1 3 
QLD (Queensland) 9 13 
NSW (New South Wales) 119 33 
NT (Northern Territory) 0 1 
SA (South Australia) 1 11 
TAS (Tasmania) 3 0 
VIC (Victoria) 15 64 
WA (Western Australia) 3 25 
Education level (0.009)# Primary 9 9 
Secondary 79 65 
University 48 75 
Other 4 0 
Employment status 
(p=0.0001)# 
Full time 23 57 
Part time 10 38 
Casual 2 9 
Not currently employed 109 3 
Retired 7 42 
Prefer not to disclose 0 1 
Other disease (p=0.0001) Yes 67 116 
No 82 34 
Regular pharmacy 
(p=0.0001) 
Yes 147 112 
No 4 38 
# p value obtained by Fisher test 
Chi-square test or Fisher Exact test (when the expected numbers are small) revealed that both 




regular pharmacy (See Table 3.1 for p values), they also differed in terms of :1) state/territory: 
the majority of Statin users were from NSW, while the majority of OC users were from VIC, 
and 2) education: OC users were more likely to had higher education status. 
Table 3.2 Comparison between Statin and OC users according to other set of variables 
Variable  Variable items Users Total 
Statin OC 
Run out of medication 
(p=0.021) 
Never  103 85 188 
Run out 45 65 110 
Ask a pharmacist (p=0.0001) Never 22 32 74 
Yes 25 13 38 
CD frequency (p=0.0001) As planned  53 26 79 
More than once 98 124 222 
Concern (p=0.0001) Not at all concerned 147 112 259 
Fairly concerned 4 38 42 
CD risk (p=.06) Yes 10 5 15 
No 124 140 267 
Neutral 9 5 14 
Prefer not disclose 5 0 5 
Table 3.2 provides information about Statin and OC users in terms of: 1) frequency of running 
out of medication (OC users were more likely to run out of their medication, 2) asking their 
pharmacist for urgent supply: Statin users were more likely to ask a pharmacist when they run 
out of their medication,[4], 3) CD frequency: OC users were more likely to agree with more 
frequent availability of CD, 4) concerns: OC users were more concerned than Statin users 
about obtaining their medication through CD method, and 5) perceived risks: there was no 









3.4 Published data: paper 1 and paper 2 
3.4.1 Introduction  
(Combined from Papers 1 and 2) 
Medications in Australia are available as: Prescription only medications (Schedule 4, and 
Schedule 8 for controlled drugs), and non-prescription medications, which include: Pharmacist 
Only (Schedule 3) which can be provided by a pharmacist, Pharmacy Only (Schedule 2) which 
can be provided by other pharmacy staff under pharmacists’ supervision, and other non-
scheduled over the counter medications (OTC) which are available for general sale. Statins 
and OCs (except for the emergency contraceptive pill) are S4 medications, (i.e. a prescription 
is required for dispensing).[5]Continued dispensing (CD) is a new medication supply method 
for certain Prescription only medications in Australia when patients run out of their 
prescriptions. According to Medicare Australia, the CD initiative “will allow pharmacists to 
supply eligible PBS [Pharmaceutical Benefit Scheme] medicines to a customer when there is 
an immediate need for the medicine, but it is not practical for the customer to get a 
prescription.”[6] As part of the Australian government’s broader National Medicines Policy, 
the PBS provides timely, reliable, and affordable access to necessary medicines for 
Australians. In regards to CD, oral contraceptive (OC) and lipid-modifying agents, namely 
Statins, are the only medication classes that can be supplied according to current CD 
guidelines.[4] This system was originally proposed to minimise the risk of patients running 
out of their medication between doctors’ visits.[5, 7]  
The usual practice for chronic disease prescribing in Australia is that the doctor writes a 
prescription for the medication for one month supply and issues up to five repeats to cover up 
to a 6-month period.[8] For patients meeting specific criteria, up to 11 repeats can be 
prescribed and therefore cover the patient for one year.[9] However, there are circumstances 
where patients run out of their medications before the next appointment.[10] As a result, they 
may need to ask the pharmacist to provide a supply without a prescription.[11, 12] The current 
system allows pharmacists to dispense under the provisions of Emergency Supply, Owing 
Prescription, or the recently introduced CD.[13] The Emergency Supply system involves 
dispensing without a prescription and prior contact with the prescriber; however, its main 
drawbacks are the limited quantity of medication that may be supplied (namely 3 days’ 
supply), out of pocket expense to the patient, and medication wastage in the pharmacy as a 
result of broken packs.[7] The Owing Prescription model requires prior authorisation by the 




pharmacy within 7 days. The prescription is used to claim reimbursement for the medication 
from Medicare Australia through the PBS system.[14] This overcomes the above mentioned 
disadvantages of the Emergency Supply system, but prior contact with the prescriber is not 
always possible or practical, and it has the potential for unpaid efforts on the part of doctors 
and pharmacists during the process of following up prescriptions. The CD model has been 
implemented to provide pharmacists with an additional option to ensure treatment 
continuation, and in doing so to overcome the practical drawbacks of the Emergency Supply 
and Owing Prescription systems.[4, 7] 
CD does not require prior authorisation by the prescriber or the need to obtain a prescription, 
and there is no extra {beyond the normal} cost to the patient or medication wastage. In 
addition, the quantity supplied under the CD method is one standard pack of the medication 
which is usually enough for one month, allowing adequate time for the patient to obtain an 
appointment with their doctor, thus avoiding potential non-adherence due to therapy 
interruption.[4, 7]   
CD aims to prevent patient medication non-adherence as it allows continuity of treatment 
when patients do not have a prescription. Patients would prefer availability of medications 
without prescription if they were easily accessible, reduced the need to visit their doctors and 
achieved at a lower cost.[15, 16] Therefore, easier access to medications, without a 
prescription or an extra cost (which CD provides) are encouraging factors to enhance patient 
adherence.[4, 17]  
On the other hand, patients’ lack of awareness and acceptance, pharmacists’ unwillingness to 
participate, and doctors’ attitudes towards CD may have negative impacts on CD 
implementation. Pharmacists have reported low levels of patient awareness of new services 
provided in community pharmacies.[18, 19] Prior to the implementation of CD in Australia, 
the Australian Medical Association (AMA),[20] declared that it was “strongly opposed to 
pharmacists dispensing prescription medication without a valid prescription and without 
reference to the patient’s treating medical practitioner.”[4] 
The current CD method may provide limited benefit to chronic disease sufferers as they are 
often on multiple medications.[21] Consequently, they may present to a pharmacy requesting 
a Statin or an OC, as well as other medications which are currently not eligible for supply 
under the CD model. In these situations, conducting CD may confuse the patient who can, for 
instance, obtain their Statin without a prescription but cannot obtain their antihypertensive 




The above suggests that the list of CD eligible medications may need to be expanded to cover 
a wider range of common diseases, as is the case with pharmacist supplementary prescribing 
models in other countries. Pharmacist supplementary prescribing is a partnership between 
doctors and pharmacists where doctors retain their diagnostic role.[22] Patients who 
experienced supplementary prescribing have shown their support for pharmacists to prescribe 
a variety of medications such as, but not limited to, medications to treat diabetes, epilepsy, 
cancer, cardiovascular, respiratory, renal, skin, gastrointestinal, thyroid and blood coagulation 
diseases.[23] Furthermore, pharmacist interventions with treatment of chronic diseases have 
been proven to be effective.[24-26] Therefore, applying more responsibility to pharmacists 
through an expanded version of CD may assist in achieving CD’s goals; i.e. a more convenient 
way for patients to obtain their medication in a timely manner, prevent treatment interruptions, 
utilise pharmacists’ skills and decrease overload on doctors. The AMA has described the 
current (limited) CD as unsafe and inappropriate.[20] This was in contrast with results of a 
survey of Statin and oral contraceptive (OC) users, where the majority of the respondents did 
not perceive CD would pose any risks. They also trusted their pharmacists would conduct CD 
only when it was safe to do so and that their pharmacist would refer them to their doctor when 
needed. Furthermore, respondents thought pharmacists are more easily accessible than 
doctors; that CD would save their and their doctor’ time, and that it would help them to not 
miss any doses of their medications.[4, 5](IC)] It is worth mentioning that patients surveyed 
had no personal experience with CD as the study was conducted before the actual 
implementation of CD in Australia, so the results represent participates’ perceptions rather than 
their actual experience. Moreover, patients are not necessarily qualified to identify precisely 
when it’s safe or not to obtain a medication without a prescription.[5] 
Another limitation of the CD is its restriction to be conducted only once in any 12 month 
period. This timeframe has been proposed to prevent patients avoiding doctors’ visits.[7] It 
may lead, however, to treatment interruptions in two ways: if the additional supply is not 
enough until the next available appointment with the doctor,[27, 28] and/or if the patient runs 
out of valid prescriptions for their medication more than once in a 12 month period. This may 







 (Combined from Papers 1 and 2) 
As patient attitudes towards obtaining medication through the CD provisions have not been 
previously researched, this study aimed to explore their attitudes towards CD, including any 
perceived concerns and/or risks related to CD.[4] 
Another aim of the study was to explore patients’ attitudes towards expansion of CD to include 
a broader range of medications and hence increase the access to the service.  
The study was conducted before the actual implementation of CD on September 1, 2013. In 
doing so, we were able to assess respondents’ attitudes before they had experienced the service, 
and hence without any potential bias of personal experience.[5] 
3.4.3 Methods  
(Combined from Papers 1 and 2) 
This study was approved by the human research ethics committee of Curtin University 
(approval number PH-06-13; Appendix 3.2). Data were collected by a telemarketing company, 
CDM Direct Communication Services, using computer-assisted telephone interview (CATI). 
This method was chosen as it has the advantages of time and cost saving, and is practical when 
taking into the account the geographical expanse of Australia.[29] It also allows respondents 
to ask the interviewer questions if clarification is needed. Additionally, the questionnaire 
usually takes less time and has been reported to be more enjoyable to answer when compared 
with those that are self-administered.[4, 30, 31]   
A telephone number list was generated via a random number generation function based on a 
broad breakdown of the Australian population as outlined in the June 2013 Australian Bureau 
of Statistics data,[4] (i.e. New South Wales 32%, Victoria 25%, Queensland 20 %, South 
Australia 7 %, Western Australia 11%, Australian Capital Territory 2%, Tasmania 2% and 
Northern Territory 1%).[5, 32] Telephoning was carried out via random digit dialing within 
each state. The final target list generated had a total of 25,000 records. Telephoning was carried 
out by staff members of the telemarketing company who were not part of the study, therefore 
minimising potential bias. This sample {300 participants} allowed for a prevalence estimation 




the respondent had to be 18 years or older and English-speaking. Respondents who used both 
medications were interviewed as OC users. Eligible candidates were told that the interview 
would take about 15 minutes and were considered consented if they answered yes to: “Would 
you like to participate in this interview?” If the person appeared to need assistance, then 
another household member was allowed to assist the respondent. Respondents were also 
offered to be called at another time if the first call timing was not convenient, and they could 
withdraw at any time during the interview.[4] Participation was voluntarily and no incentives 
were used.[5] The study was conducted in July 2013, before the actual start of the CD supply 
method in Australia (September 2013). Therefore, respondents’ views were not affected by 
any positive or negative experience with CD, thus minimising study bias.[4, 33, 34]  
3.4.3.1 Questionnaire design 
The participants were interviewed using a questionnaire (Appendix 3.3) consisting of 38 
closed ended questions, with the option ‘other: please specify’ for some questions. The 
responses to “Other” option were entered into a database verbatim.[5] A literature review and 
experience from a previous study,[29] assisted in developing the questionnaire.[4] 
The questionnaire contained three parts: Part 1, which collected demographic information; 
Part 2, which collected basic information about other disease(s) and medication, and Part 3, 
which focused on patients’ perceptions of concerns and risks associated with CD, their 
thoughts on maximum number of CD utilisations in a 12-month period, and whether other 
medications should be included within the CD provisions. A five-point Likert scale was used 
to measure respondents’ attitudes towards the questions in Part 3 of the questionnaire.[4] The 
main focus of the questionnaire was to identify areas of CD extension and expansion, 
particularly what other medications may potentially be included into the CD system. The 
challenge was to carefully select potential medication classes and medical terms that were 
easily understandable by the general population. The study tool was assessed for face and 
content validity by staff members within the pharmacy practice group at Curtin University and 
by the telemarketing company group CDM Direct Communication Services.[5]  
3.4.3.2 Data analysis 
From Paper 1: “Patient attitudes towards a new role for pharmacists: Continued 
dispensing.”[4]  
Qualitative data collected through the option “Other please specify” in the questionnaire were 




questions was undertaken in three steps using Statistical Package for the Social Sciences 
(SPSS) version 22. Step 1 was a descriptive analysis and was carried out to describe the 
distribution of the answers. Step 2 included assessment of respondents’ overall support of CD. 
The study participants were not asked directly if they supported CD; instead they were asked 
two questions, namely, if they perceived CD as a source of any concerns and risks. For the 
purpose of analysis, the respondents were divided into three groups: those who perceived CD 
as a source of either concerns or risks (Group A), those who perceived CD as a source of both 
concerns and risks (Group B), and those who did not perceive CD as a source of either 
concerns or risk (Group C, i.e. fully supportive). Step 3 aimed to determine if there were any 
statistically significant associations between participants’ concern and risk perceptions. In 
contrast with the null hypothesis, the alternative hypothesis assumed that participants’ 
perceptions of concerns were affected by their perception of risks. Therefore, the binary 
logistic regression test was used to predict the association between perceptions of concern and 
risk. A P-value <0.05 was considered to be statistically significant. 
From Paper 2: “Continued dispensing: What medications do patients believe should be 
available?” [5] 
SPSS version 22 was used for statistical analysis. In this regard, frequency distribution analysis 
and Chi square test were employed to assess associations between variables. Answers were 
collected on a 6 point Likert scale (where 1 = Strongly disagree, 2 = Disagree, 3 = Neutral, 4 
= Agree, 5 = Strongly agree, and 6 = Prefer not to disclose). For the analysis purposes, the 
scale was trichotomized as follows: Agreed, which included options 4 and 5, and Disagreed, 
which included options 1 and 2, and Neutral which included options 3 and 6. 
3.4.4 Results  
3.4.4.1 Demographic data and response rate 
(Combined from Paper 1 and 2) 
There were 10,479 attempts to make phone calls. However, there was a large number of failed 
calls (7,019) due to various reasons, including: number disconnected, answer phones, 
answering machines, no answer or call busy. This resulted in 3,460 successfully contacted 
individuals. Among these 2,443 individuals were screened out because of ineligibility (n = 
2,146 who were either under 18 years or not taking a Statin or OC, and 297 respondents were 




addition, there were 716 outright refusals, these were the most problematic because they 
refused to participate at an early stage, before it was clear if they were eligible or not. Since 
the outright refusals were likely to have a mixed eligibility, the 716 outright refusals were 
considered to have the same proportion of eligible individuals as the screened sample (i.e. 11% 
which was calculated by dividing 301 respondents by 2,744). {The 2,744 came from the 
subtraction of the 716 outright refusals from the total contacted 3,460}. This resulted in an 
estimated 380 total eligible candidates, giving a response rate of 79% (301 respondents of the 
total 380 eligible individuals). However, if all the outright refusals were eligible, which is 
highly improbable, the response rate could have been as low as 30%. Irrespective of the 
response rate the targeted sample size was successfully obtained.[5] 
The respondents were made up of 151 Statin and 150 OC users.[5] The respondents were 
predominantly female (80%; n=241). Just over half of respondents (51.5%; n=155) were 60 
years of age or younger.[4] {Statin users were more likely to be older than OC users, 
p=0.0001}. The participants were recruited from all Australian states and territories.[5] Almost 
half of the respondents (50.5%) were from the state of New South Wales (Figure 3.1), and the 







Figure 3.1 Distribution of respondents by their state or territory of residence in Australia 
Source paper 1[4] 
 
Paper 1: “Patient attitudes towards a new role for pharmacists: Continued 
dispensing” [4]  
3.4.4.2 Disease and medication data 
Atorvastatin (e.g. Lipitor®) was the most commonly used Statin (37.7%; n=57) followed by 
rosuvastatin (Crestor®); 26.5%; n=40), then simvastatin (e.g. Zocor®); 15.8%; n=24). 
Ethinylestradiol 30 μg + levonorgestrel 150 μg (e.g., Levlen® or Monofeme®) was the most 
frequently used contraceptive agent (38.6%; n=58) followed by ethinylestradiol 30/40/30 μg 
+ levonorgestrel 50/75/125 μg (e.g., Trifeme®, Triphasil®, or Triquilar®) which was used by 
12.6% (n=19) of OC users. Of the respondents, over a third reported having at least one other 






















Table 3.3 Respondents’ Characteristics 
Source paper 1[4] 
3.4.4.3 Medication supply history 
One hundred and ten (36.5%) of the respondents had run out of either their Statin or OC 
medications in the previous 12 months (Table 3.3). Of these 35.4% reported that they 
temporarily stopped the medication until they could see their doctor, while 33.6% sought an 
extra supply from their pharmacists until they could see their doctor. {OC users were more 
likely to run out of their medication compared with Statin users (p=0.021}. 
3.4.4.4 Regular pharmacy 
The majority of respondents (86%; n=259) reported having a regular pharmacy (Table 3.3). 
However, this differed amongst OC users and Statin users (74.9% versus 97.4%, respectively; 
P<0.0001). 
3.4.4.5 Perceived concerns and risks related to CD 
The questionnaire was designed to explore patients’ concerns about CD and whether they 
thought it would be safe to obtain their medication through CD. In order to simplify and 
explain CD to the participants, CD was presented in the questionnaires as obtaining one 
additional supply from the pharmacist when the patient ran out of medication and it was not 
practical to see the doctor. 
When patients obtain medication through CD, they need to discuss their health issues with the 
Characteristic Responses n(%) 
Suffer of medical conditions No  183 (60.8) 
 Yes 116 (38.5) 
Prefer not to disclose 2 (0.7) 
Approximate number of occasions in past 12 
months when respondents reported running 
out of their medication 
0  188 (62.5) 
1 52 (17.3) 
2 33 (11.0) 
> 2 25 (8.3) 
Prefer not to disclose 3 (1.0) 
If impractical to see usual doctor action taken 
by respondents to acquire further medication 
supply 
Nil, stop treatment 40 (35.4) 
Ask pharmacist 37 (33.6) 
See after hours doctor 8 (7.1) 
See another doctor 17 (15.0) 
Borrow  4 (3.5) 
Other 5 (4.4) 
Prefer not to disclose 1 (0.9) 
Regular customer of a pharmacy No 42 (14.0) 




pharmacist, and answer a range of questions in order for the pharmacist to determine whether 
CD is appropriate and safe. The majority of respondents were not concerned with the planned 
CD initiative (89.4%; n=269), mainly because they trusted their pharmacist’s judgment in 
determining if it would be appropriate for them to obtain medication through this method of 
supply (72.8%; n=219). Other reasons given in support of CD were “the pharmacist will refer 
me to the doctor if needed”, “pharmacists are easier to access than doctors”, “it will save my 
time”, and “it allows me not to miss any doses of my medicine” (Table 3.4). 
3.4.4.6 Respondents’ perception of concerns and risk 
Amongst the 30 respondents who expressed concerns regarding CD, the main issues raised 
related to consultation privacy and pharmacists’ lack of access to their medical records. Some 
respondents stated they would prefer to see their doctor (n=4), lacked confidence in the 
pharmacist’s capabilities or training (n=4), or saw CD as a way patients might abuse 
medications (n=1). The majority of respondents (88.7%; n=267) did not see any risk associated 
















Table 3.4 Respondents’ perceptions of concern and risk  
Source paper 1 [4] 
3.4.4.7 Estimation of CD support 
As outlined in the Methods section, support for CD was assessed on the basis of the combined 
responses of respondents to Q16 (Perceived concerns in discussing health issues with the 
pharmacist as part of CD) and Q20 (Perceived risks from pharmacists providing an additional 
supply of medication without a valid prescription). Respondents were deemed to be fully 
supportive of CD if they disagreed about any concerns or risks associated with CD (Figure 
3.2). 
Two hundred and forty-nine respondents (82.7%) disagreed with both questions (i.e. those in 
Group C, no concerns and no risk) whilst eight (2.6%) agreed with both questions (i.e. those 
in Group B, both concern and risk). These results indicated a high level of support for CD by 
potential users. 
Question Response n (%) 
Do you have any 
concerns regards 
CD? 
No 269 (89.4) 
Yes 30 (10.0) 
Prefer not to disclose 2 (0.7) 
Reasons for lack of 
concern 
Pharmacists know if it is safe or not to take an 
additional supply when I run out of my medication 
219 (72.8) 
The pharmacist will refer me to the doctor if I needed 177 (58.8) 
Pharmacists are easier to access than doctors 171 (57.0) 
Reduce work load of my doctor 141 (47.2) 
It saves my time 167 (55.5) 
It makes me not miss any dose of my medicine 160 (53.2) 
All of the above 147 (48.8) 
Other 19 (6.3) 




Lack of privacy in the pharmacy 6 (20.0) 
The pharmacist has no access to my health records 10 (33.3) 
All of the above 6 (20.0) 
Other 8 (26.7) 
Prefer not to disclose 1 (0.3) 
 
Do you believe CD 
poses any risk? 
No 267 (88.7) 
Yes  15 (5.0) 





Figure 3.2 Proportion of respondents (n=301) who fully supported CD  
(i.e., disagreed with both Q16 & Q20). Where Q16 = Perceived concerns to discuss health issues with the pharmacist when 
providing an additional supply; and Q20 = Perceived risks for pharmacists providing an additional supply of medication without 
a valid prescription)  
Source paper 1 [4] 
 
3.4.4.8 Relationship between respondents’ perceptions of concerns and risks 
Binary logistic regression analysis was used to examine if participants’ perceptions of concerns 
were affected by their perception of risks. The null hypothesis assumed no such relationship. 
This analysis revealed a highly statistically significant association between respondents’ 
perceptions of concerns (independent variable) and perceptions of risks (dependent variable; 
P<0.0001). “Disagreed” was the reference group. The odds ratio was 16.7, meaning that 
concerned respondents were 16.7 times more likely than unconcerned respondents to agree 
that there would be risk associated with CD. This suggests that participants who were 




Paper 2: “Continued dispensing: What medications do patients believe 
should be available?” [5]  
3.4.4.9 Participants’ attitudes towards a modified version of CD  
3.4.4.9.1 CD extension: increased access to CD 
Participants were asked how many times they thought CD should be allowed within a 12 month 
period. The majority of participants (73.3%; n = 222) disagreed with the current CD limitation, 
and selected more than one CD within a 12 month period. Among those who wanted more CD; 
16.3% selected ‘twice a year,’ 5.9% selected ‘three times a year,’ and 51.1% of the participants 
selected ‘any time my repeats run out and I am not able to get an appointment with my doctor.’ 
3.4.4.9.2 CD expansion: addition of more medications to the current CD list 
Participants were asked about their thoughts (i.e. agreement levels) on expanding the current 
list of CD eligible medications. Table 3.5 shows the proportion of participants who agreed with 
inclusion of medications for specific diseases/disorders. 
Respondents’ support to include particular additional medications into the CD method was 
associated with the condition to be treated. For example, 78.4% (n = 236) of the participants 
agreed to the inclusion of asthma medications; however, only 44.2% (n = 133) agreed to the 
inclusion of antidepressants. The participants’ support for the inclusion of different 
medications can be divided into three levels based on level of agreement. Level 1: included 
medications to treat asthma, arthritis, chronic skin problems, indigestion, hypertension, 
diabetes (oral hypoglycaemic) and chronic bronchitis, where over 60% of the participants 
supported their inclusion within the CD provision. Level 2: included emphysema medications, 
chronic pain medications, and anticoagulants where more than 50% (but less than 60%) of the 
participants agreed to their inclusion, and Level 3: included medications for thyroid disorders, 









Table 3.5 Respondents’ preferences for medications to be covered under CD 
Source paper 2 [5] 
3.4.4.9.3 Views of other disease suffers 
More than one third of participants suffered from other chronic diseases (38.8%; n = 116). The 
most prevalent co-morbidities were hypertension, type 2 diabetes mellitus, arthritis, 
depression, asthma, ingestion, and thromboembolic disorders requiring anticoagulation. Table 
3.6 compares the views of participants with these particular diseases with those without. 
Generally, in all diseases except type 2 diabetes and indigestion, the proportion of disease 
suffers who agreed with their medication’s inclusion into the CD provisions was higher than 
the proportion of the total study cohort. However, the only statistically significant difference 
was between participants supporting inclusion of antidepressants, where participants with 
depression supported inclusion of these medications more than participants without this 





 Disease/disorder/medication  Neutral/did not disclose n (%) Disagreed n (%) Agreed n (%) 
 Asthma  34 (11.3)  31 (10.3)  236 (78.4) 
 Arthritis  39 (13.0)  35 (11.6)  227 (75.4) 
 Chronic skin disorders  40 (13.3)  39 (13.0)  222 (73.8) 
 Indigestion  42 (14.0)  40 (13.3)  219 (72.8) 
 Hypertension  40 (13.3)  48 (15.9)  213 (70.8) 
 Diabetes  62 (20.6)  37 (12.3)  202 (67.1) 
 Chronic bronchitis  58 (19.3)  55 (18.3)  188 (62.5) 
 Emphysema  67 (22.3)  59 (19.6)  175 (58.1) 
 Chronic pain  54 (17.9)  86 (28.6)  161(53.5) 
 Blood clotting  62 (20.6)  85 (28.2)  154 (51.2) 
 Thyroid  84 (27.9)  67 (22.3)  150 (49.8) 
 Glaucoma  80 (26.6)  71 (23.6)  150 (49.8) 
 Anxiety  58 (19.3)  98 (32.6)  145 (48.2) 




Table 3.6 Associations of experience with the disease on respondents’ attitudes to the inclusion 
of particular medications in CD 
Source paper 2 [5] 
 
3.4.5 Discussion 
Paper 1: “Patient attitudes towards a new role for pharmacists: Continued dispensing” 
[4]  
This study explored attitudes of Statin and OC users towards the CD method of medication 
supply. It was conducted almost 2 months before the actual implementation of CD in Australia 
in September 2013, hence the results represent respondents’ attitudes before any positive or 
negative experiences with CD which may have influenced their views.[34-36]  
In the present study, the vast majority of the respondents strongly supported CD, and did not 
see it as a source of any concerns or risks. The potential explanations for this may be related 
to consumers’ trust in pharmacists assuming additional responsibilities and/or related to the 
nature of CD itself. Pharmacy consumers’ trust of pharmacists assuming new roles has been 
reported previously in the Australian literature.[29] In the present study, almost three quarters 
of respondents selected “Pharmacists know if it is safe or not to take an additional supply” 
option. Further, they thought that their “Pharmacist would refer them to the doctor when it is 
needed”, which is consistent with previous findings.[37, 38] Additionally, CD reserves the 
diagnosis to doctors, with pharmacists able to continue the treatment until patients can see 
their doctors. In previous studies,[29, 39] of attitudes towards expanded pharmacists’ roles, 
the majority of respondents (patients and pharmacists) strongly supported expanding the role 
of pharmacists to prescribe medications for diseases that were previously diagnosed by doctors 
(supplementary prescribing) rather than pharmacist diagnosing and prescribing (independent 
pharmacist prescribing). This is in contrast with the negative attitude of doctors towards CD 
 Disease 
 Agreed participants without the 
disease n (%) 
 Agreed participants with the 
disease n (%) 
 P 
value 
 Hypertension  180 (68.7)  33 (84.6)  0.06 
 Diabetes mellitus  186 (67.4)  16 (64.0)  0.91 
 Arthritis  211 (75.1)  16 (80.0)  0.81 
 Depression  120 (41.8)  13 (92.9)  0.001 
 Asthma  225 (77.9)  11 (91.7)  0.23 
 Indigestion  214 (72.8)  5 (71.4)  0.61 




as reported by the AMA prior to its implementation.[20] The AMA described CD as an unsafe 
process. Whilst recognising that not all respondents may have been qualified to estimate any 
risk associated with CD, all were chronic medication users and the majority did not see it as a 
risky method for obtaining their medications in the short-term. This may be due to their long-
term use of medication and prior experience with pharmacists positively influencing their 
views. 
As a method of medication supply, CD was instigated to minimise patient non-adherence with 
their medications, particularly as a result of treatment interruption, which occurs when patients 
run out of medication before they are able to obtain a new prescription. Although more than 
half of the respondents reported never being in this situation, a significant proportion had 
(~37%), and of these, over a third temporarily stopped treatment until they saw their doctor. 
Temporary discontinuation of a medication may have negative health outcomes;[17] further, 
it may lead to permanent treatment cessation.[40] Discontinuation of Statins has been reported 
as a source of concern to doctors and pharmacists.[38, 41] Significant Statin discontinuation 
rates have been reported, especially amongst younger patients and asymptomatic cases.[42, 
43] In the case of OC users, Rosenberg and Waugh,[44] reported that 80% who stopped using 
their OCs either adopted another less effective method of contraception or completely 
discontinued, even though they were still at risk of unwanted pregnancy. In an Australian 
study,[45] approximately 90% of pregnancies amongst women aged under 18 years were 
unintended and 80% amongst those aged 18–24 years. In the present study, OC users, who are 
younger than their Statin counterparts, reported running out of their medication more often 
than Statin users (P=0.021). In the case of Statins, other studies have shown older users report 
being more adherent than younger users.[42, 43]   
Approximately one third of respondents who experienced running out of their medications had 
requested an additional supply from a pharmacist. Before implementation of CD in Australia, 
pharmacists had only two options if they were to grant such requests, i.e. Emergency Supply 
or Owing Prescription. Both options have their disadvantages. Issues with the first include 
increased out of pocket expense for patients and wastage for pharmacies from open packs. 
Emmerton et al. reported that the additional medication cost may deter some patients from 
purchasing medications under Emergency Supply.[16] The other method, Owing Prescription, 
represents an administrative burden and involves unpaid effort for both doctors and 
pharmacists. In order to assist patients to obtain their medications at a lower cost, a pharmacist 
may supply a full pack of the medication and then follow up with their doctor to obtain a new 




restricted for regular pharmacy customers only, where a dual trust exists between the 
pharmacist and the patient. 
Statin users were less likely to run out of medications than OC users (P=0.021). There are a 
number of possible reasons for this significant difference. Firstly, Statin users were older, being 
more likely to be aged 60 years or over (P<0.0001). It has been reported that those who are 
older are likely to be more adherent to their medications.[43] Secondly, Statin users are more 
likely to have other diseases and use more medications (P<0.0001), so may have more regular 
contact with their doctors.[42] Thirdly, Statin users were more likely to have a regular 
pharmacy than OC users (97% versus 75%, P<0.0001), and this would lead Statin users to 
interact more with their pharmacists and be more likely to ask them for an additional supply if 
they ran out between doctors’ appointments. In addition, pharmacists would empathically 
dispense when they have the medication history of the patient, which is most likely to be 
available for regular customers. [44, 46] Finally, OC users were more likely to have full-time 
jobs (P<0.0001) when compared with Statin users, so may have more difficulty in organising 
a doctor’s appointment.[47] {Another reason for the increased likelihood of compliance with 
Statins could be the risk or fear of myocardial infraction or stroke}. Furthermore, OC users 
have the option of considering alternative contraceptive methods if they run out of OCs.[44]  
Among those who had run out of medication, less than a quarter reported seeing another doctor 
or an after-hours doctor (~15% and ~7%, respectively). The more common actions were to 
stop treatment until they saw their regular doctor or ask for an additional supply from the 
pharmacist (~36% and ~33%, respectively). This indicates that patients are not in favor of 
changing their doctor to another doctor. This is consistent with a study of patients with asthma 
that reported patients becoming less adherent to their medications if they received care from 
colleagues of their doctor {i.e. other doctors working in the same clinic}.[48]  
Patient acceptance of any new service is conditioned by how they perceive it. Minimising the 
risk of treatment interruption, hence non-adherence, is the ultimate goal of CD, which enables 
more convenient access to medications. Since pharmacists are more accessible than 
doctors,[35] CD seems to have the capacity to gain client support. This is confirmed by the 
results of our study, where 57% of respondents agreed with “Pharmacies are easier to access 
than doctors”. Additionally, there were other reasons that were reported by some respondents, 
including trusting the pharmacist, pharmacy keeping records of dispensing, and being a regular 
customer and having a personal relationship with the pharmacist. On the other hand, lack of 




small number of respondents concerned about CD. From a pharmacy perspective, inability to 
check medication histories for non-regular customers has been cited as a deterrent to more 
positive interactions,[44] whilst customers’ personal experiences and perceptions, positive or 
negative, about pharmacists may strongly affect their attitudes towards pharmacists’ current 
and future roles.[35]  
The limitations of this study are acknowledged. This study was conducted via landline 
telephone which may limit the representation of individuals who only use mobile phones, 
especially younger individuals.[49] In addition, some population groups were not included, 
i.e. those who could not speak English and those aged under 18 years, acknowledging that 
Australia is a multicultural country,[50] and OCs can be prescribed to teenagers younger than 
18 years.[51] Finally, the plan was to obtain a stratified sample of consumers according to the 
population distribution in Australia, but this was not achieved. The main factors potentially 
contributing to this were the high number of non-connections, consumers’ preference to 
participate, and project budget and time constraints, which may limit the generalisability of 
this study. 
Future work should explore the attitudes of Statin users and OC users who have experienced 
CD to find out if their experience with CD has had positive or negative effects on their 
perceptions of CD. At the same time, the experiences and views of community pharmacists 
need to be gathered to assess whether they believe CD is an ideal solution to deal with patients 
who run out of their regular medications. Further areas of research may include the attitudes 
of patients with other chronic disease diseases regarding inclusion of their medications in the 
CD provisions.[4] 
Paper 2: “Continued dispensing: What medications do patients believe should be 
available?” [5] 
To the best of our knowledge, this is the first study to explore the views of Statin and OC users 
in regards to potential extension and expansion of the CD system in Australia. More 
specifically, their support to increase the maximum number of times that CD can be utilised 
within a 12 month period (i.e. CD extension) and expansion of the range of medications 
allowed to be dispensed under CD (i.e. CD expansion). Regarding CD extension, the majority 
of participants disagreed with the current restriction of CD to once in every 12 month period, 
and preferred the option of using it more frequently. Interestingly, more than half of the 
participants wanted CD to be available until it was possible for them to see their doctor. This 




if, for any reason, an appointment with their doctor could not be achieved. Previous studies 
have reported that patients have difficulty in seeing their regular doctor without a prescheduled 
appointment.[52, 53] Furthermore, it has been reported that patients often do not organise 
appointments in advance or failed to attend appointments.[54] 
On the second question regarding expansion of the medications available through CD, 
participants generally supported inclusion of more medication classes. However, this support 
was influenced by the use of those medications. In this regard, the lowest level of support was 
for medications for the treatment of depression and the highest support was for asthma 
medications. This profound support for the inclusion of medications to treat a broad range of 
diseases/disorders may be related to patients’ confidence in their self-management and the 
ability to judge the severity of these diseases. Additionally, this may be related to their 
confidence that pharmacists can provide monitoring for diseases such as diabetes and 
hypertension. In a previous study,[55] patients provided reasons for preferring to buy short 
acting beta agonists (SABAs) without a prescription or with repeats of a previously issued 
prescription rather than visiting their doctor and obtaining a new prescription after a clinical 
examination. These reasons included their perception of the worthlessness of visiting their 
doctor just to obtain a new prescription, their perceptions of medication not requiring such 
visits and their long experience with the disease, making them feel that they were able to 
manage and control asthma without the need to see a doctor. This is despite evidence by Braido 
that “self-reported symptoms poorly correlate with pulmonary function measures”.[56] 
Another study reported that obtaining SABAs without a prescription did not lead to poorer 
asthma control; instead, it supported the claim that OTC availability of these medications 
benefits patients with asthma.[57] Moreover, the availability of some medications to treat 
asthma such as (SABAs) as Pharmacist Only medications in Australia, that do not require a 
prescription, may have increased participants’ confidence to obtain more asthma medications 
without a valid prescription. On the other hand, other studies reported that OTC asthma 
medicines have resulted in under-treatment and less consultation with doctors. Furthermore, 
assessment and counselling provided by pharmacists or other pharmacy staff has been reported 
to be less than optimal.[58] However, this inadequate counseling may have resulted from 
unwillingness of patients with long term chronic diseases to discuss with healthcare 
professionals what they believed they already know. This controversy about effectiveness and 
benefit of dispensing asthma medications without a doctors’ review raises the need to ensure 
that optimal patient outcomes are being achieved through appropriate monitoring. This 
suggests that down scheduling of Prescription Only Medication to Pharmacist Only 




supervision is essential, as is referral to the doctor whenever deemed necessary.[4](IC)] 
Disease sufferers were more likely to support inclusion of their medications into CD with the 
exception of patients with diabetes mellitus and indigestion. This is probably because of low 
sample size of patients suffering from indigestion. Interestingly, more than 92% of patients 
with depression supported inclusion of antidepressants in CD, even though the overall support 
for the inclusion of medication for depression was the lowest. The exact reason for the 
difference in support for the inclusion of antidepressants is unclear. However, it may reflect a 
poorer level of mental health literacy amongst the general population without depression, in 
which diseases like depression still have a social stigma. {Mental health literacy has been 
defined as “knowledge and beliefs about mental disorders which aid their recognition, 
management or prevention.”}[60] The lack of support for the availability of anxiolytics may 
also be explained in the same way, although the potential for abuse of these medications may 
also be another explanation. On the other side, the fact that most antidepressants are labelled 
with warnings “do not stop abruptly” may explain why patients with depression were more 
supportive than the overall participants. In addition, patients on long-term treatment for 
depression may not see the need for another visit to the doctor, especially if they do not 
perceive that they receive any new information during their routine appointments.[61] The 
latter may apply to chronic diseases in general, where patients after several years on the same 
medication may accept that nothing will be changed and see their doctor’s appointments as 
adding little value to their management. 
Participants’ support to include additional medications under the CD provisions is consistent 
with practices in Canada, where pharmacists in some provinces are permitted to undertake 
short-term dispensing to allow patients to avoid interruption of their continuing therapies.[62] 
It is also consistent with the overall trend to expand pharmacists’ roles through rescheduling 
more prescription only medicines to non-prescription status that requires additional 
pharmacist’s intervention (i.e. Pharmacist Only Medications). This includes medications to 
treat asthma, hypertension and hyperlipidemia.[59, 63, 64] Conversely, doctors have expressed 
their concerns about safety and appropriateness of CD,[65] as well as any further reclassifying 
of prescription only to non-prescription status.[66]   
Limitations of this study have been reported in detail previously.[4](IC)] These include the 
respondents’ distribution, with almost half of the participants being from one state (i.e. New 
South Wales); other factors included the exclusion of those who were under 18 years old, did 




regard to this section of the study, participants’ support to include more medications in the CD 
model was not based solely on their personal experience, as no participant had all the listed 
diseases/disorders. In addition, the number of participants who suffered from other diseases 
was low; therefore their support to include these medications may not be generalisable. 
However, participants’ responses may reflect, amongst other things, their general awareness 
of the disease/disorder, the experience of a friend or relative and/or being a health care 
professional. The fact that the participants were all either Statin or OC users, may bias the 
results as they may have different views from the general public or patients with the specific 
diseases, which may limit generalisability of the results of the current study. However, there 
are factors that contribute towards the study strengths, such as being the first about patients’ 
views on the current CD system and, therefore, it can provide novel insights into how the 
system may be extended and expanded in the future. 
Future research should explore specific diseases in relation to CD, including clinical and 
economic implications. Further, it is important that research undertaken to assess whether 
patients’ expressed desire to expand and extend CD is in their best health and economic 
interests. Given the limitations of the current CD method, other medication supply models to 
patients in cases where there is lack of valid prescription should also be explored.[5]  
3.4.6 Conclusions  
Presented here are the combined conclusions from Papers 1 and 2. 
Australian users of Statin and OC medications showed a high level of support for CD. Given 
that a significant proportion of patients temporarily stop treatment when they run out of 
medications and have no valid prescription, CD may alleviate the negative consequences of 
therapy interruption in Statin users and OC users in the short-term.[4]  
Current restrictions on CD may limit its capacity to serve its goals, as suggested by this study 
with participants highly supporting a more flexible and broader CD system. The currently 
eligible utilisers of the CD system seem to prefer inclusion of additional medications, and 
more opportunity to use CD at any time they cannot see their doctor. These findings suggest 
that ongoing review of CD is essential and changes which do not compromise patient safety 
or allow the abuse of CD would be welcomed by patients.[5] 
Strategies addressing the issue of supply beyond the one month allowable and the currently 




The overall conclusion of this study can be summarised as; Statin and OC users highly 
supported the current CD. At the same time, they supported a modified version of CD that 
enables them to obtain additional supply when they cannot see their doctor, and allows them 
to obtain other medications (for chronic co-morbidities) not only Statins or OCs. Therefore, 
the study participants think the current CD is one step towards more convenient access to their 
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This chapter consists of three parts. Part A is entitled: Avoiding treatment interruptions: What 
role do Australian community pharmacists play? This part consists of a manuscript which has 
been submitted to the journal PloS One for consideration. Part B is titled: Additional 
information. This part contains more details about the reasons for patients requesting 
medications without a valid prescription, as reported by pharmacists. Part C is entitled: 
Community pharmacists’ attitudes towards continued dispensing and its expansion.  
4.2 Note: Manuscript changes from the submitted version 
The Abstract and Reference list have been removed, and this is within the terms of the Creative 
Commons Attribution Non-Commercial 2.0 Generic License,[1], and according to PloS One 
copyright notice.[2] Permission from co-authors has been obtained (Appendix 4.1). No 
changes (except spelling) from the original publication have been made regarding content, 
grammar and headings. While the references used in this article are unchanged from the 
original publication, they have been renumbered in line with the single reference list in the 
thesis. The numbers and style of the Appendix, Figure, and Tables have also been aligned with 











4.3 Part A: Avoiding treatment interruptions: What role 
do Australian community pharmacists play?  
4.3.1 Introduction 
Pharmacists in community pharmacies worldwide are often faced with customers requesting 
supply of prescription medication without a prescription or without a current valid 
prescription.[3-5] In this paper, ‘invalid prescription’ refers to an out of date prescription or a 
prescription without any remaining repeats. In Australia, except in the case of controlled drugs, 
prescriptions are valid for one year from the date of issue, or six months for controlled 
medications.[6] When the prescription expires, the patient must see their regular prescriber or 
any registered prescriber (e.g. doctor, nurse practitioner) to obtain a new prescription. 
However, there are situations when obtaining an appointment with the prescriber is not 
practical and this may result in treatment interruption.[7]  
When customers run out of their prescription medicines, they may ask their regular pharmacy 
(or any other pharmacy) to supply their medication without a valid prescription, based on their 
last valid prescription. In this situation in Australia, pharmacists have the right to Not Supply 
(NS), or supply using: (a) Owing Prescription (OP) system, or (b) Emergency Supply (ES) 
system.[8] In the case of OP, the pharmacist is required to contact the prescriber to approve 
the OP supply, if the prescriber is not contactable, the pharmacist must not use this method. 
This method is funded nationally through Pharmaceutical Benefits Scheme (PBS). The PBS is 
a Government subsidy system for medication costs and professional fees for all Australian 
residents. Therefore, customers supplied with their one repeat of medication through this 
system are not charged beyond the usual co-payments. It requires a verbal approval (and a 
paper prescription within a week) by the original prescriber, and this may not be practical or 
possible in some situations.[7] Therefore, OP is not always available. The second method of 
supply (i.e. ES) does not require contact with the original prescriber. However it only enables 
pharmacists to supply a limited amount of the medication and customers are charged a 
premium for the cost of medication (i.e. a broken pack fee) and a dispensing fee.[9] 
Disadvantages of the above systems have led to a new method of supply in the absence of a 
valid prescription, namely Continued Dispensing (CD). CD has been implemented in the 
majority of Australian states/territories since September 2013. CD allows the dispensing of 
one standard pack of the medication. However it is currently only allowable for Statin and 
Oral Contraceptive users.[7] An expanded version has been supported by its eligible users (i.e. 




Society of Australia.[11] It is worth mentioning that at the time of conducting the present study, 
CD was either not implemented (i.e. time of initial survey), or had just implemented (i.e. for 
less than one month at the time of reminders). Therefore, this study collected information about 
community pharmacists’ practice before (or just shortly after) CD implementation.  
Several factors may influence the method that pharmacists use to deal with medication 
requests without a valid prescription.[12] Firstly, the type of prescription. In Australia there 
are three types of prescriptions (according to what medications can be prescribed, number of 
repeats and funding): Standard PBS Prescriptions (Standard), PBS Authority Prescriptions 
(Authority) and Private Prescriptions. The PBS contains a list of medications (dispensed at a 
Government-subsidised price) which may be prescribed using Standard Prescriptions or 
Authority Prescriptions. Standard Prescriptions are the most commonly used for medications 
on the PBS list because they do not require a third party authorisation. However, the prescriber 
must abide by the prescribing conditions such as the indication of use and number of repeats 
for individual Standard PBS items.[13] Authority Prescriptions are used to prescribe PBS 
listed medications which have restricted supply conditions (e.g. for a particular indication) or 
are prescribed in greater quantities or with more repeats than usually available through the 
PBS. For both prescription types, patients’ co-payments range from AU $6.10 to AU $37.70 
(2015 figures) depending on their status of concession. The rest of the medications’ costs and 
pharmacists’ fees are paid by the PBS.[14] Private Prescriptions are generally used to prescribe 
medication not listed in the PBS and/or when supply is not eligible under the PBS rules, in this 
case patients pay the full cost of the drug and supply.[8] Printed Standard and Authority 
Prescriptions are required to enable pharmacists to claim reimbursement from the PBS system, 
The administrative complexity to obtain a new prescription (particularly Authority 
Prescriptions) to cover medication supply without a valid prescription varies according to 
prescription type.[9] Consequently, pharmacists are likely to take this factor into their 
consideration in their decision to supply, and if so using what method of supply.  
Secondly, customer type may also influence the method that pharmacists choose in dealing 
with a medication request in the absence of a valid prescription. Since pharmacies keep records 
of medication supply for each customer, pharmacists can review the customer’s medication 
dispensing history.[15] In addition, pharmacists may establish a relationship with their regular 
customers.[7, 16] Therefore, pharmacists may provide different (and potentially more 
preferable) options for regular compared to non-regular customers.[4] For example supply 




Thirdly, the type of the medication. This factor may have a positive or negative impact on 
pharmacist‘s decision.[4] For example requesting an antihypertensive medication is entirely 
different from seeking a benzodiazepine without a valid prescription. While the motivation for 
requesting an antihypertensive is likely to be solely for medical reasons, the request for the 
benzodiazepine may not always be medically motivated.[17]  
Fourthly, the frequency of request may also affect pharmacists’ decisions.[4] For example, if 
the customer repeatedly requested the same medication under the guise that they were unable 
to see their regular prescriber, this would probably reduce the likelihood that the pharmacist 
would provide an additional supply. However, without a fully implemented electronic health 
record, pharmacists may not be able to identify if a previous supply without a valid prescription 
was made in another pharmacy.   
Finally, pharmacists’ decisions may differ according to their demographic status. Previous 
studies have shown that pharmacists had different practices according to their age, gender and 
pharmacy location.[18-20] Therefore, these factors may affected pharmacists’ decisions to 
supply or refuse to supply medications without a valid prescription.  
This study investigated: (a) the frequency of requests by different customer types, (b) how 
would Australian pharmacists deal (supply or not supply and which method of supply they 
use) if they faced with hypothetical scenarios of customers requesting medications without a 
valid prescription) and (c) factors which influence their decisions. 
4.3.2 Methods 
Australia has six states and two territories. They can be arranged according to percent of 
registered pharmacists as New South Wales (NSW) (31%), Queensland (QLD) (26%), Victoria 
(VIC) (20%), Western Australia () (11%), South Australia (SA) (7%), Tasmania (TAS) (3%), 
Australian Capital Territory (ACT) (2%), and Northern Territory (NT) (1%). A self-
administered questionnaire was sent to a randomly selected sample of community pharmacies 
in Australia. All pharmacies in each Australian state or territory (on the Yellow Pages website) 
were entered into an ExcelTM file, and then a random sample (20% of pharmacies) was selected 
using a simple random technique. A 20% sample was chosen as it allows a representative 
sample to be drawn from a large number of potential respondents. Therefore, 
1490 questionnaires were distributed with an anticipated response rate of 
approximately 40% (it was anticipated to lead to approximately 600 responses, with 95% 




electronic randomizer (http://www.randomizer.org/). The Yellow Pages website was the only 
readily available source to obtain postal and email addresses of Australian pharmacies. Efforts 
were made to obtain these addresses from licensing bodies, however, these attempts did not 
succeed. Sample selection depended on a number of pharmacies in each state/ territory. A total 
of 1490 pharmacies were selected: 464 from NSW, 378 from VIC, 326 from QLD, 135 from 
WA, 120 from SA, 39 from TAS, 16 from ACT and 12 from NT. The questionnaire was sent 
during late August 2013 by post. Whilst postal and email reminders [173 emails, (those where 
email addresses were available)] were sent out a month later (i.e. before and after 
implementation of the CD system in most Australian States).[21] Therefore, the questionnaire 
did not contain the option CD as a potential method of supply. In other words, the questionnaire 
explored the pharmacists’ reported practice before CD became an additional option to supply. 
The questionnaire did not collect information about pharmacies characteristics, such as the 
number of employees, the number of prescriptions dispensed or ownership of pharmacy. The 
postal survey was chosen because it is a cost-effective method to contact a relatively large 
number of pharmacies in Australia given its geographical size.[22] Participants were 
considered consented if they returned the questionnaire. No incentives were provided for 
participation. 
4.3.2.1 Questionnaire design  
Results of a literature review and experience from previous studies were used in the 
development of the questionnaire.[7, 22] The questionnaire’s face and content validity were 
assessed for by piloting it with five pharmacists and eight pharmacy academic staff members 
working in the area of pharmacy practice at School of Pharmacy, Curtin University. After 
incorporation of the suggested changes, such as deletion of some questions (because they were 
deemed irrelevant), the final questionnaire contained 19 questions. In this manuscript, we 
report only five questions that cover two areas; (a) frequency of medication requests without 
a valid prescription by regular and non-regular customers, and (b) the reported practice by 
pharmacists when dealing with such requests. In addition to these areas we also report 
participants’demographic information (age, gender of the participant and pharmacy location; 
urban (population > 100,000) or rural (population < 100,000)).[23] A regular customer was 
defined as a customer who attended the pharmacy five times or more in the past 12 months, 
while the a non-regular customer was defined as a customer who: attended the pharmacy fewer 
than five times in the past 12 months. These definitions were obtained from the Australian 
Health Department website and were provided within the questionnaire.[24] The first question 




medication(s) without a valid prescription. The second question looked at what the participants 
would do (NS, OP, ES or Other) when facing a medication request without a valid prescription. 
Therefore, they were asked to report what they would normally do when dealing with a request 
for each of the 19 different medication classes (See Appendix 4.2). In this case the request 
was made by a regular customer with a stable chronic disease (as judged by the participant 
after consultation with the customer) and based on a previous supply with: a) Standard 
Prescription, b) Authority Prescription, or c) Private Prescription. Therefore, three different 
scenarios were used. We assumed that the pharmacist would not supply when it was not safe 
to do, would try to contact the original prescriber to supply using OP, or dispense a limited 
quantity of the requested medication using ES if the communication with the prescriber was 
not possible (they could also use the “Other” option to report their other actions). The third 
question was about the reported practice if the same customer requested the same medication 
(regardless the prescription and medication types) for a second time without seeing the 
prescriber. The fourth question was the same as the second, whilst the fifth was the same as 
the third, but both dealt with non-regular customers. Questions 3 and 5 were used to explore 
only the effect of the frequency of request and customer type on participants’practice. 
Therefore they were shortened to include only these factors. This has the advantage 
of decreasing the time needed to answer the questionnaire (which contained a total of 19 
questions), without changing the intended meaning and purpose of the questions. Yet, 
Questions 3 and 5 provided valuable data particularly comparing participants’reported 
practice with regular and non-regular customers. Further details of the questionnaire are 
provided in the Appendix 4.2.  
4.3.2.2 Ethical approval  
This study was approved by The Human Research Ethics Committee of Curtin University 
(Approval number: PH-07-13; See Appendix 4.3).  
4.3.2.3 Data analysis  
Answers to each question were analysed using SPSS® version 22 (http://www-
01.ibm.com/software/au/analytics/spss/). Responses to questions were entered into an ExcelTM 
file, and then transferred to an SPSS® data file. SPSS® was used to summarise data and produce 
frequency tables and to describe the reported practice according to customer, prescription and 
medication types. Since the same participant was asked twice (i.e. first, would they supply or 
refuse to supply for regular customers, and second for non-regular customer), the McNemar 




customers. This test was initially utilised through the Transformed Process in the SPSS® to 
convert responses into the dichotomous responses of Not Supply (NS) and Supply which 
included ES, OP and ES&OP responses. Multinomial regression was used to investigate the 
effect of demographic variables: age, gender, and pharmacy location description (urban or 
rural) on participants’ decisions to supply and what method of supply they used (i.e. ES or 
OP). Participants were compared according to: age for the purpose of analysis this variable 
was re-grouped into two groups only (the younger group i.e. ≤ 40 years vs the older group > 
40 years of age), gender (male vs female), and pharmacy location (urban vs rural). For all tests 
a p value of ≤ 0.05 was taken to indicate a statistically significant association. Multinomial 
regression was used because it is appropriate to model a 3-level categorical outcome 
variable.[25] According to Tabachnick and Fidell, “regression analysis with over 
approximately 150 responses are adequate to identify independent variables which exhibit a 
moderate effect size” [25]. It does not require a large sample and 10 cases in each variables 
were considered sufficient.[26] Finally, Mann-Whitney test was used to detected differences 
between those who responded to the initial questionnaire and those who responded to the 
reminder. This test was used because it is appropriate to compare two independent samples.  
4.3.3 Results 
4.3.3.1 Response rate  
The total questionnaires received were 385 and there were 111 undelivered questionnaires. 
There were 268 responses from the first mail-out and 117 from the reminder (including six via 
email). There were only 63 responses from the states were CD was actually implemented. No 
statistically significant differences (Mann-Whitney test and Wilcoxon test) were detected 
between those who responded to the initial questionnaire and those who responded to the 
reminder. The overall response rate was 27.9% of delivered questionnaires. Response rates 
from states and territories ranged from 0% in Northern Territory to 51.4% in Tasmania.  
4.3.3.2 Demographic data 
Males were the dominant gender group of the respondents. According to age, the respondents 
were almost equally divided into two groups (≤40 years old and > 40 years old). The 
distribution of the respondents within states/territories corresponded to the number of 
pharmacies (hence the sample selected) in each state/territory. The participants’ primary place 
of work was community pharmacy (96.6%). Our demographic data is comparable to data 




are shown in Table 4.1. 
Table 4.1 Demographic characteristic of the participants (n=385) 
Variable Categories Survey Data 
n (%) 
Australian Data#  
Gender Male 210 (54.5) 8,916 (41.8) 
Female 155 (40.3) 12,415 (58.2) 
Prefer not to disclose 20 (5.2) *NA 
Age 20-30 90 (23.4) NA 
31-40 98 (25.5) NA 
41-50 83 (21.6) NA 
51-60 83 (21.6) NA 
> 61 26 (1.8) NA 
Prefer not to disclose 5 (1.3) NA 
State or 
Territory  
ACT (Australian Capital Territory) 5 (1.3) 373 (1.7) 
QLD (Queensland) 92 (23.9) 4,197 (20.0) 
NSW (New South Wales) 90 (23.4) 6,584 (31.0) 
NT (Northern Territory) 0 (0) 157 (0.07) 
SA (South Australia) 31 (8.1) 1,625 (7.6) 
TAS (Tasmania) 18 (4.7) 554 (2.6) 
VIC (Victoria) 92 (23.9) 5,465 (25.6) 
WA (Western Australia) 54 (14.0) 2,367 (11.0) 




Urban (Metropolitan)  279 (72.5) 16,225 (76.0) 
Rural (rural, remote and other) 100 (26.0) 5,088 (24.0)  
Prefer not to disclose 6 (1.6) NA 
# Source Health Workforce Australia 2014, [24] according to this source the total number of pharmacists in 2012 was 21,331 
working in different pharmacy settings (13,454 (63.1%) were working in community pharmacy).*NA: not applicable 
 
4.3.3.3 Weekly requests  
The participants were asked to estimate the number of medication requests without a 
valid prescription that pharmacy received from regular and non-regular customers on weekly 
basis. Four options were offered to participants to select; zero, one or two, three to four, and 
five or more. The most reported number of requests per week was five or more made by 




times reported by 19.5% (n= 75) and one or two times reported by 8.6% (n= 33), while only 
2.9% (n=11) reported that they did not face such requests from regular customers and 
nine participants did not answer this question. Interestingly, one participant reported the 
number of requests from regular customers as 50 per week. In the case of non-regular 
customers, one or two requests per week was the most frequent, reported by 48.3% (n= 186) 
of the participants followed by five or more reported by 21.3% (n=82), three to four times 
reported by 10.1% (n=39), and zero times was reported by 9.4% (n= 36).There were 42 
participants who did not answer this question.  
4.3.3.4 Reported practice  
The participants were asked about what they would do (Not Supply [NS], Owing 
Prescription [OP], Emergency Supply [ES] or Other) when dealing with hypothetical scenarios 
of a patient with a stable chronic disease requesting listed medications without a valid 
prescription, if this request was based on a previous supply with either a Standard, Authority, 
or Private Prescription, and was made by: (A) a regular customer or (B) an non-regular 
customer. The frequency of supply and the reported practice differed according to prescription, 
customer and medication type is outlined below.  
4.3.3.4.1 Total Supply 
Figure 4.1 displays the overall supply according to customer, prescription and medication 
types. Results are summarised below. 
According to customer type 
Regardless of prescription or medication type, for all listed medications the likelihood of 
supply for regular customers was greater than for non-regular customers (Figure 4.1).  
The McNemar test was used to compare the NS and supply for each medication as 
dichotomous dependent variables between the two customer types as dichotomous 
independent variables. In all cases, the difference was statistically significant (p < 0.0001), 







According to prescription type 
The lowest rate of supply was for Authority Prescriptions, irrespective of customer or 
medication type. The highest rate of supply was associated with Standard Prescriptions (for 
regular customers) or Private Prescriptions (for non-regular customers), depending on 
medication type (Figure 4.1).  
The McNemar test revealed statistically significant differences between the supply, based on 
Authority Prescriptions and the other prescription types, for all medication types (p value < 
0.05) and for each customer type. However, in some cases there were only significant 
differences between Standard and Private Prescriptions (see Figure 4.1 for more details). Note 
in the case of psoriasis medication (and similar cases) for regular customers, the percentages 
of participants who decided to supply in both prescription types were identical (i.e. 68.3%), in 
these cases the significant differences arose from the differences in the numbers of participants 
who did not supply. For example, in the case of psoriasis medication for regular customers, 
there were 111 participants who selected NS in the case of Standard Prescription and 85 
participants in the case of Private Prescriptions. 
According to medication type 
All listed medications, except opioids, were supplied by over 50% of participants’ regardless 
of prescription type if the request for supply was made by a regular customer. If the request 
was made by a non-regular customer, there were more medications that would not be supplied 
by pharmacists in the case of Standard or Private Prescriptions (Figure 4.1).  
However, if the prescription was an Authority Prescription, the majority of the participants 





Figure 4.1 Comparison between the supply (%) for regular and non-regular customers according to prescription and medication types 
COPD: Chronic Pulmonary Disease, OC: Oral Contraceptives, GORD: Gastroesophageal Reflux Disease 
Differences between total supply to regular and non-regular customers were all highly significance (p <0.0001). Significant differences between Standard and Private Prescriptions were only in: a) requests 
made by regular customers (shown in red); depression (p= 0.007), schizophrenia (p=0.001), hyperthyroidism (p=0.007), opioids (p=0.013), arthritis (p=0.039), psoriasis (p=0.001) and glaucoma (p=0.039), 




4.3.3.5 The reported practice  
Regular customers 
The most reported practice of medication supply was OP (Figure 4.2) in the case of either 
Standard or Private Prescriptions, except in the case of chronic pain non-opioids, antianxiety 
medications, and opioids. In the case of opioids, the majority of participants reported NS as a 
usual practice, whereas for non-opioids and antianxiety, there was no clear cut practice as the 
responses were distributed through NS, ES or OP. In the case of Authority Prescriptions, if 
participants provided medications they used ES more frequently than OP; however there was 
a greater level of NS compared to Standard and Private Prescriptions.  
Non-regular customers  
In the case of non-regular customers, there was a greater incidence of NS for all prescription 
types, and for all types of medication (Figure 4.2). In the case of supply, the preferred method 
of supply was ES. In contrast to regular customers, the frequency of OP use was 
more for Private Prescriptions than Standard Prescriptions.  
4.3.3.5.1 Frequency of request 
The usual practice was NS for both types of customers in cases where a second consecutive 
request was made before the patient obtained a new prescription. However, the likelihood of 
obtaining the medication was higher for regular than non-regular customers (26.3% [19.0% 
ES + 7.3% OP] vs 6.3% [5.5% ES + 0.8% OP], p< 0.0001). In addition, 12.9% of the 
participants in the case of regular customers and 5.1% of participants in the case of non-regular 










Figure 4.2 Method of supply (%) for regular and regular customers according to prescription and medication types  




4.3.3.5.2 Effect of some variables on the usual practice  
Multinomial regression analysis revealed that participants’ demographic variables (age, 
gender, and pharmacy location description) had significant effects on the usual practice of how 
participants dealt with medication supply requests. In general and depending on the 
prescription and customer type, older participants were more likely than the younger 
participants to supply the following medications: antianxiety, non-opioids, and opioids. 
Younger participants, however, were more likely to provide antidepressants, psoriasis 
medications, Statins, and non-Statins. Participants who worked in urban areas were more 
likely to supply antianxiety, arthritis, and Gastro-Oesophageal Reflux Disease (GORD) 
medications than participants worked in rural areas, while male pharmacists were more likely 
to supply opioids than female pharmacists (See Table 4.2). 
4.3.3.6 Alternative model for medication supply 
A small number of participants (ranged from 0 to 0.08 %) reported they used a hybrid model 
of ES and OP for some sub-questions (2-5). In this case, the customer is provided with the 
minimum applicable quantity of the medication (three days’ supply or the full pack [e.g. for 
an inhaler medication]) and required to pay the full cost (i.e. ES) and then when the customer 
presents a new valid prescription they are provided with the remaining quantity and either pay 






















Regular Antianxiety Standard Older (> 40 years) 0.008 
Antianxiety Authority Urban 0.044 
Antianxiety Private Older (> 40 years) 0.022 
Antidepressants Standard Younger ≤ 40 years) 0.033 
Antidepressants Authority Younger (≤ 40 years) 0.005 
Antidepressants Private Younger (≤ 40 years) 0.023 
Non-opioids Standard Older (> 40 years) 0.006 
Non-opioids Authority Older (> 40 years) 0.023 
Non-opioids Private Older (> 40 years) 0.022 
Statins Standard Younger (≤ 40 years) 0.007 
Statins Authority Younger (≤ 40 years) 0.015 
Statins Private Younger (≤ 40 years) 0.022 
Arthritis Standard Urban 0.016 
Arthritis Authority Urban 0.003 
Arthritis Private Rural 0.028 
Opioids Authority Older (> 40 years) 0.03 
Opioids Private Male 0.027 
Psoriasis Standard Male 0.008 
Psoriasis Private Female 0.012 
Psoriasis Private Younger (≤ 40 years) 0.028 
Anticoagulants Authority Female 0.028 
GERD Private Urban 0.003 
     
Non-regular Statins Standard Younger (≤ 40 years) 0.03 
Statins Private Younger (≤ 40 years) 0.048 
Non-Statins Standard Younger (≤ 40 years) 0.046 
GORD: Gastro-Oesophageal Reflux Disease  
4.3.4 Discussion 
To our knowledge, this is the first study to explore thereported practice of Australian 
community pharmacists when dealing with medication requests in the absence of a valid 




Worldwide there have been a number of changes in legislation to allow pharmacists to supply 
medication in urgent situations. For example, in some Canadaian Provinces, pharmacists 
may legally adjust the medication dose, or change the dosage form of prescribed medications 
to ensure treatment continauion when access to the original prescriber is not practical.[29]  
Results of the current study showed that Australian community pharmacists face such requests 
on a weekly, if not daily, basis. Inability of customers to obtain same-day appointments was 
reported as a cause in both the Australian and international literature.[30, 31] In a recently 
published Australian study, Garth et al. reported that not all patients requesting same day 
appointments would be able to be seen by their doctor.[30] In regards to medication requests 
without a valid prescription, regular customers were more likely to make such requests 
compared to non-regular customers (5 or more vs. 1-2 times per a week). In a previous study, 
requesting medication without a valid prescription was also reported by approximately one 
third of patients who ran out of their medication.[7] In a recently published study from the 
UK, Morecroft et al. reported that requests for urgent medication supply were more likely 
around weekends and when other services were not available.[4] In the current study, where 
possible and appropriate, community pharmacists assist customers by providing an ongoing 
supply until they can see their doctor. However, they are more likely to provide ongoing supply 
if the medication requested is not a drug with abuse potential, the customer is a regular and 
the prescription is either a Standard or Private Prescription, where obtaining a new prescription 
is less difficult than Authority Prescriptions. The reported practice of pharmacists dealing with 
medication requests in the absence of a valid prescription emphasises the importance of 
customers having a regular pharmacy.[12] 
Results of this study indicated that there were substantially different practices by pharmacists 
when dealing with hypothetical scenarios of medication requests without a valid prescription 
according to the customer, prescription and medication types, and frequency of the request. 
There were a number of factors associated with lower rates of medication supply and more 
usage of the ES or NS as the most reported practices. These factors included (1) non-regular 
customer (probably due to lack of dispensing history), (2) Authority Prescription (this seems 
a result of potential difficulties in obtaining a new valid prescription, which might result in 
breach of legal requirements and/or financial loss), and (3) medication type, in particular 
chronic pain non-opioids, anti-anxiety medications and opioids (probably because of abuse 
potential). Indeed, as these factors augmented, the medication supply became less frequent, 
resulting in more NS decisions. While the NS decision is recommended to deal with 




legitimate requests for medical purposes such as patients with cancer.[17]  
The ES method was the most commonly reported method of supply, in cases of the presence 
of one or more of the above factors, presumably because ES does not require contact with the 
prescriber or a future prescription. However, it is a costly method for the customer and allows 
only a three days’ supply. As a result of the cost,[32, 33] customers may refuse to obtain their 
medications through ES.[17, 21] Consequently, non-regular customers had a significantly 
lower overall rate of supply than regular customers (p < 0.0001). This is consistent with a 
previous study, where non-regular customers reported they ran out of their medications more 
frequently than regular customers.[7] The main reason related to these factors may be a 
potential lack of trust as reported by Hoti et al. in the pharmacist prescribing context.[34] 
Pharmacists may not feel confident to supply to customers for whom they do not know their 
medication supply history, do not trust them to accurately report their health issues and/or 
bring a new valid prescription back to the pharmacy, particularly in the case of Authority 
Prescriptions which require a third party approval.  
The OP method was the most commonly reported method of supply for requests made by 
regular customers, based on a previous supply with a Standard or Private Prescription, and 
when the medication was not a chronic pain non-opioid, anti-anxiety medication or opioid. It 
is not clear whether participants used the ‘Standard OP’ procedure (i.e. supply only after the 
pharmacist communicated with the prescriber) or the “in advance” OP which is conducted 
without such communication.[7] ‘In advance" OP is not strictly a legal method of supply; 
however it is used when the pharmacist is satisfied a regular customer will bring a valid 
prescription following their next visit to the prescriber. This is similar to ‘loan’ supply in the 
UK, which is used to supply medication for urgent requests without a prescription but with a 
future prescription anticipation. Morecroft et al. reported that avoiding additional cost to 
customers was one of the motivations for pharmacists’ use of this method.[4] We assume that 
pharmacists will firstly try to contact the prescriber and if that is not possible (thus the Standard 
OP is not applicable) then they may refuse to supply, use ES, or use the ‘in advance’ OP method 
of supply. In the case of non-regular customers, OP was less frequently used (ranged from 2.1 
to 20%). This may reflect difficulty to communicate with the original prescriber of non-regular 
customers.  
Frequency of requests also affected pharmacist’s decisions. If the same patient requested a 
second consecutive supply because of continued inability to see their regular prescriber the 




customers, through providing them an ES supply, compared with non-regular customers for 
whom the possibility to obtain a second supply was very small (p <0.0001). This may answer 
the question from a previous research project about “at what point does the pharmacist say, 
“We will no longer supply until you see the doctor?”[9] This indicates that pharmacists do not 
endlessly supply medication without a valid prescription and at the same time they appreciate 
patients’ difficulty in seeing their regular prescribers. In a previous study, repeated requests 
was also reported as a source of distress for pharmacists, particularly if they perceived them 
as system abuse by patients to avoid medical review, which they have to pay for or take time 
off work to have done.[4] 
Some demographic variables affected pharmacists’ reported practice. This effect of 
demographic variables is consistent with previous studies which demonstrated the association 
between pharmacists’ demographics and their decision making process and/ or their attitudes 
towards patients.[18-20]. Older, males and/or pharmacists working in rural areas were more 
likely (than their younger, female and/or urban counterparts) to supply chronic pain non-
opioids, anti-anxiety medications and opioids. This may have resulted from the experience of 
the pharmacist, where male pharmacists tended to be older than females (p < 0.05), working 
more on a full time basis and probably they were more likely to be a pharmacy owner.[27] 
Thus they may have had longer relationships with their customers and their customers’ doctors. 
Therefore, they may be more confident that they would obtain the anticipated prescription 
and/or as owners they were more able to take the financial risk of supplying medication 
without prescription if the anticipated prescription could not obtained. Furthermore, 
pharmacists working in rural areas may have had more regular customers (as result of fewer 
pharmacies in rural areas) and/or longer relationships (due to nature of living in rural areas) 
with their customers than their counterparts in urban areas.[35]  
An alternative method to supply medications was also reported. As far as we know, this method 
has not been reported in the Australian literature before. It is a combination of both ES and OP 
methods. This seems to be a practical way to satisfy the customers’ needs for urgent medication 
supply without strictly breaking the rules, as well as avoiding any financial loss if the 
anticipated prescription is not obtained. Several steps have been taken by the pharmacy 
regulatory bodies to improve access to medication when it is impractical to obtain a renewed 
prescription, such CD. However, this method is restricted in terms of its frequency and its 
eligible medications. 




state/ territory the low response rate was the main limitation of this study, which is consistent 
with the difficulty of obtaining high response rates from healthcare professionals in general, 
including pharmacists.[36, 37] In addition, there were a number of undelivered questionnaires 
which may have resulted from outdated addresses on the Yellow Pages website. Access to a 
more accurate mailing list and greater access to email addresses may have enhanced the 
response rate. The fact that there were 63 responses from states where CD had been 
implemented could be seen as a confounding factor. However, there were no statistically 
significant differences between those who responded to the first mail out and those who 
responded after the reminder (which was returned less than one month after CD became 
an available option. Moreover, CD uptake by pharmacists was reported to be very low in the 
first 10 months of its implementation).[21] No measures were made to identify who 
participated and who did not, whilst this makes a comparison between respondents and non-
respondents not possible, it has the advantage of collecting more truthful data that reflects the 
actual behaviours of the respondents.[38] There were a large number of pairwise comparisons 
undertaken, which suggested the existence of a number of significant associations. Because 
use of the Bonferroni adjustment is not appropriate in this setting (inappropriate null 
hypothesis), we acknowledge that some p-values may have been less than 0.05 by chance 
alone (type I error).  Furthermore, for statistical purposes we compared participants according 
to their age as a dichotomous variable, hence decreasing error probability, however, age may 
not be a valid indicator of pharmacist experience. Finally, results of this study are based on 
reported behaviours to hypothetical scenarios rather than observation of real 
practice. Consequently, although the fact that the majority of participants of this study faced 
similar requests in their practice, minimises the possibility of natural variance between the 
reports and reality, there is still a possibility that participants may deal differently with actual 
customers in real practice (i.e. they may have been self-reporting their ideal behaviours rather 
than their actual practice). Factors which contribute to the strengths of present study, include 
being the first to explore this area in such detailed way, the sample was selected from all 
Australian states and territories, and the use of hypothetical scenarios method has been proved 
to be effective and inexpensive tool to reflect the actual practice by healthcare professionals 
(doctors) with high content and face validity.[39] Moreover, anonymous reporting by study 
participants would eliminate “Hawthorne effect” (i.e. participants enhancing their actions 
under surveillance) that may occur during direct observation studies.[40] According to Evans 
et al.[41] case vignettes are appropriate to approximate, isolate, manipulate, and measure key 
aspects of the decision-making processes that individuals use in real world situations, and 




can be highly generalisable to “real life”behaviour, while overcoming the ethical, practical, 
and scientific limitations associated with alternative methods (e.g. observation, self-report, 
standardised patients, archival analysis).”[41] Finally, although study generalisability may be 
negatively affected by the low response rate, our sample successfully reflected the national 
figures regarding pharmacists’ demographic information, which supports study 
representativeness. This study is likely to prompt further investigations of the issues raised by 
its findings. 
 Future studies should focus on exploring the use of technology in enhancing the probability 
of obtaining a medication supply without a valid prescription in cases where contacting the 
original prescriber is not practical. It should also explore ways to improve communication 
between healthcare professionals with the view of minimising requests for medication in the 
absence of valid prescriptions.  
4.3.5 Conclusions 
Results of the current study showed that pharmacists face requests for medications without a 
valid prescriptions on a weekly, if not daily basis from both regular and non-regular customers. 
Our results emphasise the importance of patients having a regular pharmacy to minimise 
medication interruption when obtaining a new prescription for a chronic medication is not 
practical. In advance arrangement to obtain a new prescription is highly recommended to avoid 
such interruptions, particularly for medications with the potential for abuse and for medication 
that requires authorisation prior to prescribing. Moreover, models of allowing pharmacists to 
supply without a valid prescription, when it is safe to do, should be explored and implemented 
especially given that being a regular customer of a pharmacy does not guarantee supply. Future 
research should investigate reasons for medication requests without a valid prescription, why 
they are so frequent and what impact might these reasons have on pharmacists’ decisions, 
particularly taking into account the work by Morecroft et al. who highlighted that a perception 
of a “genuine mistake” can occur in different responses to a deliberate choice to try to deviate 
from standard practice.[2] Further, timely and cost-effective ways of communication between 
healthcare professionals, accessible electronic health records and/or pharmacists prescribing 






4.4 Part B: Additional data: Reasons for medication request 
without a valid prescription 
4.4.1 Overview 
This section contains additional data not reported in the submitted Plos One manuscript (See 
above). This part details answers obtained from the above study participants about reasons for 
customers’ inability to obtain a new prescription.  
4.4.2 Data analysis  
There were two types of data: quantitative and qualitative. The quantitative data were obtained 
through answers to a set of potential reasons (options) that were provided to the participants. 
These options were: (a) ‘Inability to obtain an immediate appointment with their doctors’; (b) 
‘They realised that they ran out of medication during weekends or public holidays’; (c) ‘The 
prescriber is on leave’, and (d) ‘All of the above’.  
The quantitative data were analysed using the SPSS (Version 22). Data frequencies were 
analysed to find the most reported reason(s). 
The qualitative data were obtained through answers to the option (e) ‘Other; please specify’. 
These answers included two types of reasons: (i) Type 1: Reasons usually cited by the 
customers to explain why they are not able to obtain a renewed prescription for their regular 
medication, and (ii) Type 2: Reasons provided by the participants (pharmacists) themselves. 
These reflected the participants’ views about medication requests without a valid prescription.   
The qualitative data were transcribed verbatim and were analysed thematically using Nvivo 
(V10 for windows). Content analysis was also used to find out the frequency of each reason 
(theme). Content analysis was carried out by counting the number of participants who reported 
each theme. The star sign (*) and the number refer to the number of participants mentioning 
the theme.  
4.4.3 Results  
For more details about demographic information please see Section 4.3.3.2 In regard to this 
question, it was answered by all study participants (385). Some of them chose more than one 




4.4.3.1 Agreement with suggested reasons 
Participants were asked to select all applicable reasons from the list of potential reasons (see 
above Methods). Eleven participants did not answer this question. The other participants (374) 
either selected one, two, or all the suggested reasons (this means the total number of responses 
is greater than the actual number of participants). The latter was selected by 203 participants.  
Figure 4.3 shows distribution of answers according to the suggested reasons. The numbers 
displayed are those who selected any reason, either a sole reason or with other reasons and 
including the option ‘Other; please specify’ (Please see Section 4.4.3.2 below for more details 
about the option ‘Other’). 
Note: Some participants selected more than one reason, hence the total answers are more than participants who answered the 
question. 
Figure 4.3Distribution of answers according to the suggested reasons 
 
4.4.3.2 Other reasons for requests of medication without a prescription 
Key themes emerging from the 'Other reasons' option (See above) are summarised in Table 4.3 
below.  
There were eight themes identified from reasons provided by study participants either when 





what they think are the reasons for this issue (Type 2, see Section 4.4.2): 
Theme 1: Travelling without medications (*n= 34) 
This was the most frequently reported reason. This resulted from interstate visitors who forget 
to take their medication and/or prescriptions.  
Theme 2: Unaware of last repeat or its requirements (*n= 25)  
This theme is about some patients who were unaware of their “last repeat” and they had 
consumed all the repeats in the prescription during the last dispensing. In addition, some 
patients may not be able to understand the repeat system requirements. Old patients and those 
on multiple medications may find it hard to remember to make an appointment after the last 
supply and to manage their repeats properly. 
Theme 3: Appointment difficulty (*n=20) 
The participants’ comments provided further insight into this issue, as the majority of the 
participants had previous ticked options (b) and/or (c) (See above). For example, some patients 
experienced long waiting times before their appointment ranging from 10 days to one month. 
Moreover, other participants commented that some patients were unable to see any doctor 
(including their regular doctor) or they were reluctant to see another doctor at the time of the 
request, or were not physically able to go and visit a doctor.  
Theme 4: Expired prescription (*n= 19) 
Patients were unaware that prescriptions may expire (one year after issue date) even though 
the prescription still has repeats. Examples of expired prescriptions were Thyroxine and OC 
prescriptions.  
Theme 5: Patient lack of responsibility/planning (*n= 17)  
These opinions centred on patients’ lack of responsibility and good planning to arrange 
appointments in advance before they run out of medications. This indicates that while 
participants accept that there are legitimate reasons for medication request there are patients 
who try to avoid doctor’s appointments, or those who are pharmacy shoppers for medications 




Theme 6: Lost prescription/ medications (*n= 11) 
For various reasons some consumers may lose their prescription or medication. For example, 
damaged or stolen prescriptions or medication. This theme may reflect that patients, 
particularly with chronic disease, are confounded with multiple challenges in maintaining 
adequate supply of their medications. In addition, it may indicate that patients see the 
pharmacy as the first point of help in such situations. 
Theme 7: Time, work or financial constrains (*n= 9) 
Patients working on full-time basis may have difficulty in arranging appointments during the 
normal working hours. Pharmacies have longer opening hours than surgeries. Patients’ 
financial hardship to pay for a doctor visit was also cited. 
Theme 8: Doctor related reasons (*n= 4) 
This theme emerged from comments that described why some patients may run out of 
medication as a result of poor or miscommunication with the prescriber regarding what the 
medication is being used for and how long it needs to be taken. Communication issues between 














Table 4.3 Themes emerging from reasons reported for urgent medication requests without a 
valid Prescription 
The * and the number indicate how many times the theme was repeated 
4.4.4 Discussion 
There were several reasons commonly given by customers when they requested medications 
without a valid prescription the most frequent being “Inability to obtain an 
immediate appointment with the doctor”. This is consistent with a previous survey about 
management of same day appointments in Australia.[30] According to that study, the high 
demand for immediate appointments affected GPs’ ability to adequately address the issue, in 
some cases providing a repeat prescription without a face to face consultation. However, more 
Theme Comments ( examples) 
Travelling 
without medications  
* n= 34 
“Came on holiday with no meds [medications] or not 
enough meds [medications].”R1 
“Interstate visitors without medication and forgot to bring 
medication.” R23 
Unaware of last repeat or 
its requirements 
 *n= 25 
“Did not record the date of last supply which said [the] 
last repeat.” R69 
“Inability to understand archaic repeat system.” R140 
“Bring in the duplicate thinking it is a valid script.”R240 
Appointment difficulty  
*n= 20 
“Have an appointment within the next 2 weeks.”R186 
“Dr is so busy- no available appointment, have a waiting 
period of about 10 days.” R224 
“Our town has a 4-6 weeks wait to see regular GP.”R268 
Expired prescription  
*n= 19 
“Medications [repeats] do not run, but prescriptions do 
e.g. Thyroxine.” R279 
“Prescription has expired- usually for OCPs [Oral 









“Lost their script after taking last dose of a previous 
supply.” R87 





“Too busy to see [the] doctor. They have not had time to 
go to [the] doctor.” R282 
“Cannot get away from work.” R124 
“Financial hardship to visit [the] GP.” R37 
“[They] do not want to pay $ 5 charge Dr`s charge on 
scripts.” R64 
Doctor related reasons 
*n= 4 
“Dr insists unnecessary on not providing repeats.”R267 
“[The] Specialist told GP to change meds [medications] 
but GP not aware of any change.”R227 
“They are reluctant to see another doctor if they could not 




commonly a prescription could not be obtained without a consultation. This then resulted in a 
need to “squeeze” the GP’s schedule, thus impacting of their service to other patients.[30]  
Some patients may be unable to obtain an appointment not only immediately but also even 
within several days, particularity those in remote areas. This difficulty in making appointments 
was also reported by Services for Australian Rural and Remote Allied Health (SARRH).[42] 
SARRH cited this reason to justify its support for the CD, It is worth mentioning that when 
the AMA announced its opposition to the CD, the AMA claimed that surgeries have 
arrangements to address this issue.[43] However, it seems these arrangements are not enough 
to face the high demand for urgent appointments.[30] This demand may be increased by other 
factors that were reported by the study participants; lack of responsibility or proper planning 
by consumers, uncontrolled reasons such as lost prescription/ medication, travel, regular 
doctor on leave, lack of time, and other constraints such as work or financial hardship. It is 
worth stating that the reasons we report were obtained from a sample of pharmacists not from 
patients. Hence, we cannot exclude bias in reporting. However, most of the reasons have been 
cited in previous publications.[30, 42] 
4.4.5 Conclusions 
There are several reasons for urgent supply requests for medications without a valid 
prescription. These reasons are centred around the patient’s inability to obtain a new 
prescription for the regular medications. Health policymakers must consider implementing 
solutions that reflect the magnitude of this issue. Expanding the medications available through 
CD is one possible solution. This could be facilitated by providing pharmacists with access to 








4.5 Part C: Pharmacists attitudes towards CD 
4.5.1 Introduction  
Continued Dispensing (CD) was implemented in Australia in September 2013,[7] except in 
the state of Queensland.[21] It aimed to minimise treatment interruption when patients run out 
of their medications and are unable to obtain a new prescription to replenish their supply.  
As a theoretical model “Medication Maintenance” (MM) was the hypothetical version of the 
current CD. It was initially proposed by Bessel et al. in 2005,[9] to avoid patients running out 
of medication in Residential Aged Care Facilities (RACF) when all repeats were consumed 
and there was no valid prescription before the GP’s next regular visit. The proposed solution 
was to allow pharmacists to “generate a PBS reimbursable form to authorise one month’s 
supply”.[9] All RACF patients were considered eligible and no particular medication classes 
were proposed to be eligible pending further consultations; however, there was a suggestion 
to exclude medication of abuse. There were also some proposed requirements such an ongoing 
need for the medication, the patient had to have been reviewed by a medical doctor, and the 
patient’s ‘condition was stable without significant side effects. In addition, the MM model was 
restricted to one supply. Bessel et al. recommended implementation of the MM model initially 
within RACF.[9] This model was criticised because it was only a “postponement rather than a 
solution” and because of concerns about inappropriate continuation of the supply.[44]  
The CD model has some basic components of the MM model such as restriction to one supply 
and the need to inform the prescriber about the supply. However, the key difference is the 
implementation setting, i.e. community pharmacy rather than only RACFs. Thus the CD 
method encompasses more potential users, however the eligible medications were restricted 
to Statins and oral contraceptives (OCs). Under the CD model, medication supply can only be 
done once in any 12 months period. Patients must be at least six months on the same 
medication. In addition, CD guidelines also involve documentation of CD activity by the 
pharmacist.[45]  
The CD method was implemented to complement other urgent medication supply methods 
that can be conducted without a valid prescription (i.e. Emergency Supply [ES]) or without an 
official paper prescription, only a verbal or faxed prescription (i.e. Owing Prescription [OP]). 
[46] The Owing Prescription (OP) system which is a legal way to supply one additional repeat 
without a hard copy of the prescription, however the pharmacist must contact the original 




not require a valid prescription, written or verbal. However, only limited amount of the 
medication can be supplied. 
The OP method requires a verbal authorisation by the prescriber and a follow up prescription 
and because of this it may be refused to be utilised by pharmacists. On the other hand, patients 
may refuse the ES method as a result of cost involved.[32] In addition, non-regular customers 
may not be supplied due to their inability to provide enough information to allow safe 
dispensing.[7] These factors may cause treatment interruption and increase the risk of patient’s 
non-adherence to their medications. Moreover, the requirement that the prescriber should send 
a follow-up prescription, to allow pharmacists to apply for reimbursement from the PBS 
system, has the potential to increase the work load on prescribers without any income.[7]   
The CD model of medication supply was designed to address these drawbacks and increase 
patient adherence.[47] Also, providing patients with a timely and convenient way to obtain 
their medications when obtaining an appointment with the prescriber was impractical.[7] Even 
though some surgeries have their arrangements for urgent appointments, this system may not 
be adequately effective.[30] While the AMA has announced its opposition,[43] the Consumers 
Health Forum of Australia (CHF), [48] other organisations,[42, 49, 50] members of the 
community,[51] and users of Statins and OCs,[7, 10] have already shown their support for CD. 
In addition, CD supporters recommend more chronic disease medications be included and 
more frequent utilisation opportunities to cover patients’ needs.[10, 42, 52]      
4.5.2 Aims 
Community pharmacists’ attitudes towards the current CD, its expansion (to include more 
eligible medication) and extension (to be used more frequently) have not been researched thus 
far. Therefore, the aim of this study was to explore these attitudes.  
4.5.3 Methods  
More details on the methodology employed are reported above in Section 4.3.2. In brief, a 
self-administered questionnaire (Appendix 4.2) was sent to 1490 randomly selected 
pharmacies within Australia. A 20% sample was chosen as it allows a representative sample 
to be drawn from a large number of potential respondents. 1490 questionnaires were 
distributed with an anticipated response rate of approximately 40% (it was anticipated to lead 
to approximately 600 responses, with 95% confidence level with +/-2.5 confidence interval. 




currently eligible CD medications (Statins and OCs), and for the possible inclusion of more 
medications under the CD system. Participants were asked to indicate from list of 17 
medication classes (developed from a literature review) which they believed could be 
included. This list was similar to the list of medications used in our previous survey of Statin 
and OCs users.[10] Further, there were additional questions that focussed on participants’ 
support of CD extension (i.e. to be utilised more frequently). Finally, participants were asked 
about their level of agreement with statements about: (a) CD increasing patient adherence to 
medications, (b) CD decreasing waste production, (c) the prescriber annotating the 
prescription to allow or disallow CD, and (d) their support for pharmacists’ access to patients’ 
electronic health records. This study was conducted less than one month before CD 
implementation in Australia, and a reminder was sent one month later. Therefore, although 
pharmacists were aware of CD, it is unlikely that their responses were affected by any 
experience with the CD. This should minimise potential bias arising from actual experience 
with CD. 
4.5.3.1 Ethics approval 
This study was approved by The Human Research Ethics Committee of Curtin University 
(Approval number: PH-07-13). (See Section 4.3.2.2 and Appendix 4.3) 
4.5.3.2 Data Analysis  
The data analysis process in part has already described in Section 4.3.2.3. A 5 point Likert 
scale was used to assess participants’ agreement levels. For the purpose of statistical analysis 
responses were collapsed to: Agreed (strongly agree and agree), Disagreed (strongly disagree, 
disagree), Neutral/ Preferred not to disclose, and missing answers. The option ‘Other; please 
specify’ was also used to provide additional qualitative data. The analysis of quantitative data 
was conducted by using SPSS (version 22). The participants were divided into groups of two. 
Firstly, according to the age they were (≤ 40 years old, and >40 years old,). Secondly, 
according to gender (male participants and female participants). Finally, according to 
pharmacy location, into participants working in urban areas and participants working in rural 
areas. The Mann-Whitney test was used to find any difference between these groups. Wilcoxon 
test was used to find the difference between participants’ decisions according to customer type 
for the same medication class (e.g. compare responses about asthma medications for regular 
customers vs. non-regular customers). Chi-square and nominal logistic regression tests were 
used to identify any significant relationships between independent variables (gender, age, 




oral hypoglycaemic medications). 
The qualitative data were obtained through participants’ answers to open-ended questions and 
their comments on the option ‘Other; please specify’. This type of data was thematically 
analysed. Answers and comments were analysed to identify themes and subthemes, using 
Nvivo (V10 for Windows®). The study team agreed on the concluded themes and subthemes. 
The content analysis was done by counting how many times a theme or subtheme was 
repeated. A star sign and a number (e.g. *n=10) was used to indicate the number of repetitions 
of the theme (or the subtheme). If a comment was made by only one participant, then the term 
‘additional note’ was used to described such comments. 
4.5.4 Results 
4.5.4.1 Demographic data 
See section 4.3.3.2 for more details. Briefly, there were 385 participants (54.5% were males). 
The response rate 37.9% and 48.8% of participants were ≥ 40 years old. The majority of the 
participants were working in urban areas with only 26% working in rural areas. None of the 
participants was from the NT (Northern Territory). 
4.5.4.2 Participants’ support for the current CD 
Study participants highly supported dispensing of Statins and OC using the CD method for 
regular customers. Statins were supported by 89.1% (343) and OC by 87.8% (338) of the 
participants. The support for supply of these medications through the CD method was far less 
(p values were < 0.0001) in the case of non-regular customers. Only 51.4% (198) of the 
participants supported Statins, and 52.7% (203) supported OC. 
4.5.4.3 Additional comments about CD 
Participants provided further comments about CD. These commentaries reflected their 
attitudes towards the current CD and what modifications they thought should be made to the 
current CD. These comments can be divided into negative, conditional (modification 
required), or positive views. These comments were reported in different parts of the 
participants’ response mainly to Question 19 of the questionnaire about what solutions they 
could suggest for the issue of patients requesting medications without a valid prescription. 
Below is a thematic analysis from the verbatim transcription of their responses (any comment 




Theme 1: Negative views: Identified disadvantages of the CD (*n=8)  
Negative views were expressed by participants who were concerned about the disadvantages 
of CD. The following disadvantages were identified by study participants.  
Subtheme 1.1: CD is a bad idea (*n=5)  
Some participants were concerned about: a) how patients would receive the CD especially 
participants who do did not understand why they need a prescription for non-eligible 
medications or why they cannot obtain another supply within a 12 months period, b) CD makes 
patients reliant on pharmacists and therefore they do not take responsibility to arrange 
appointments to obtain prescriptions and c) concerns about GPs’ acceptance of CD. This is 
illustrated by the comments below: 
“Continued supply is a very bad idea, customer will not understand its limitation and further 
make life hell for pharmacist.” R231 
“A pharmacist is not in the position to decide if therapy with any agent should continue. We 
have no access to any medical results (e.g. blood tests).” R386 
“It is [the CD] further making the patient not take responsibility for their own health.”R180 
“The GPs I work with will not agree with continued dispensing.” R286 
“I do not agree with continued dispensing.” R170 
Subtheme 1.2: Abuse potential (*n=3) 
Participants were also concerned about CD abuse by patients who may avoid visiting their 
doctor or obtain medication of abuse potential. Concerns were also raised about CD abuse by 
some pharmacy owners or particular pharmacy groups, as illustrated by the comments below:    
“Patients’ abuse of CD.” R13 
“Continued dispensing will be a program that will be exploited by pharmacy owners.” R286 





Theme 2: Conditional views: Modifications required (*n= 6) 
Some participants suggested that the current CD needs modification. 
Subtheme 2.1: CD expansion (*n=2) 
Participants thought the current CD does not provide enough solutions for patients prescribed 
multiple medications. Thus, they suggested addition of more medications. This is illustrated 
by the comments below: 
“CD should not be restricted to Statin & OC. We should be able to supply a wider range of 
medication to actually improve the compliance of the patient e.g. Antihypertensive, 
Antidepressants etc.” R294  
“Increase the scope of medicines that can be issued under CD, not just 2 currently.” R270 
Subtheme 2.3: Pharmacists remuneration (*n= 3) 
Some participants complained that they usually do not obtain payment that reflects the amount 
of work they do. See comments below: 
“Pharmacists already do more than we are remunerated for.” R286  
“They need to pay a fee – so we can continue providing their service as I have no doubt that 
they will take more of the pharmacist time i.e Talking to the patient , reviewing their history, 
making sure of the correct dosing + strength. If you are going to push for their CD` service, 
then you must push for reimbursement to the pharmacist/ pharmacy for providing it from the 
beginning. We are sick of doing this For Free. Our service becomes de-valued by consumer!!” 
R206 
“Consider the time and effort needed by the pharmacist when facing this situation.” R54 
Additionally, one participant thought the currently eligible medications (Statins) might not 
require an urgent supply, and they suggested that more urgently needed drugs should be 
available. 
“Depending on the medication and whether regular, daily therapy is essential for safety, 
e.g. cardiovascular therapy as opposed to say a Statin whereby missed doses/ time is not 




Theme 3: Positive views: Identified CD advantages (*n= 6)  
On the other hand, there were positive attitudes towards CD as shown below. 
Subtheme 3.1: Less administrative burden (*n= 5) 
Some participants thought the CD has the advantage of “no prescription need”, hence posed 
less of an administrative burden. This would enable patients to be more adherent, and 
encourage pharmacist supply. This is illustrated from the comments below: 
 “I worry about customers having OP scripts [Owing Prescriptions] for say Seretide®, never 
dispensed wanting an owning. But generally a great idea less waste + less chasing up owing 
scripts!! & better patient outcomes due to continued supply. I work with some pharmacists 
that would not even give an emergency supply for an antidepressant if they have not been to 
us before & that causes worse patient outcomes.” R240 
R145“Continued dispensing is the way to go! [for emergency supply of medication without a 
valid prescription].” R258 
In addition one participant suggested CD provided an opportunity for medication review as 
CD involves consultation with patients, and hence a good opportunity to identify any 
medication-related issues, such as side effects or drug interactions.  
“Good opportunity to assess treatment and it is progress.” R301 
4.5.4.4 Participants’ support of CD expansion 
Participants were asked to show their support to include more medications into the CD method 
(i.e. CD expansion). They were presented with a list of 17 medication classes plus those 
already eligible under the current CD method (i.e. Statins and OCs). Their responses are 
summarised in Table 4.4. 
The first finding of this study was that the already eligible medications for CD were supported 
by ~ 87-89% of participants for regular customers and by ~ 51-52% for non-regular customers. 
However, these medications were not the most supported medications to be available through 
CD by participants. The most supported medications were antihypertensives for regular 
customers (90% agreed) and asthma medication for non-regular customers (53% agreed). 
Customer type significantly influenced participants’ support for inclusion in the CD method. 




provisions for regular rather than non-regular customers (p < 0.0001, using Wilcoxon test). 
Participants’ support to include particular medications within CD provisions differed 
according to customer type. All medications, but four, were supported by the majority (i.e. 
more than 50%) of participants in the case of regular customers. This was in contrast to non-
regular customers for whom there were only four medications supported by the majority of 
participants including the two already available under the current CD (i.e. Statins and OCs). 
The support was stronger (61-90%) in the case of regular than non-regular customers (51-
53%). The support to include opioids, in particular, and medications such as anti-anxiety, non-
opioid analgesics and medications to treat schizophrenia was very low for both customer type. 
The participants were more likely to choose “Neutral” than “Disagreed” in the case of the 
regular customers. However, in the case of non-regular customers they tended to select 
















Table 4.4 Participants’ agreement and disagreement to include the selected medications under the CD provisions  
Medication/ disease Regular customer Non-regular customer 
Agree (%) Neutral (%) Disagree (%) Agree (%) Neutral (%) Disagree (%) 
Antihypertensives 347 (90.1) 13 (3.4) 18 (4.7) 191 (49.6) 67 (17.4) 95 (24.7) 
Asthma 343 (89.1) 18 (4.7) 18 (4.7) 204 (53.0) 63 (16.4) 86 (22.3) 
Statins 343 (89.1) 15 (3.9) 21 (5.5) 198 (51.4) 65 (16.9) 90 (23.3) 
COPD 339 (87.8) 23 (6.0) 16 (4.0) 197 (52.7) 69 (17.9) 87 (22.6) 
OC 338 (88.1) 20 (5.2) 18 (4.7) 203 (51.2) 64 (16.6) 86 (22.3) 
Non-Statins 323 (83.4) 27 (7.0) 26 (6.0) 189 (47.0) 72 (18.7) 92 (23.9) 
Hypoglycaemic 321 (83.1) 22 (5.7) 30 (7.8) 181 (49.1) 67 (17.4) 104 (27.0) 
GORD 314 (81.6) 30 (7.8) 32 (8.3) 184 (47.8) 64 (16.6) 105 (27.3) 
Glaucoma 294 (76.4) 38 (9.9) 40 (10.4) 178 (46.2) 71 (18.4) 103 (26.8) 
Hypothyroidism 284 (73.8) 53 (13.8) 39 (10.1) 149 (38.7) 92 (23.9) 111 (28.8) 
Arthritis 284 (73.8) 60 (15.6) 32 (8.3) 158 (41.0) 85 (22.1) 110 (28.6) 
Hyperthyroidism 263 (68.3) 64 (16.6) 48 (12.5) 140 (36.4) 89 (23.1) 123 (32.0) 
Anticoagulants 256 (66.5) 53 (13.8) 61 (15.8) 143 (37.1) 62 (16.1) 144 (37.4) 
Psoriasis 241 (62.6) 76 (19.7) 61 (15.8) 139 (36.1) 81 (21.0) 133 (34.5) 
Antidepressants 235 (61) 58 (15.1) 82 (21.3) 124 (32.2) 72 (18.7) 156 (40.5) 
Schizophrenia 175 (45.5) 71 (18.4) 127 (33.0) 94 (24.4) 80 (20.1) 178 (46.2) 
Non opioids 153 (39.7) 66 (17.1) 155 (40.2) 74 (19.2) 74 (19.2) 204 (53.9) 
Anxiety med 105 (27.3) 86 (22.3) 183 (47.5) 47 (12.2) 68 (17.7) 236 (61.3) 




4.5.4.5 Effect of demographics 
Gender, age and pharmacy location significantly affected participants’ support to include 
the listed medication (Table 4.5 displays more details). Significant differences were detected 
for the gender variable in 12 cases out of 38 (31.6%), in four cases (10.5%) for the age variable, 
and in one case (2.6%) for the location variable. Males and /or older participants were more 
likely to show stronger support than females and/or younger participants. Except for 
antidepressants for non-regular customers, in which case stronger support was indicated by 
the younger participants. 
The only effect of pharmacy location (i.e. Metropolitan vs. Rural) was for the inclusion of 
opioids for regular customers which was supported more by participants working in rural areas 

















Table 4.5 Statistically significant effects of demographic variables on participants’ support of 
the CD 


















Male* (n=210) 22 (10.5)  188 (89.5) 0.0001 
Female (n=155) 40 (25.8) 115 (74.2) 
Non-opioids Male* 111 (52.9) 99 (47.1) 0.0001 
Female 112 (72.3) 43 (27.7) 
COPD Male* 19 (09.0) 191 (91.0) 0.042 
Female  25 (16.1) 130 (83.9) 
Arthritis Male*  45 (21.4) 165 (78.6) Male 
Female  53 (34.2) 102 (65.8) 
Glaucoma Male*  41 (19.5) 169 (80.5) 0.018 
Female  47 (30.3) 108 (69.7) 
Non-Statins Male*  25 (11.9) 185 (88.1) 0.007 
Female  35 (22.6) 120 (77.4) 
Non-regular  Oral 
hypoglycaemic 
Male*  99 (47.4) 111 (52.9) 0.011 
Female  94 (60.6) 61 (39.4) 
Antihypertensiv
es  
Male*  91 (43.3) 119 (56.7) 0.004 
Female  91 (58.7)  64 (41.3) 
COPD** Male*  92 (43.8) 118 (56.2) 0.038 
Female  85 (54.8) 70 (45.2) 
Glaucoma Male*  102 (48.6) 108 (51.4) 0.031 
eFameF 93 (60.0) 62 (40.0) 
Statins  Male*  91 (43.3) 119 (56.7) 0.030 
Female  85 (54.8) 70 (45.2) 
Non-Statins Male*  95 (45.2) 115 (54.8) 0.022 
Female 89 (57.4) 66 (42.6) 
Regular  Anxiety  ≤ 40 (188) 148 (78.7) 40 (21.3) 0.012 
˃ 40* (192) 129 (67.2) 63 (32.8) 
Hypothyroidism
  
≤ 40 60 (31.9) 128 (68.1) 0.015 
˃ 40* 40 (20.8) 152 (79.2) 
Hyperthyroidis
m  
≤ 40 69 (36.7) 119 (63.3) 0.045 
˃40*  52 (27.1) 140 (72.9) 
Non-regular Antidepressants  ≤ 40* 117 (62.2) 71 (37.8) 0.027 
˃ 40 140 (72.9) 52 (27.1) 
Regular  Opioids  Metropolitan 
(n=279) 
257 (92.1) 22 (7.9) 0.043 




4.5.4.6 CD extension 
Participants were asked (Q15) to report their views on the current frequency of CD utilisation 
(i.e. once in any 12 months period) and their support to increase the frequency of utilisation 
(i.e. an extended version of CD). 
Just over half of the participants (51.4%; n=198) agreed with the current utilisation frequency 
of CD. The remainder did not agree with the current restriction and suggested more frequent 
CD. This included 116 (30.1%) who supported twice in any 12 months CD, 53 (13.8%) who 
supported utilising the CD three times in any 12 months, and 17 (4.4%) who supported CD 
availability until it is possible for the patient to obtain a renewed prescription. One participant 
(0.3%) did not answer the question. 
4.5.4.7 Participants’ comments about CD extension 
Participants were asked to give reason(s) for their answers to the Q15. A thematic analysis of 
these comments was then undertaken and the results of which are provided below.  
Analysis of the comments, provided to explain why the participants selected a 
particular frequency of CD, revealed that were a three main themes that emerged from 
these comments: 1) Why the frequency must not be increased, 2) Why a particular frequency 
is needed, and 3) The CD frequency should be left at the pharmacist discretion (See Table 4.6). 
Theme 1: Why the frequency must not be increased (Safety must always be priority) 
This theme has been repeated 216 times, which is far more the other two themes. This theme 
emerged from participants who were trying to explain that the CD frequency, which they had 
selected, must not be increased otherwise there would be negative consequences. For example, 
decrease in medical reviews by doctors and/or abuse of the system. Therefore, the theme was 
generally related to justifying maintaining the status quo (i.e. one CD/ 12 months). More 
details are given below. 
a. The need for medical review  
The need for the medical review was the most cited reason to limit the frequency of CD 
utilisation, because any increase potentially decreases the chance for a review by the doctor. 
This reason was cited a total of 101 times. By 78 (77%) participants to defend why CD must 




limited to twice in 12 months. The following examples illustrate the participants’ reasons for 
the need for medical reviews: 
“Patient’s condition may change and needs to be checked/assessed by a medical practitioner.” 
R111 
 Patient need to have follow up/ check-up regularly to ensure that their condition is under- 
control.” R84 
“Community pharmacy setting does not allow for proper monitoring on long-term basis. 
Changes may not be picked up and differences in therapy cannot be detected.” R147 
b. Patient must take more responsibility  
This subtheme was repeated 41 times, to justify why frequency of CD utilisation must not 
exceed once (29; 71%) or twice (7; 17%), in any 12 month period. Participants thought some 
patients did not make enough effort to arrange for appointments before they ran out of 
medications. Therefore, they were concerned that more frequent CD may encourage patients’ 
dependence on pharmacists. This subtheme is illustrated by the following examples: 
“Patients must take responsibility for their own medication management. More frequently CD 
encourages laziness/ apathy / irresponsibility.” R180 
“Increased frequency will reduce customers’ incentive to take responsibility for their own 
health.” R195 
c. Potential abuse of CD by patients  
This subtheme was repeated 38 times. It was mainly used to justify why CD must not be more 
than once in any 12 months in the majority of cases (84%). Participants who cited this reason 
to limit CD were concerned that any increase in CD frequency will increase the probability of 
patient abuse of the system to obtain medications without visiting their doctors. This can be 
illustrated by the following examples:  
“To avoid the customer choosing not to see their primary healthcare provider.” R279 
“Some patients may take advantage of this to avoid seeing the doctor. Also, chronic conditions 




d. The selected frequency provides enough time  
This was assigned as a low relevance subtheme. It was repeated 24 times and was only used 
to defend why CD must not be no more than once (83%) or twice (17%) in any 12 months 
period. As illustrated by the following example: 
“Once is enough, people need to make arrangement & also see their doctor at least annually.” 
R287 
e. CD must be emergency only  
This theme was assigned very low relevance as it was repeated only 12 times. It was mentioned 
only to justify why the CD must be limited to once in any 12 month period. The following is 
an example of such comments: 
“Since it is an emergency supply and should be enough.” R148 
 Theme 2: Why a particular frequency is needed (Improve access to medications) 
This theme emerged from those who were defending the number they selected (regardless of 
the number). For example, some of participants who selected once in any 12 months and others 
who selected twice stated that the nominated frequency provides enough time to obtain an 
appointment with the doctor. This theme was more commonly used to defend an increase to 
twice in any 12 months. This theme has three subthemes: 
a. Appointment difficulty/Doctors availability 
This subtheme was repeated in comments 51 times, and it was used to explain why the 
participant chose a specific frequency of CD. For example, this theme was used 28 times (55%) 
to defend that CD must be twice in any 12 months period. Participants stressed the difficulty 
and delays in obtaining an appointment because of high demand which resulted from doctors’ 
shortages. As illustrated by the following examples: 
“Shortage of GP`s, many times – Dr only writes Rx- no consultation – increase load to [the] 
Medicare for no extra service – will free our Drs time.” R37  
“It is very hard to get appointment with Drs these days, px [patients] cannot get in at their right 




b. Allow continuity of treatment and regular medical review  
This subtheme was repeated 48 times mainly to justify the use of CD once in any 12 months 
by 44% of the participants and twice by 35%. Here participants thought that these CD 
frequencies were reasonable, because while easing access to medications they still ensure 
medical review by doctors at least once annually. As illustrated by these comments: 
“To provide continuity of medication, but still need to see Doctor every 6 months.” R346 
“Patient who has co-morbidities should regularly checked to prevent progression of disease. 
Occasional supply without script under certain circumstances provided patient is stable should 
be acceptable.” R303 
c. Prescription life span 
Forty-eight participants reported the above reason to justify their selection of the CD 
frequency. Since the majority of participants (82%) mentioned a six months life span for 
chronic disease prescriptions, this subtheme was mainly used to explain why the frequency of 
CD utilisation should be increased to twice in any 12 months. An example of these comments 
is:  
“Each Rx [prescription] is only for 6 months, so 1 extra supply per Rx [prescription] is 
considered acceptable.” R23 
Theme 3: CD frequency should be left to the pharmacist’s discretion (Pharmacist skills) 
This theme has emerged from participants who, although they selected a frequency of CD, 
they thought the CD frequency should be decided by the pharmacist who faced the request for 
urgent supply. Here the pharmacist would consider all influencing factors such as the 
medication type and the probability to obtain an urgent appointment. This theme was generally 
used to justify a greater frequency of CD. There were two subthemes emerged from this theme: 
a. Pharmacists are able to manage 
This subtheme emerged from 16 comments used to justify more frequent CD, particularly three 
times in any 12 months (in 8 cases; 50%). As illustrated by this example: “A pharmacist can 
easily use their professional discretion to determine where there is a genuine need for 




done for many years – CD will formalise and legalise this practice.” R208. 
b. According to the situation 
This subtheme was also mentioned 16 times. Interestingly, this subtheme was used by 
approximately 25% of participants to justify each selected frequency (See Table 4.6). This 
example illustrates this subtheme: “It is dependent on circumstances & no hard & soft rule 
should apply. Professional judgment should be applied.” R51 
Table 4.6 Reasons for participants’ selection of a particular CD frequency number 












must not be 
increased  
The need for medical review  (101) 0 (no CD) 1 (0.9) 
1 78 (77.0) 
2 18 (18.0) 
3 4 (4.0) 
Anytime#  1 (1.0) 
Patient must take more responsibility (41)   1 29 (71.0) 
2 7 (17.0) 
3 3 (7.0) 
Anytime  1 (2.0) 
Potential abuse of CD by patients (38) 1 32 (84.0) 
2 4 (11.0) 
3 2 (5.0) 
The selected frequency provides enough time 
(24) 
1 20 (83.0) 







Appointment difficulty/Doctors availability 
(51)  
1 8 (16.0) 
2 28 (55.0) 
3 13 (25.0) 
Anytime  2 (0.04) 
Allow continuity of treatment and regular 
medical review (48) 
1 21 (44.0)  
2 17(35.0)  
3 8 (17.0) 
Anytime 1(0.2) 
Prescription life span (46) 1 3 (7.0) 
2 38 (82.0) 
3 3 (7.0) 
Anytime 2 (4.0) 
Theme 3 
 (32)  
CD frequency 




Pharmacists are able to manage (16) 1 2 (12.0) 
2 4 (25.0) 
3 8 (50.0) 
Anytime  2 (12.0) 
According to situation (16) 1 4 (25.0) 
2 4 (25.0) 
3 3 (19.0) 
Anytime  4 (25.0) 











Figure 4.4 displays where each theme was cited most. Theme 1 was mainly used to justify one 
CD, Theme 2, was mostly used to justify two CD, Theme 3 was mostly used to justify three 
CD. It can be concluded that participants who were concerned about negative consequences 
of more frequent CD were more likely to cite Theme 1 (Safety always must be priority) which 
included five subthemes: The need for medical review, Patients must take more responsibility, 
Potential abuse of CD by patients, The selected number provides enough time and, CD must 
be for emergency only. Participants who were more concerned about urgent access to 
medication in urgent situations were more likely to cite Theme 2 (Improve access to 
medications), which included: Appointment difficulty/Doctors availability, Allow continuity 
of treatment and regular medical review, and Prescription life span. Participants who wanted 
more flexible CD cited Theme 3 (Pharmacist skills), which included Pharmacist able to 
manage, and According to the situation. 
4.5.4.8  CD advantages, annotation and health record 
Participants indicated their level of agreement/disagreement with the statements presented in 
Questions 17(17.1-17.4) and 18. The first three statements were about potential advantages of 
CD (i.e. CD advantages question). The fourth statement was about a suggestion to allow 
doctors to annotate the prescription to make it clear that the medication is not to be continued 
without review by the treating medical practitioner (i.e. doctor’ annotation question). Question 
18 was about pharmacists being able to supply according to the Patient Controlled Electronic 
Health Record without the need for a hardcopy prescription (i.e. Health Record question). 











Table 4.7 Participants’ agreement with CD advantages, annotation and health record 
# ‘OP’: OWING PRESCRIPTION  
In general, the majority (80.8-84.9%) of participants agreed with all the proposed advantages 
of CD, and 84.9% agreed with suggestion to allow doctors to annotate patients not suitable for 
CD. However, only 68.6% of participants agreed with the Health Record question (i.e. 
pharmacists should be able to able to supply according to Patient Controlled Electronic Health 
Record without the need for a hardcopy prescription). Multinominal regression analysis 
revealed that male participants agreed more that ‘CD may increase patient adherence’ (p = 
0.002), and younger (p= 0.026) and male participants (0.024) agreed more that ‘CD may 
alleviate the administrative burden of the OP compared to older and/or female participants.   
4.5.4.9 Comments about Doctor Prescription Annotation  
While the majority agreed with doctor annotation, there were some participants who voluntary 
reported additional comments about the Q17.4. See below: 
Additional note 1: Overuse of annotation: some doctors may use this authority to prevent CD: 
"Note @ question 17.4 above- some medications would only be appropriate for supply after 
review by doctor, if patient is unstable, however some doctors will ‘ tick the box’ block supply 
all the time to prop up their visits therefore income.” R246 
 

















Q17.2 CD is likely to lessen the administrative 







Q17.3 CD will decrease the wastage that occurs 
when an original pack of medication has to be 
broken to adhere to the Emergency Supply 








Q17.4 The prescriber should be able to annotate the 
prescription to make it clear that the 
medication is not to be continued without 







Q18 Pharmacists being able to supply according to 
Patient Controlled Electronic Health Record 










Additional note 2: Annotation may be impractical 
Pharmacists may not be able to know doctor’s decision (doctor annotation) if the customer did 
not present the previous paper prescription. The comment below by one of the participants 
illustrates this issue: 
 “Agree [with doctor annotation] but how do we know if we do not see the script at the time 
of continued supply.” R211 
4.5.4.10 Suggested solutions to address urgent medication requests 
The study participants were asked to suggest solutions for urgent medication requests without 
a valid prescription. Thematic analysis of these comments produced 6 themes and 18 
subthemes (Figure 4.5). The star sign and the number, for example, *n=46, indicates that there 
were 46 participants who suggested the theme “better use of technology”, and *n=9 indicates 













Theme 1: Better use of technology (*n=46) 
Five subthemes emerged from this theme. The participants thought that technology could 
provide the following benefits: 
Subtheme 1.1: Communication with the prescribers and access to health record 
(*n=25) 
Participants suggested more communication with the prescribers and access to health 
record. The following examples illustrate this: 
“Better Electronic communication between doctor & pharmacist.” R28  
“Being able to access health record of non-regular customers.” R222 
Subtheme 1.2: Electronic prescription system (*n=9) 
Electronic prescription system was also suggested. The following examples illustrate this: 
“Access to ERx [Electronic Prescription] data?” R11 
 “Rx [prescription] request and response system.” R75 
“Better interaction in our dispensing software & DR [doctor] s` software to request new Rxs 
[Prescriptions].” R28 
Subtheme 1.3: Reminder system (*n=7) 
A reminder system was also suggested: 
“SMS reminder service – notifies if last repeat.” R66  
Subtheme 1.4: Appointment booking (*n=3) 
Appointment booking was also suggested:  
“Medical practice could forward book appointment & use SMS messaging to request patients 





Subtheme 1.5: Prior approval (*n=2) 
Prior approval  was also suggested: 
“Prior Dr approval for continued supply via electronic record & approval” R37 
Theme 2: Modification of the current system (*n=44) 
Participants suggested modifying the current medication supply systems, and five subthemes 
emerged in this regard: 
Subtheme 2.1: Owing Prescription (OP) modification (*n=15) 
Participants mentioned the following modifications to the OP system: 
A. To avoid issues of obtaining a prescription 
“Pharmacist should be able write a once off Rx after confirmation with Dr [doctor] that will 
minimise the paperwork and also gives time (28-30 days) for Pt [Patient] to seek regular GP 
for check-up/ Rxs [prescriptions].” R158 
“Penalties on doctors not supplying Rx`s [prescriptions] after faxed requests from pharmacists 
after writing up treatment charts for nursing home patients. Pharmacists left holding the bag 
legally.” R328 
B. Stop patients abuse of OP 
“The inclusion of PBS legislated owing script fee paid by the patient may encourage patients 
to be more aware of how many repeats they have left.” R65 
 “Owing Rx`s should be outlawed; if you run out of medication then you must see your Dr 
[doctor] or pay a private price for one month continuation of supply. This would save on all 
the administrative work as well as forcing the patient to see the Dr [doctor].” R163 
Subtheme 2.2: Emergency supply (ES) modifications (*n=10) 
Most suggestions were about increasing the quantity available through ES. The comments 




“Emergency supply should allow for one original pack to be supplied rather than just 3 days.” 
R162 
“The sample size packs ( normally 1 week) that drug companies give to GP ( doctors) to start 
the patients on – should be made available, even if is at cost, to pharmacies to on sell to patients 
if they need them.” R7 
“The legal supply is for 3 days only as emergency supply. 3 days’ supply is not sufficient when 
most patients cannot get an apt [appointment] within 3 days. 3 days should be extended to one 
week.” R212 
“I think 3 days ES is not enough time for a lot of people – 7 days would be better and could 
keep the same arrangements intact as present for everything else.” R227 
Subtheme 2.3: More legal prescriptions (*n=10) 
Allowing faxed and emailed prescription was also suggested to address issues of delays in 
obtaining a new prescription from the doctor. The following examples illustrate this: 
 “Law can allow faxed prescriptions to be valid as long as the original is posted to the 
pharmacy.” R207 
“Email your GP who emails script to pharmacy.” R8 
Subtheme 2.4: Repeat system modifications (*n=6) 
The repeat system was also another area of suggested modifications: 
Allow non-medical control over repeat system 
“Regular nurses supplying repeat script at surgeries as long as monitoring is completed 
annually.” R269 
“Using repeat authorisation in your pharmacy and request direct to Dr [doctor] if more repeat 
are needed.” R101 
“If the Dr [doctor] placed an electronic note in the patient’ file as to whether or not they would 
be ok with an emergency / owing supply then we could ring up with the clinic and the 





Extend time frame of the repeat system 
 “Longer repeats e.g. why not make Oral contraceptive last for 2 years of 11 rpts [repeats] for 
Antihypertensives.” R16 
“Increase the expiry date and number of repeats on the prescription.” R151 
Subtheme 2.5: Use an alternative model (*n=3) 
Some participants suggested the use of an “alternative model” (See Section 4.3.3.6). The 
following comments explain this: 
“What about "pharmacy prescriptions" - the pharmacist fill the script and paid by 
Medicare Dispense as owing, however, only supply 3 days’ worth and when patient brings in 
prescription from their doctor, give balance of tablets.”  R147 
“Emergency supply, patients to pay full price then do a refund when scripts have been 
received.” R84 
“Px [patient] pays full private price for 1 week`s supply for a whole pack (like a bond) – then 
gets refund if Rx [prescription] returned.” R227 
Theme 3: More prescribers (doctors/nurse practitioners) are needed (*n=16) 
This comments related to this theme produced two subthemes:  
Subtheme 3.1: More doctors for phone calls in clinics (*n=11) 
This was suggested to increase cooperation by doctor with the OP system. This comment 
explains this subtheme:  
“Dr`s being more contactable for verbal prescription & write late or just allowing pharmacist 
to supply a box to continue.” R169 
Subtheme 3.2: Greater availability of prescribers (*n=4) 




holiday was identified as an issue. The following comments illustrate this subtheme: 
“Quicker access to rural GPs!” R268 
“On call general practitioner or nurse practitioner available in town or by phone.” R131 
 “A doctor being available on weekends and public holidays.” R235 
Additionally one participant suggested; “…..[having] a GP in every pharmacy.” R194 
Theme 4: Educating patients to take responsibility (*n=16) 
Comments supporting this theme related to educating patients to take more responsibility for 
their own medication supply, as illustrated below: 
“Patient education, it is not rocket science to count the number of tablet you have left in the 
pack.” R64 
“More patient education about compliance to increase patient understanding responsibility.” 
R275 
Theme 5: Better use of pharmacists’ skills (*n=10) 
Some participants argued that allowing pharmacists to prescribe would address the issue of 
urgent medication requests without a prescription. The participants did not specify whether 
they meant collaborative or independent prescribing rights.  
“Pharmacist consultation and pharmacist- issued prescription if clinically safe and responsible 
per any prescription issued.” R267  
 “pharmacist is able to prescribe once only for regular medication, if he follows the disease 
state management of his patient.” R220  
Theme 6: Referral to hospitals or emergency department (*n=8) 
Referral to hospitals or emergency department also emerged as solutions. The following 
examples illustrate this theme. 




 “In our town we send the patient to the hospital to get supplied with medications.” R136 
  “We often refuse emergency supply due to accumulation of unsellable stock & instead refer 
customers to the hospital ED [Emergency Department] for scripts.” R195 
4.5.5 Discussion 
This study aimed to explore the Australian community pharmacists’ attitudes towards CD, to 
estimate their support for an expanded CD version (include more medications), and an 
extended CD version (more frequent utilisation). As far as we know, it is the first study in 
Australia to explore community pharmacists’ attitudes towards CD. 
Results of this study confirmed the relevance for the patient being a regular pharmacy 
customer.[7] Participants supported medication supply using the CD method more strongly for 
regular customers than non-regular customers (p values< 0.0001) across a range of medication 
classes. This indicates that participants of this study do not supply unless they have the 
essential patient information they need. This is consistent with CD guidelines which 
recommend that the pharmacist must contact the original prescriber or the regular pharmacy 
of the non-regular customer to verify any information obtained from non-regular 
customers.[45] Moreover, this difference between participants regarding their support of the 
CD according to customer type may be affected by the difficulty to refuse a request from 
regular customers.[4] This may be confirmed by the fact that participants of the current study 
were more likely to select the option ‘Neutral’ if they did not agree rather than the options 
‘Disagree/ Strongly Disagree’ in the case of regular customers. However, in the case of non-
regular customer the participants tended to selected “Disagree/Strongly Disagree”. 
The currently eligible medications for CD (Statins and OCs), were supported by the majority 
of participants, with stronger support for using CD to supply medication to regular customers 
more than non-regular customers. However, other medications (e.g. asthma medication) were 
supported more by participants. The fact that Statins and OCs are already eligible CD 
medications may have affected their support by the participants. This support for 
antihypertensives was explained by participants who commented that antihypertensives are 
more urgently needed than Statins. This is consistent with the AMA, which stated that Statin 
users can safely break their Statin treatment for one or two weeks.[43] However, there are 
studies which have reported harmful effects of short-term Statin discontinuation.[53-55]  




views about the CD and they could be divided into negative, conditional (modification 
required) and positive views. Firstly, the negative views came from participants who thought 
CD may confuse patients prescribed multiple medications because they cannot obtain all 
medications through the CD. This confirms previously reported concerns by Services for  
Australian Rural and Remote Allied Health (SARRAH).[42] It is worth mentioning that 
according to PSA, the pharmacist must not use CD if there is a risk of patient confusion.[45] 
Other participants were concerned about potential abuse of CD by the patients or some 
pharmacy groups, and others thought CD would not be accepted by doctors.[56, 57] Secondly, 
participants with conditional views thought CD must be expanded to include other urgently 
needed medications.[42] Finally,  positive views reflected that CD may alleviate other supply 
systems drawbacks, such as issues with prescription follow up for OP system or quantities 
available through ES.[7, 9] Some participants believed that CD is capable of encouraging 
continuity of care and patient adherence to their medications. Therefore, those participants 
supported the primary driver for CD implementation.[45] 
The study participants supported CD expansion to include more eligible medications from a 
list of medications. This support differed according to customer and medication type. In the 
case of regular customers, all the medications were supported by the majority of participants 
except opioids, anti-anxiety, non-opioids analgesics and schizophrenia. However in the case 
of non-regular customers, only four medication classes (asthma, Statins, OCs, and COPD) 
were supported by the majority of participants. Medication type also affected the level of 
support. For example, opioids were supported by less than 10%. However, antihypertensives 
and antidepressants for regular customers were supported by more than 90% and 60% of the 
participants, respectively. 
In a previous study, about down scheduling selected prescription-only medications (POM) to 
Pharmacists only Medication, 37.7% of respondent pharmacists supported supplying selected 
antihypertensives medications without a prescription, 42.3% for selected Statins, and 51% for 
selected birth control drugs.[58] This level of support is far less than the results of the current 
study, probably because of the differences between CD and POM provisions, where the CD 
does not include diagnosis and establishment of the therapy as in the case in the POM system. 
In another study 85% of respondent pharmacists supported initiating and supplying OCs 
without a prescription.[59] This is consistent with our results, and it potentially reflects that 
patients think they are safe and the pharmacist can provide them without a prescription.[60] 




differences as a result of participants’ demographics. However, in some cases males were more 
likely than females to support CD expansion. This may be explained by the same factors that 
were used to explain why male participants were more supportive to supply medications in 
urgent cases (See Section 4.3.4). In brief, more work experience (gained from working longer 
hours and on a full-time basis) and being pharmacy owners are probably contributing factors 
towards stronger support by males. Also, males were significantly (p values < 0.05) more 
likely than females to see more CD advantage in increasing patient adherence and decreasing 
the administrative burden of OP system. In a previous, study pharmacy owners were more 
supportive to expanding pharmacist roles.[44] Other variables (age and pharmacy location) 
affected only a limited number of responses where older, and participants working in rural 
areas were often more supportive. 
Regarding CD extension, the participants were almost equally divided into two attitudes; 
51.4% of participants were satisfied with the current utilisation frequency of CD (i.e. once in 
any 12 months), the rest of the participants supported more frequent CD. The thematic analysis 
of comments provided by participants to explain why they selected a particular frequency for 
CD revealed that whatever the selected frequency was the participants had tried to balance 
patient safety and improving urgent access to medications. Therefore, there were some 
comments to allow the pharmacist who faced a medication request to decide to use or not use 
the CD depending on circumstances and the clinical status of the requester rather than having 
a fixed frequency as explained by this comment: “As pharmacists we have a strong 
understanding of pharmacotherapy and the considerations based on questioning and history if 
it is appropriate. A set number cannot help define the so many reasons that can arise.” 
Regarding participants’ agreement/disagreement with some statements about the CD, the 
majority of the participants agreed that CD may improve patient medication adherence, [7, 9] 
and overcomes some of other supply system disadvantages.[7] 
Irrespective of concerns expressed by some participants about potential use of this feature to 
prevent appropriate CD supply by some doctors, the majority of the participants agreed that 
the original prescriber should be able to annotate the prescription to make it clear that the 
medication is not to be continued without review by the treating medical practitioner. This 
indicates that the participants are supportive of the AMA’s suggestion to include prescription 
annotation by doctors,[61] and more cooperative communications with prescribers to ensure 
patient safety.[62] This may explain participants’ support of the pharmacist being able to view 




also demanded by participants of a previous study that sought pharmacists’ (and others) 
attitudes towards the hypothesised version of CD (i.e. MM).[9] In this regard, pharmacists 
may inform doctors about all the medication the patient uses including OTC medication.[63] 
Participants were asked to suggest other solutions to medication requests without a valid 
prescription. Three themes emerged from their responses. Firstly, Theme 1: “Solutions to 
decrease the need for urgent supply”. This included solutions using technology to remind the 
patients to book appointments, more prescribers available in rural areas and during 
weekends/public holidays (or at community pharmacies), and patient education. This is 
consistent with a previous report about GP shortages in rural areas in Australia, where “The 
number of services per person in the lowest-access rural areas is less than half that of the major 
cities”. [64] It is also consistent with a previous study in the UK where requests for urgent 
supply tends to be more common during weekends/public holidays.[4] The surprise call for “a 
GP in every pharmacy” is not consistent with doctors shortage in Australia.[42, 65] Moreover, 
in the UK pharmacists are assisting in the relief of the doctors’ shortage through work in GP 
surgeries.[66] Secondly, Theme 2: “Solutions to decrease the need for an urgent prescription”. 
This theme included suggestions by participants about electronic prescribing, better 
communication, and modification of the current urgent supply systems. All of these 
suggestions have been reported in earlier studies [9, 44, 67]. Thus, our results confirm the need 
to review the current systems and implement changes to make them more efficient and 
effective. Participants of the current study also suggested prior approval, more doctors to 
approve the OP, and pharmacist prescribing. Pharmacist prescribing rights was deemed by the 
study participants as other non-medical prescribing in Australia. In Australia nurse 
practitioners, midwives and optometrists have prescribing rights under the PBS.[52] Thirdly, 
Theme 3: “Solution to refer patients who need urgent care by a doctor”, such as referral to  
hospital or emergency departments. Although this is a valuable safety measure, it has the 
disadvantage of applying more pressure on already crowded emergency departments and it 
also may affect access to medical services for more urgent patients.[68] 
Study limitations have been reported in Section 4.3.4. The low response rate was an issue in 
this study. Although participants had similar views regarding their support of CD, CD 
expansion and CD extension, it may be that the non-responders had different opinions. Also, 
non-responders may not have been interested in the CD method due to a lack of experience 
with it, and their satisfaction with the currently available supply methods. This study was 
conducted before CD implementation in Australia. Therefore, future research needs to explore 





The study participants (i.e. Australian community pharmacists), whilst supporting the current 
version of CD, also highly supported CD expansion for regular customers and to a lesser CD 
extension. While some participants reported concerns about the CD method, regarding its 
limitation and potential abuse, others thought CD would overcome disadvantages of other 
urgent supply methods. 
Study participants also suggested other proposed solutions to address or minimise urgent 
requests for medication. Pharmacists’ access to health records and more communications with 
other health care providers may assist the pharmacists to conduct safe and appropriate CD with 
all customers, including non-regular customers. Health policy makers may use results of this 
study to evaluate the current CD system and it may provide scope for enhancements. Other 
suggested solutions to address urgent access to medication should also be further explored. 
4.5.7 Summary of findings 
Given there are three parts in this chapter, below is a summary of the main findings: 
Part A of this chapter showed that pharmacists have different practices in regards urgency 
supply according to type of the customer. They were more likely to supply medications 
urgently, without a valid prescription, to their regular customers than non-regular clients. This 
confirms the need for patients to have a regular pharmacy to minimise treatment interruption 
when obtaining a new prescription is not practical. Prescription-type and medication type also 
affected pharmacists’ decisions to supply. The participants were less likely to supply 
medication in urgent situations if the patient was not regular, the medication had an abuse 
potential, and/or the prescription was an authority prescription. 
Part B of this chapter described the reasons usually cited for urgent requests of 
medications. All the reported reasons were centred around the difficulty to obtain a new 
prescription. These included, doctors/ appointment unavailability. Traveling without 
medications, patients’ unaware of last repeat or its requirements, expired prescription, and 
patients’ lack of responsibility/planning were also reported among other reasons. Health 
policymakers must consider implementing solutions that reflect the magnitude of this issue. 
Part C examined pharmacists’ attitudes toward the current CD and modifications of the CD 




it to be a more practical solution for urgent supply of medication. In particular these included 
the inclusion of more eligible medications, and appropriate pharmacist remuneration. 
Participants also suggested other solutions such as better use of technology and modification 
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Continued Dispensing (CD), is a medication supply method which does not require a valid 
prescription. Only one health professional conducts the CD, namely pharmacists. Therefore, 
there is no “second check” of the process.[1] The pharmacist reviews the patient’s history and 
supplies the medication according to last supply with a valid prescription. While this eases 
access to medication, it has the potential to be used inappropriately.[2] 
In order to optimise CD conduct and minimise the inappropriate use of CD, the Pharmaceutical 
Society of Australia (PSA) has developed guidelines for pharmacists who supply medication 
using the CD method.[3] According to the PSA guidelines, a pharmacist who faces a request 
for an urgent supply of a Statin and/or Oral Contraceptive Pill (OCP) must establish that there 
is an urgent need for the medication to be continued and a prescription could not be obtained 
for practical reason(s). Besides, the patient’s therapy has to be stable on the requested 
medication, and the medication needs to have been prescribed after a clinical review by the 
prescriber. Therefore, medication supply via CD outside these requirements is not appropriate. 
In addition, if the customer is not a regular customer of the pharmacy, the pharmacy where the 
medication was last supplied and the customer’s regular pharmacy (if they have one) must be 
contacted to verify information obtained from the patient.[4] Hence, it is implied that supply 
to non-regular customer without prior contact with their regular pharmacy is not appropriate. 
To illustrate how the CD guidelines should be applied, the PSA has published six case 
scenarios (Available from: https://www.psa.org.au/download/guidelines/medication-
management/continued-dispensing-scenarios.pdf) involving medication provision through the 
CD model.[4] Each scenario portrays a customer requesting an eligible medication (i.e. a Statin 
or OCP) without a valid prescription as it was not practical for them to obtain an appointment 
with the prescriber. In each scenario, the PSA discusses why CD supply is or is not appropriate. 
For example, in the PSA’s Scenario 2 the customer was not a regular, however, the use of CD 
was listed as “May be appropriate”. This “may be” indicating that CD could be appropriate if 
the information provided by the customer has been validated from the customer’s regular 
pharmacy. In Scenarios 3, 5 and 6, CD was not appropriate according to the PSA. The reasons 
provided to justify the inappropriateness of the use of CD for these scenarios were: the 
customer was not stabilised on the treatment, no prior clinical review by a prescriber or 





Pharmacists may differ in their interpretation of some parts of the guidelines.[5] For example, 
opinion may differ on the urgency of request. In this regard, while some pharmacists may 
consider a request from a customer, who had only a few tablets left an urgent request, others 
may think that there is still time to obtain a prescription. Timing of the request may also affect 
the degree of urgency, particularly with requests occurring during weekends or public 
holidays.[6] Pharmacists may also differ in their assessment of treatment interruption; is one 
or two days without a medication long enough to consider that the treatment has been really 
interrupted? OC users are still considered adherent to therapy after two days of missing 
pills.[7] Similarly, a customer may request eligible and non-eligible medications (e.g. Statin 
and antihypertensive) at the same time and for the same reasons. In this case pharmacists’ 
decisions may vary; some may use CD for the Statin and another method for the 
antihypertensive, whilst other pharmacists may consider patient confusion that may result from 
using different methods, and supply both medications via an alternative method.[4]  
Pharmacists’ adherence to PSA guidelines may be measured by various methods. For example, 
it may be measured by direct observation. However, this method has disadvantages of high 
cost, being time-consuming to conduct and obtain a suitable number of cases, and potential 
bias as a result of the Hawthorne effect (i.e. participants enhancing their actions 
under surveillance).[8] Adherence to guidelines needs to be measured using lower cost valid 
and reliable methods.[9] Written case vignettes meet these requirements.[10] Compared to 
video case vignettes the pencil and paper vignettes save research time and resources.[8]   
5.2 Aims and objectives 
This study aimed to explore: 
1. The appropriateness of pharmacists’ application of the CD guidelines across a range 
of clinical scenarios.  
2. Pharmacist general views about CD after eight months of its implementation in 
Western Australia.  
5.3 Methods  
Purposeful sampling was used to collect the data in this study. Purposeful sampling is “a 
technique used for the identification and selection of information-rich cases for the 




groups of individuals that are especially knowledgeable about or experienced with a 
phenomenon of interest.”[11] A questionnaire containing six case vignettes was distributed to 
pharmacists who attended the PSA Western Australian Branch seminar, Perth Western 
Australia, May 2014, along with a participant information sheet. Respondents were also given 
a ticket to go into a draw for a $100 Gift Voucher. Participants were considered consented if 
they returned the completed questionnaire.   
5.3.1 Questionnaire development  
The scenarios used in case vignettes were adopted from the “Continued Dispensing Scenarios 
for Pharmacists” which were developed by the PSA to guide pharmacists conducting the CD 
(Available from: https://www.psa.org.au/download/guidelines/medication-
management/continued-dispensing-scenarios.pdf).[4] Amendments made were to the original 
scenarios to provide more details such as inclusion of consumer age, changing the medicine 
type from statin to OC, or vice versa, changing hospitalisation time from 3 weeks to 12 days. 
The questionnaire also had a section to collect demographic information about the respondents 
(Appendix 5.1). The participants were also asked to comment on their experience with the CD 
method. The questionnaire was reviewed for face and content validity by staff members from 
the pharmacy practice team, School of Pharmacy, Curtin University. The study was approved 
by the Human Research Ethics Committee of Curtin University. (Approval number: PH-15-
14) (See Appendix 5.2)  
5.3.2 Development of a checklist 
As a result of the amendments that were made by the research team (the PhD candidate and 
the supervisors) to the PSA scenarios, a checklist was developed to determine scenarios in 
which medication supply through CD was or was not appropriate according to CD 
requirements (See Section 2.1; Box 2.).  
The following questions formed the checklist:   
Is the requested medication eligible?     
Is the patient a regular customer?                              
Has the patient been on the same medication for six months or more?      




For medication supply using the CD method to be considered appropriate, the first three 
questions had to be answered by YES, and the fourth question had be answered by NO.  
5.3.3 Research Team Evaluations (RTE) 
The research team made assumptions about appropriateness of CD utilisation in various 
scenarios provided. These assumptions were based on CD guidelines established by the PSA. 
These scenarios were then piloted with the pharmacy practice team in the School of Pharmacy. 
Following this process, a final decision made was that CD was appropriate for Scenarios 1, 3 
and 4 and it was inappropriate for scenarios 2 (not a regular customer), 5 (New medication 
[i.e. less than six months]), and Scenario 6 (Not stable –Recent hospitalization- GP review is 
needed).  
Example of vignettes  
Scenario 5: An 18 year old female consumer comes into the pharmacy with an empty box of 
the oral contraceptive. She says it is not practicable for her to go to her GP. The pharmacist 
reads on the label that her GP has given her a three months’ supply with no repeats. On further 
questioning, she says her GP changed her onto a new oral contraceptive three months ago. 
RTE: CD is not appropriate for this scenario because the medication was new (i.e. patient using 
it for less than six months). 
5.3.4 Data Analysis 
The data were initially entered in an Excel® (2010) spreadsheet, then imported into SPSS ® 
Version (22) for analysis. SPSS® was used to produce frequency tables and examine the 
effects of independent variables (age, gender, and years of practice) on the dependent variable, 
(i.e. participants’ decisions). A P value of ≤0.05 was considered statistically significant using 
95% confidence interval. Open-ended questions were transcribed verbatim and thematically 
analysed.  
The relevance of each theme was ranked according to their prevalence in participants’ 
comments. For example the theme that appeared four times was assigned an *n=4 and so on. 
The purpose of ranking themes was to estimate which theme was more important from the 
participant’s perception. Also, this was done to avoid unnecessary repetition of similar 




5.4 Results  
5.4.1 Response rate 
Thirty questionnaires were returned from an estimated 50 pharmacist attendees which equates 
to an approximate response rate of 60%.  
5.4.2 Demographic data 
The participants were mainly female (73.3%). The dominant age group and years of experience 
were 25-34 years and 11-20 years, respectively. Community pharmacy was the dominant 
primary area of work for 73.3% of study participants. Table 5.1 provides a summary of 
participant’s demographics.  
Table 5.1 Demographic data 
 
5.4.3 Inconsistency with the Research Team Evaluations (RTE)   
According to data provided in each scenario, the research team used the checklist to decide in 
which cases medication supply through CD would be an appropriate decision. These 
evaluations were not provided to the participants.  
Participant decisions that differed from the RTE were considered inconsistent with the RTE 
research team assumptions (Table 5.2).  
Variable Item n (%) 
Gender Male 8 (26.7) 
Female 22 (73.3) 
Age <25 3 (10.0) 
25-34 13 (43.3) 
35-44 5 (16.7) 
45-54 5 (16.7) 
55-64 2 (6.7) 
65 or older 1 (3.3) 
Prefer not to disclose 1(3.3) 
Experience as registered pharmacist < 5 years 7 (23.3) 
5-10 years 9 (30.0) 
11-20 years 13(43.3) 
> 20 years 1 (3.3) 
Primary Area of Pharmacy Practice Community Pharmacy 22 (73.3) 
Hospital Pharmacy 4 (13.3) 




Overall, 53 (29.4%) of the 180 recommendations made were inconsistent with RTE. 
Inconsistent decisions were either a decision to not use CD when it was appropriate (incorrect 
refusal: 26 decisions in 53; 49%) or a decision to use CD when it was not appropriate (incorrect 
supply : 27; 51%). 
Table 5.2 Participants’ inconsistent decisions with research team evaluations 
*Inconsistent responses with the research team’s evaluations (RTE)  
Incorrect refusal  decisions 
There were 26 incorrect refusal that occurred in relation to Scenarios 1, 3 and 4. The majority 
(65.4%) of these decisions were in Scenario 4. This scenario contained a request for two 
medications: a Statin (CD eligible) and an antihypertensive medication (not eligible for CD).  
Incorrect supply  decisions  
There were 27 (15%) incorrect supply  (or inappropriate use of the CD) which occurred in 
Scenarios 2, 5, and 6. The majority (59.3%) of these decisions were in Scenario 2. This case 
was considered by the research team as an inappropriate case for CD because the customer 
was not a regular customer. However, 16 out of 30 participants (i.e. 53.3%) decided that the 
supply through the CD method was appropriate. In other words, the majority of participants 
did not think CD was inappropriate for a non-regular customer in this scenario.   
5.4.4 Effect of demographic variables on participants’ decisions  
Table 5.3 displays effects of demographic variables on participants’ decisions. These decisions 
were categorised as: Consistent (with RTE) or Not Consistent, then they were tested to see if 
there was any effect of demographic variables on these decision. These decisions did not differ 
significantly (p > 0.05) according to participants’ demographic data (gender: males vs females; 
age: < 45 vs ≥ 45, Years of practice: <10 vs ≥10) as indicated by Chi-square and Mann-
Whitney tests.  
Scenario 
No 
RTE RTE’ reason(s) for inappropriateness *Inconsistent 
responses n (%) 
1 Appropriate None 4 (13.3)  
2 Inappropriate Not a regular customer 16 (53.3)  
3 Appropriate None 5 (16.7)  
4 Appropriate None  17 (56.7) 
5 Inappropriate New medication- less than 6 months  3 (10.0)  
6 Inappropriate Not stable –Recent hospitalisation- 
GP review needed 




Table 5.3 Effects of demographic variables on participants’ decisions 
5.4.5 Participants’ beliefs when CD must not be used 
Respondents who nominated a case as inappropriate for the CD were asked to give their 
reason(s) for their answer. In general, participants thought that CD method of supply was 
inappropriate if there was a need for medical review, no dispensing history, and if the patient 
condition was not stable. The provided reasons were ranked according to the number of 
repetitions (Table 5.4). 
Table 5.4 Themes emerging from the reasons cited for not supplying the medication via CD 
The Table 5.4 shows which reasons were more commonly cited by respondents when they 
thought CD was inappropriate. Key reasons cited for non-supply were as follows: The need 
for a medical review (*n=40) was cited as a reason for not supplying in every scenario, 
followed by: The patient was not stable (*n=20), No history (*n=14), Absence of urgency 
(*n=7), and Treatment was already interrupted (*n=4).  
5.4.6 Most reported reasons for CD inappropriateness 
The above reasons can be combined to produce two main themes: A) It was not safe to supply. 
Medical view was required (The patient was not stable; and No history), and B) It was not an 
urgent situation (Absence of urgency; and Treatment was already interrupted).   
More details and examples are provided below about why the participants thought CD was not 
Variables Scenarios (P value) 
Scenario1 Scenario 2 Scenario 3 Scenario 4 Scenario5 Scenario 6 
Gender 0.937 0.828 0.717 0.662 0.787 0.903 
Age 
groups 
0.359 0.736 0.520 0.439 0.631 0.158 
Years of 
practice  
0.359 0.290 0.748 0.961 0.631 0.828 
Themes (Reasons)  N  Scenarios Subthemes 
The need for a 
medical review  
40 1,2,3,4,5 and 
6 
The need for a medical review (n=40)  
 
The patient was not 
stable  
20 1,2,4,5 and 6 The request was for a new medication (n=11) 
Recent hospitalisation(n=5) 
Prescription has changed (n=2) 
For safety reasons (n=2) 
No history  14 1,2 and 6 The customer was not regular and/or 
Absence of medication history  (n=14)  
Absence of urgency  7 2,3 and 4 Absence of urgency (n=7) 
Treatment was 
already interrupted 




appropriate for each scenario. 
Scenario 1: A 26 year old female regular customer of the pharmacy requests repeat 
prescription of her oral contraceptive pill. Although there are still repeats, the prescription has 
expired and it is impractical for her to see her GP to renew the prescription because she is 
leaving the next day (Sunday) for a couple of week’s holiday. 
RTE: CD in this scenario is appropriate. 
Four (13.3%) decisions which were inconsistent with RTE. The reported reason(s) for not 
using CD were: 
The need for a medical review (*n=2): 
This reason was reported twice. The following examples illustrate this: 
“She has not seen GP for a long period of time.” ph4 
“Can get Rx [prescription] during the month- Should see a doctor for BP [blood pressure] 
check .etc.” ph27 
The customer was not regular and/or Absence of medication history (*n=2): 
This reason was cited by two participants. The following examples illustrate this: 
“May not be using (the medication) regularly.” ph10 
“Unknown time of last doctor` visit- time delay between commencing treatment& it beginning 
to be effective.” ph14 
Scenario 2: The wife of a 48 year old male comes into the pharmacy. She and her husband are 
visiting from another state and she says her husband has run out of his Statin a week ago. He 
would prefer not to see another GP, however they are staying for another 3 weeks, and she is 
concerned about the interruption to his treatment.  
RTE: CD in this scenario is not appropriate because the customer was not regular. 
The number of respondents whose decisions were consistent with RTE was 14 (46.7%). Their 




medication history were unknown to the pharmacist (i.e. customer was not regular). 
The customer was not regular and/or Absence of medication history (*n=6):  
 These reasons were cited by six participants. The following examples illustrate this: 
“No dispensing history for the patient.” ph9  
“Not regular customer with no history of compliance.” ph29 
“No history on stability of condition.” ph4 
Treatment was already interrupted (*n=2): 
This reason was cited by two participants. The following examples illustrate this: 
“Interruption of therapy.” ph18 
“Treatment is not continuous (week break).” ph23 
The need for a medical review (*n=1): 
This reason was cited by one participant. The following example illustrates this: 
“Need to check-up.” ph15 
Absence of urgency  (*n=2): 
This reason was reported twice. The following examples illustrate this: 
“…… time enough to organise Dr [doctor] appointment.” ph7 
“Just phone Dr [doctor] and get a Rx [prescription] faxed.” ph6 
The request was for a new medication  (*n=1): 
This reason was cited by one participant. The following example illustrates this: 





Pharmacist preferred direct consultation with the patient (*n=1): 
This reason was cited by one participant. The following example illustrates this: 
“Ask to speak to patient himself.” ph3 
Note: one participant did not provide a reason. 
Scenario 3: A 61 year old male regular consumer tells the pharmacist that he urgently needs 
some of his cholesterol medicine. He mentions that he ran out two days ago. The pharmacist 
reviews the consumer’s medication history and until this break on therapy, the consumer had 
been stable on Statin therapy for five years. 
RTE: CD is appropriate. 
Five (16.7%) decisions were inconsistent with RTE. The cited reasons for this decision were: 
Treatment was already interrupted  (*n=2):   
This reason was reported twice. The following examples illustrate this: 
“Not adherent.” ph13 
“Interruption of therapy.” ph18 
Absence of urgency  (*n=2): 
Absence of urgency was cited by two participants. The following examples illustrate this: 
“2/7 not sufficient risk.” ph24 
“Will get Rx [prescription] during month.” ph27 
The need for a medical review (*n=1): 
This reason was cited by one participant. The following example illustrates this: 





Scenario 4: A 48 year old regular female customer tells the pharmacist that she is unable to 
obtain an appointment with her doctor for new prescriptions for her Statin and blood pressure 
medicines and prefers not to see another GP. She has been taking them for about 6 months and 
now only has a few tablets left. 
RTE: CD is appropriate 
Seventeen (56.7%) decisions were inconsistent with RTE. The key reported reason(s) for this 
decision were:  
The need for a medical review (*n=10): 
This reason was cited by 10 participants. The following examples illustrate this: 
“She needs a clinical assessment of her BP [blood pressure].” ph3 
“12 months Rx [prescription].” ph13 
“Should see another GP.” ph8  
“Can see any doctor.” ph17  
The request was for a new medication  (*n=2): 
This reason was cited by two participants. The following examples illustrate this: 
“New med [medication].” ph10 
“Review for a new medication is important.” ph21 
The patient also requested ineligible medication (*n=2):   
This reason was cited by two participants. The following examples illustrate this: 
“BP [blood pressure] medicine cannot be supplied. So Rx [prescription] needed to see a GP.” 
ph14 





Absence of urgency (*n=3): 
This reason was cited by three participants. The following examples illustrate this: 
“She may still be able to contact her GP before medications runs out.” ph20 
“Will get appointment within a month.” ph27 
“She still have supply, it has been 6 months, so need to be reviewed.” ph28 
Scenario 5: An 18 year old female consumer comes into the pharmacy with an empty box of 
the oral contraceptive. She says it is not practicable for her to go to her GP. The pharmacist 
reads on the label that her GP has given her a three months’ supply with no repeats. On further 
questioning, she says her GP changed her onto a new oral contraceptive three months ago. 
RTE: CD is not appropriate for this scenario because the medication was new (i.e. patient 
using it for less than six months). 
Twenty-seven (90%) of respondents indicated CD was not appropriate (i.e. consistent with 
RTE). Their reasons for this decision were related to the need for a medical review and to the 
medication used being new and instability of the treatment. 
The need for a medical review (*n=19):  
 The need for a medical review was cited by 19 participants. The following examples illustrate 
this: 
“Refer back to GP to assess whether the new pill is suitable for her.” ph11 
“GP may change the pill she is on.” ph20 
“GP may want a review on her new pill.” ph21 
 “Needs GP review.” ph23  
The request was for a new medication (*n=8):  
This reason was cited by eight participants. The following examples illustrate this: 




“Duration less than 12 months.” ph18 
For safety reasons (*n=2): 
These reasons were cited by two participants. The following examples illustrate this: 
“Safety. Suitability.” ph22  
“Risk out?” ph24 
Scenario 6: A 36 year old female comes to the pharmacy after being in hospital for 14 days. 
Last week she ran out of the supply provided by the hospital and has not been able to visit her 
GP since leaving hospital. She would like a supply of her usual Statin. 
RTE: CD is not appropriate for this scenario because the customer was not stable on the 
medication, she had recent hospitalisation, and a medical review is needed.  
Participants who thought CD was not appropriate (22; 73.3 %) cited the following reasons: 
The need for a medical review (*n=8): 
This reason was cited by eight participants. The following examples illustrate this: 
“Needs to see GP.” ph16 
“Refer to the regular doctor.” ph19 
The customer was not regular and/or Absence of medication history (*n=6): 
These reasons were cited by six participants. The following examples illustrate this: 
“Unknown history of Statin.” ph4 
“Unknown if treatment is stable.” ph14 






Recent hospitalisation (*n=6): 
This reason was cited by six participants. The following examples illustrate this: 
 “May have had changes in hospital.” ph12 
“Hospitalisation in last 12 months.” ph18 
Prescription has changed (*n=2): 
This reason was cited by two participants. The following example illustrates this: 
“Not same Rx [prescription].” ph7 
5.4.7 What was the suitable action?  
After the question about the appropriateness of the each scenario for CD supply, participants 
were asked what would be their preferred course of action among the following four options: 
Continued Dispensing (CD), Owing Prescription (OP), Emergency Supply (ES), Not supply 
(NS), Refer to an After-Hours GP, or Other.  
The results (Table 5.5) showed that CD was preferred by at least one half of the respondents 
for Scenarios 1 and 3. Nearly a quarter of respondents preferred the CD method for Scenario 
4 where OP was the most preferred option. The least preferred option was referring patients to 
after-hours GPs in Scenarios 5 and 6. The ‘Other’ option included referring patient to a GP, the 
original prescriber, a clinic or a hospital. 
Table 5.5 Respondents' preferred course of action 
CD: Continued Dispensing, OP: Owing Prescription, ES: Emergency Supply, NS: Not Supply^ Other: ‘refer to a GP’ *One 

















1 16 (53.3) 10 (33.3) 0 1(3.3) 2 (6.7) 1 (3.3) 
2 13 (43.3) 1(3.3) 3 (10.0) 0 11 (36.7) 2 (6.7) 
3 15 (50.0) 10 (33.3) 1(3.3) 0 0 4 (13.3) 
4 8 (26.7) 10 (33.3) 1 (3.3) 4 (13.3) 4 (13.3) 3 (10.0) 
5* 1 (3.3) 1 (3.3) 1 (3.3) 5 (16.7) 12 (40.0) 9 (30.0) 




5.4.8 Respondents’ views about CD  
Respondents were asked to comment on their experience with CD particularly with a focus on 
whether they believed it is an efficient process. Only two respondents expressed positive views 
regarding the CD system while 17 respondents either identified some of CD disadvantages 
such as paperwork, and/or expressed lack of knowledge and /or experience and/or use of CD. 
The main theme emerging from these comments is low uptake of the CD by study respondents. 
More details are provided below: 
a. Positive views (*n=2) 
Two respondents (one working in community and the other in hospital) showed positive 
attitudes towards CD. Although the community pharmacist did comment that its narrow focus 
limited its useability. 
“I think it is a good idea, however as it is limited to only Statin and Oral contraceptive tablets 
I have not used it a lot at my community pharmacy.”  Ph9 
“I work in hospital pharmacy so I do not have much experience with continued dispensing but 
I believe it is a good idea.” ph11 
b. Negative views (*n=5) 
Five respondents expressed their concerns about the complexity of conducting CD. They were 
also satisfied with other current medication supply methods such as OP and ES. One 
respondent mentioned the need to contact the prescriber as an extra workload even though 
prior contact with the prescriber is not a condition to conduct the CD method, as in case of the 
OP system to obtain the prescriber’s authorisation. However, CD requirements stipulate that 
the pharmacist must inform the last prescriber. This communication may be perceived as an 
extra workload even though it is an imperative to minimise treatment duplication and 
fragmentation of care. Being time consuming and onerous paperwork were also mentioned. 
These are needed to record and claim the reimbursements and to ensure the appropriateness of 
medication supply by using the CD method. All respondents with negative views had chosen 
not to use CD in practice. More details and examples are provided below. 




 “Do not feel the need as owing Rx [owing prescription] is easier and less time consuming.” 
ph25 
“….extra workload to contact prescriber- better alternatives available/ not unhappy with 
current alternatives.” Ph8 
“…., too much paperwork, patient needs to go to Dr [doctor] eventually anyway.” ph27 
“I agree that pharmacists are capable and competent to do CD, but I do not really see the need 
for it- Emergency or owing are enough.” ph23 
c. Lack of knowledge and/or experience and/or use of CD (*n=11) 
Seven respondents stated that they have not used CD in practice at the time of the survey. In 
addition four respondents reported their lack of understanding of CD/ experience with this 
method of medication supply. See examples below: 
 “As yet, not used.” ph7 
“Have not done any continued dispensing-…..” Ph8 
“Minimal experience duo to lack of knowledge of regulations.” ph10 
“No experience.” ph17 
 “Do not quite understand the process.” ph20 
“I know very little if anything about it!” ph30 
5.4.9 Effect of CD knowledge on participants decisions  
A comparison was conducted between Group A (the 11 participants who stated Lack of 
knowledge and/or experience and/or use of CD) and Group B (those who did not report this 
[one participant], did not answer the question [17 participants], and the one participant who 
reported: I have not used it a lot). Both groups had a similar consistency with RTE. 71.2% of 
Group A decisions and 71.0% of Group B decisions were consistent with the RTE. In other 
words, the accuracy of both groups to identify when CD was appropriate or not was not 




5.5  Discussion 
This study aimed to identify how pharmacists act when faced with theoretical scenarios of 
patients requesting Statins, OC or other medications without a valid prescription and were 
unable to see their doctors. In particular it sought to determine pharmacists’ understanding of 
and experience with CD (i.e. how appropriately they conduct the CD). 
The majority of participants would only conduct CD when it was appropriate. Irrespective of 
the fact that the majority of respondents who commented about their experience with CD, did 
not use CD (hence they had no real-life experience), only a small percentage (15%) of their 
overall decisions were incorrect supply  (i.e. inappropriate use of the CD). However, these 
pharmacists may have had different views if they were dealing with real cases in practice,[12] 
as risk-taking behaviour would be less in the case scenarios as opposed to a real patient. It is 
critical to mention that the estimation of appropriateness was based on CD guidelines, which 
according to the PSA are “not definitive statements of correct procedure” rather they are a kind 
of advice about the best practice.[3, 13] Therefore, the fact that the incorrect supply  decisions 
were not consistent with guidelines does not imply that these decisions were necessarily not 
clinically inappropriate. Besides, the current respondents proved that they were considering 
patient safety as a priority and would only supply when it is safe to do so. This was an emerging 
theme from respondents’ views about why CD was not appropriate in some scenarios (see 
above). Although some pharmacists may require training about CD, the fact that the vast 
majority of pharmacists’ decisions were appropriate suggests that not all pharmacists would 
require additional training to conduct CD.[14] This was confirmed by the absence of any 
significant differences between accuracy of participants’ decisions according to their level of 
CD knowledge. Moreover, the majority of the incorrect supply decisions resulted from the 
decision of 53.3% (n=16) of respondents to use CD in case of a non-regular customer. In such 
cases, if the previous dispensing pharmacist can be contacted and can confirm the customer’s 
history, CD can be used. 
According to CD guidelines,[15] the pharmacists should contact the regular pharmacy of non-
regular customers before using CD supply. This detail was not included in the scenario. 
Respondents who decided CD was appropriate for this scenario may have been affected by 
their experience in which they have no difficulty in contacting the regular pharmacy of non-
regular customers. Furthermore, less preferred supply options available to supply for non-
regular customers may affect respondents’ decisions. For example, pharmacists who have a 




with non-regular customers.[16] Therefore, pharmacists may see CD as a potential solution 
for those customers. It is worth mentioning that Consumers Health Forum of Australia (CHF) 
recommended that there should be no “ambiguity” to identify the legitimate requests from 
non-regular customers.[17] 
The incorrect refusals were the decisions to not use CD when it was deemed appropriate to do 
so. The majority of these decisions were in relation to Scenario 4. This scenario contained 
medication supply requests for two medications; one was eligible (Statin) according to current 
CD guidelines, and another one was not eligible (i.e. an antihypertensive). While CD was 
appropriate for the eligible medication, 17 in 30 respondents (56.7%) decided that the CD was 
not appropriate. This decision may indicate that pharmacists may not use the CD method with 
customers who are concurrently requesting eligible and illegible medications. This is likely to 
be the case for patients prescribed multiple medications, particularly with Statin users who 
usually diagnosed with other co-morbidities and use other medication.[18] This avoidance of 
the CD could negatively affect the circumstances under which to utilise CD in practice. It is 
worth mentioning that the PSA recommends not using CD if there is a risk of patient confusion 
as a result of using more than one method to supply the requested medications.[15] This could 
contribute to the low uptake of CD, particularly with Statin users who have comorbidities.[19] 
This study provides insights into circumstances where pharmacists thought CD was not 
appropriate. The respondents thought CD was not appropriate if there was a need for a medical 
review, particularly if the patient had not seen the GP for a long period, or patient status was 
not stable on the same medication. This confirms the previous reports by Statin and OC users 
that their pharmacists would refer them to their GP when it was needed.[16] Furthermore, they 
thought CD was inappropriate if they did not know the patient or did not have a dispensing 
history, or the medication was new (i.e. prescribed less than six months ago). Patients who 
were recently hospitalised were also deemed unsuitable to utilise CD. This indicates that 
pharmacists are practising according to CD guidelines,[4] and they know their practice 
limitations and refer patients to doctors when that is deemed necessary. These results may 
alleviate the AMA’s concerns about the CD. Communication and cooperation between 
healthcare professionals results in optimisation of patient care and treatment outcomes.[20]  
Another reason for not using CD that was cited in three scenarios was the absence of urgency. 
It is worth mentioning that the AMA has stated that Statins are not urgently needed 
medications.[2] Respondents reported that there was a possibility to obtain a prescription, or 




see the doctor. However, according to the study results this may be a grey area and would be 
subject to variation in the interpretation of urgency of the request among the pharmacists. 
Moreover, some respondents cited “treatment already interrupted” after one week without the 
medication. In the guidelines, there is no determination of the duration without treatment after 
which the medication must not be supplied. Hence, there is a need for more clarification of 
CD guidelines by authorities.  
Results of this study also showed that the vast majority of respondents did not conduct CD. 
This was despite the fact that it had been implemented in Western Australia for more than eight 
months (from September 2013 to May 2014). This is supported by reports of low CD uptake 
by community pharmacists.[21] Study respondents also reported negative views about the CD. 
The key reason for these negative views included that they do not see the need for CD. This 
supported the AMA claim that CD is a solution for a problem that does not exist.[2] 
Respondents also think that the OP is much easier, and CD involves significant paperwork. 
These factors may be contributing to low uptake of CD by pharmacists,[21] particularly those 
who are still confused by the CD process.[22] Low uptake of new pharmacy services has been 
reported in the literature.[23, 24] For example in Canada, only one-third of pharmacies 
participated in the Ontario Pharmacy Smoking Cessation Program after more than 25 months 
of the program implementation.[23] Moreover, respondents also reported a lack of knowledge 
or understanding of the CD process despite the fact that a copy of guidelines was “distributed 
to each registered pharmacist in Australia during August 2013”.[25] This is consistent with 
previous studies, which reported low knowledge of guidelines.[10, 13]  
This study has a number of limitations and strengths. The research tool was not piloted with 
the actual respondents. Although for the fact that majority of the participants primary place of 
work was the community pharmacy setting improves study representativeness. However, the 
respondents were the attendees at an annual seminar; therefore those who did not attend were 
not represented. Further, respondents’ responses to hypothetical scenarios may differ from 
actions in clinical practice, which is a general disadvantage of case vignettes studies. Case 
vignettes may not provide the full context, do not provide opportunity for questions and 
simplify the request. Moreover, inconsistency between some respondents’ decisions and RTE 
should not suggest that these decisions were clinically inappropriate rather they represent be 
different clinical evaluations of the presented scenarios. Public availability of the original 
scenarios on which the study vignettes were based, on the PSA website, may have biased 
participants’ responses. Finally, the sample size was small. These limitations may have 




there are some strengths such as being the first to use case vignettes to study the CD model of 
medication supply. The study also explored pharmacists’ limited experience with CD after its 
implementation. As a method of measurement, case vignettes reflect the actual practice by 
doctors with high content and face validity.[9] Therefore, this method is likely to reflect the 
actual practice by pharmacists when they are dealing with medication requests without a valid 
prescription. This reflection of the actual behaviours may has been improved by the fact that 
participants were not observed when they completed the survey tool.   
Further research should be undertaken to explore how CD could be improved to enhance its 
utilisation by community pharmacists. 
5.6 Conclusions 
The majority of the respondents correctly identified the inappropriate cases for CD based 
supply, even though they had little or no personal experience with the CD. They rarely used 
the CD and preferred other options to supply medications in urgent cases without a valid 
prescription. The need for a medical review, absence of dispensing history, health or 
medication instability, and non-urgency were the main reasons that may cause pharmacists to 
avoid CD on clinical grounds. Other practical reasons such as patient confusion, co-
morbidities, CD paperwork, time-consumption and the presence of other more convenient 
alternatives may have also contributed to low CD uptake. Irrespective of CD guidelines, it 
seems that the respondents considered that CD is still safe with non-regular customers if they 
were stable on their medication, no medical review was needed, and the request was urgent. 
Other regulations to ease non-regular customers’ difficulty to obtain their medications should 
be explored. An expanded version of the CD (i.e. adding more eligible medication classes) 
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6 Chapter 6: Views of a small sample of General 












A prescription is required to obtain a supply of a Schedule 4 “Prescription Only Medication 
(POM)” in Australia. Legally accepted prescriptions may come from medical practitioners or 
other authorised healthcare providers (i.e. Nurse Practitioners, Dentists, Optometrists, or 
Midwifes).[1] However, Continued Dispensing (CD) involves the supply of POMs without a 
valid prescription to eligible patients. Currently, the only eligible patients are Statin and Oral 
Contraceptive (OC) users. To be eligible, patients must: (a) have been prescribed these 
medications before from a registered prescriber (e.g. GP, nurse practitioner or midwife);[2] (b) 
have been stable on these medications for at least 6 months; and (c) have not utilised CD in 
the past 12 months.[3] The Australian Medical Association (AMA) has voiced its opposition 
to CD. According to the AMA, there are two main reasons for this pronouncement, namely 
concerns about the safety of dispensing without a clinical review and obscurity of the 
emergency.[4] 
The AMA concerns about the safety of the CD supply may have risen from the absence of 
medical assessment before supply. Ideally, doctors would not renew the prescription without 
appropriate medical checks to ensure that the medication is still needed and it is safe to be 
used.[4] However, in practice there would be cases where the GPs may renew a prescription 
without seeing the patient. For example with the Owing Prescription (OP) system (i.e. 
prescription issued based on a phone call between the pharmacist and the GP).[5] Further, if 
the GP was unable to see the patient, the GP might renew the prescription, if appropriate, based 
on the patient’s medical record.[4, 6] This indicates that there are situations where prescription 
renewal may be made safely without a medical review. In other words, not all renewed supply 
without GP – patient face to face consultation is unsafe. Furthermore, CD supply is only 
possible if the patient cannot see the GP.[3] Therefore, pharmacists must balance the risks of 
supplying including delays in medical review with the risk of treatment interruption.  
The other concern by the AMA is the absence of emergency for CD supply in case of Statin 
therapy. According to the AMA, “a patient’s medical condition was unlikely to deteriorate 
without lipid modifying agents for one or two weeks”. This opinion is consistent with the 
conclusion made by McGowan that a short period of Statin washout does not lead to significant 
clinical risk for patients with stable cardiac disease.[7, 8] However, there is evidence of rapid 
adverse effects on healthy volunteers and patients with different types of chronic diseases as a 
result of Statin short-term discontinuation.[9] Statins’ pharmacological actions are not limited 




term consequences of Statin discontinuation on healthy students were related to lower NO 
bioavailability.[9] Heeschen et al.[9] researched the effect of Statin short-term interruption on 
three patient groups. A “Statin Discontinued” Group, those who stopped Statin on or shortly 
after hospital admission, “Statin Continued” Group, those who did not stop Statin and “No 
Statin” Group for those who never used Statin. After one week of Statin discontinuation by 
the “Statin Discontinued” group, the cardiac risks increased compared to the other two groups, 
even though the baseline characteristics did not differ significantly between “Statin 
Discontinued” and “Statin Continued” groups. The study authors concluded that Statin 
discontinuation had demolished previous benefits of Statin therapy. An additional benefit seen 
in those who continued Statin therapy compared with those who did not was their hospital 
admission period was shorter. The drawbacks of the Heeschen et al. [9] study were that its 
results were based on retrospective data, and the results may have been affected by the lower 
sample size of the Statin Discontinued Group (86 patients).[9] 
It is important to appreciate that the short treatment interruptions may result in a complete 
discontinuation. Particularly, if patients are asymptomatic and/or do not notice any difference 
after stopping the medication. [10-13] In a previous study, 13% of those who stopped statins 
reported “no longer needed” as a reason.[14] Medication use only if there were symptoms was 
previously reported by 62% of patients with asthma, despite the fact they were prescribed it as 
a continued therapy irrespective of symptoms.[15]  
Another concern for the AMA was pharmacists’ conflict of interest related the CD. The AMA 
claimed that CD enables the pharmacist to become prescribers and dispensers.[16] This was 
also reported by participants in a previous study about a theoretical model of CD (i.e. 
Medication Maintenance).[17] However, the Pharmacy Guild of Australia (PGA) has stated 
that “the issue of conflict of interest with the pharmacist being both the prescriber and 
dispenser is addressed by the proposed expansion of the existing continued dispensing 
provisions, rather than proposing full independent pharmacist prescribing.”[18] However, the 
potential for conflict of interest may not have been completely eliminated.[19]  
GPs’ attitudes towards the CD have not been explored before. It is not clear whether GPs have 
similar or different views from those of the AMA. It is not essential that an organisation’s view 
represents its members’ views. For example, in an article in Health IT Outcomes, September 
7, 2011 [20] it was reported that 77% of American doctors disagree with the American Medical 




GPs may have mixed views on CD. It has been reported that GPs are frustrated by patients 
requesting urgent appointments for prescription renewals.[6] In such cases, they may need to 
squeeze other appointments or they may not be able to see the patient.[6] GPs have also 
complained about writing owing prescriptions.[21] Further, communication with the 
pharmacist seeking authorisation to supply an OP may also place more pressure on the GP’s 
schedule. Therefore, GPs may see some benefit for themselves and/or their patients from the 
CD. Conversely, GPs may see CD as a source of financial concern as it enables patients to 
obtain an additional supply without the need to visit the doctor.[17, 22] It is worth emphasising 
that this financial concern seems very limited as the current CD is restricted in terms of its 
eligible medications and frequency. In addition, GPs may be concerned that CD may delay 
medical reviews.[17, 22] Provision of an additional supply may result in delays in patients 
seeking medical reviews. However, when reviewing the safety of supplying through the CD 
the pharmacist should take into consideration the patient’s clinical status and all other 
medications.[23] In doing so, the pharmacist can identify any significant patient issues that 
would necessitate referral to a GP or emergency department.[24]  
GPs attitudes towards the CD are critical for CD utilisation by their patients. Patients generally 
see that doctors have a higher authority over their healthcare than pharmacists.[25-28] 
Therefore, if the doctor advised the patients to not use the CD, it is likely that the patient will 
take that advice. GPs may not accept the expanded role of pharmacists, particularly those who 
perceive pharmacists as shopkeepers rather than healthcare professionals, or if they think the 
new role may adversely affect their authority on patient treatment.[29, 30] They may see 
pharmacists as competitors and/or be concerned about CD’s effect on their relationship with 
the patient.[17, 31] According to Ernieda et al. [31] GP acceptance of new services by 
pharmacists depends on the service significance, its benefit to their patients and their practice, 
and their awareness of pharmacists skills. A low level of CD uptake by community pharmacists 
has been reported. There were only 2390 CD transactions (0.0016%) among all 
Pharmaceutical Benefit Scheme (PBS) transactions in the 10 months  from 1 September 2013 
to 30 June 2014.[32, 33] GPs may improve CD uptake through instructing their patients to use 
their regular pharmacy to obtain additional supply if they run out of medication before the next 






6.2 Aims  
The primary aim of this study was to explore GPs’ views about the current CD model of 
medication supply. Other aims were to obtain GPs’ views on CD expansion (to include more 
medication), and CD extension (more frequent usage) including how CD may be improved.  
6.3 Methods 
6.3.1 Investigation of GP’s attitudes/perceptions towards CD 
A self-administered questionnaire was used to collect the data (see Appendix 6.1). The 
questionnaire contained seven open-ended questions. It was validated for face and content by 
staff members of pharmacy practice department at School of Pharmacy, Curtin University. The 
estimated time to complete the questionnaire was 10 minutes. A $50 gift voucher was offered 
as an incentive for participation. The target was to obtain approximately 24 respondents, a 
number that would normally allow the achievement of data saturation.[34] The questionnaire 
was mailed to a sample of GPs in Western Australia. Phone calls were used as reminders. 
Receptionists were contacted and asked if they would remind the GP in their practice who 
received the questionnaire to complete and return it. Participants were considered consented 
if they returned the questionnaire. 
6.3.2 Questionnaire development  
Results of previous research on patients’ and pharmacists’ attitudes to CD informed 
the development of the questionnaire.[5, 35] The questionnaire contained seven questions. All 
questions were open ended to allow participants more freedom to express their opinions. The 
challenge with the questionnaire development was to ask sufficient and appropriate questions 
to cover the study topic, whilst, at the same time, considering GPs’ time constraints. Some 
similarity with previous questionnaires used in the patient and pharmacist surveys was 
essential to obtain comparable views from stakeholders. In contrast to the previous surveys, 
the GP questionnaire did not contain a list of medication to be added to CD eligible 
medications. Instead, they were asked to suggest any potential medications. This was to keep 
question number to the lowest possible, and better utilise GP’s time, in an attempt to attain a 




6.3.3 Reason for use the mail questionnaire method 
Whilst it was initially planned to conduct face-to-face interviews, difficulties in identifying 
GPs willing to participate in these led to the use of a mail survey instead. The mail 
questionnaire method has a number of advantages compared to face-to face interviews, namely 
there is no interviewer bias, it allows the participants to choose a convenient time to respond 
and is less costly than face to face interviews to conduct.[36-38] In addition, according to Van 
Geest et al. postal questionnaires had a better response rate compared to other methods such 
as email or the Internet-based surveys.[39] In the literature, there are a mixed reports regarding 
the difference in response rates and quality of data obtained from self-administered mail 
surveys and face-to-face interviews.[40] The more accepted opinion among researchers is that 
face-face interviews yield better response rates and more detailed answers, particularly with a 
presence of well trained and motivated interviewer.[41] However, some authors reported 
comparable results between mail questionnaires and face-face interviews.[40, 42]  
6.3.4 Variation in methods  
Due to the poor response rate to the initial questionnaire sent out, two additional strategies 
were used in an attempt to enhance the response rate, (See Figure 6.1).  
 






Method 1: GPs identified from Health-engine website  
The questionnaire was sent to a sample of 36 GPs practising in Perth, Western Australia. It 
was sent in late November 2014. The sample pool was identified from all recorded doctors’ 
postal addresses available on the Health Engine website in November 2014 
(https://healthengine.com.au/). Two lists of 36 doctors were randomly selected using an 
electronic randomiser (http://www.randomizer.org/). The first list was the key one whereas the 
second list was used as a back-up to replace any ineligible doctors from the first list (because 
the doctor was a specialist rather than a GP, or more than one GP from the same practice).  
Method 2: GPs identified from the Yellow Pages website 
As a result of the low response rate using Method 1 and the significant number of undelivered 
questionnaires returned with a note “the GP has left the address” from the sample list generated 
from Health Engine, another sample was randomly selected (by the same procedure as the 
above) from the Yellow Pages website (https://www.yellowpages.com.au/). This time an 
additional step was employed. A phone call was made to ensure that the address was still valid 
for each doctor and to confirm he/she was a GP, not a specialist. Through this process 20 of 
the selected doctors were deemed to be ineligible for the survey for the following reasons: the 
GP had left the practice, had retired or was on leave, the landline phone was disconnected at 
the time of calling, or in one case the doctor was a specialist, not a GP. Therefore, the substitute 
list was used to replace the non-eligible doctors. Phone calls were again made to confirm the 
doctor’s eligibility (i.e. a GP not a specialist) and address. Through this process a final list of 
24 GPs was compiled. The questionnaire was sent out during February 2015. This was 
followed by a phone call to confirm that the questionnaire had been received and also to ask 
the receptionist to remind the GP to complete it if they were willing to do so.  
Method 3: In person visits to GP surgeries 
Given the disappointing response rate achieved through Method 2 another attempt was made 
to improve the response rate through in-person visits made by the primary researcher (SA). 
Four surgeries were visited; one each in Cannington, Bentley, St James, and at Curtin 
University Bentley campus. Fifteen questionnaires were distributed to the receptionists 
corresponding to the number of GPs in each surgery. On one occasion, the investigator was 
invited to see the GP at which time an informal interview was carried out. The visited surgeries 
were selected through a convenience sampling technique; however all the GPs in these 




6.3.5 Ethical approval  
This study was approved by The Human Research Ethics Committee of Curtin University 
(Approval number: PH-17-14 ; See Appendix 6.2). 
6.3.6 Data analysis  
Answers to the open-ended question were transcribed verbatim and thematically analysed. 
Answers to each question were coded according to the themes which emerged. Discussion 
between the study team (PhD candidate and the supervisors) resolved any doubts about the 
analysis. 
6.4 Results 
6.4.1 Response rate and demographic information 
In addition to one GP recruited through Method 3 (the informal interview), only five 
questionnaires were returned from the mail surveys, despite reminder phone calls in an attempt 
to enhance the response rate. There were three respondents from the Method 1, and two from 
Method 2. There were a total of 11 undelivered surveys from Method 1. In these cases, the 
questionnaires were resent to other GPs. This meant that a total of 75 questionnaires distributed 
through the three methods.   
The overall response rate was disappointing at just 6.6% (or 8% if the interviewed GP was 
included). Out of the five questionnaires returned, two respondents did not fill the 
demographic part. The three GP participants who provided their demographic information 
were female, aged 45 years or more and had more than 20 years practice experience. The 
interviewed GP was also female.  
6.4.2 GP perceptions of CD based on survey responses 
Results are presented under three main categories: attitudes towards current CD, attitudes 
towards CD expansion, and attitudes towards CD extension. Themes are bold and subthemes 
are italic and bold. 
Since only five GPs participated in this study there were some comments that were made be 
one participant only. Therefore they cannot be considered as a theme or subtheme. 




6.4.2.1 Category A: GPs attitudes towards current CD 
Theme A.1: GPs had positive attitudes towards the current CD method 
GPs described their experience with CD as a positive experience, and they had not had any 
issue with CD. However, they also mentioned little awareness of CD by its eligible users. The 
following examples illustrate this:  
“I have had no problem.” GP1 
“Very positive.” GP2 
“Quite good. I have been aware of patients who have been supplied with both medicine groups. 
Most patients, especially contraceptive patients, are not aware.” GP3 
“……..I have not encountered any problems to date….” GP4 
Theme A.2: CD has advantages (Reasons behind positive attitudes) 
Subtheme A.2.1: Continuity of treatment 
CD would minimise treatment interruption and the resultant consequences. The comments 
below illustrate this:  
 “Continuity.” GP2 
“Prevent patient from running out.” GP1  
“Prevention of cessation of contraception (and risk of pregnancy) if pharmacy can supply 
urgently.” GP5 
Subtheme A.2.2: CD is convenient for patients 
It is easier and faster for patients to obtain their medication through CD when they run out of 
their medication and are unable to see their doctor. See comments below: 
“The main benefit for patients is convenience if they forget to book an appointment before 
script [prescription] runs out.” GP4 




Subtheme A.2.3: CD would minimise GPs being interrupted  
This subtheme is further divided to a sub-subtheme and an additional note. As below:  
Sub-subtheme A.2.3.1: CD may minimise GP interruption through patients 
(unnecessary) demand for urgent appointment 
Patients who ran out of medications may request an immediate appointment with their doctor. 
It is not always possible to find time for these patients if the doctor is fully booked. Requests 
for urgent appointments may interrupt doctors (and other patients) as they have to decrease the 
time available for the already booked appointments.    
“Cannot always fit extras in.” GP1 
“It saves having to squeeze patients in for let in appointments and making you run out behind 
schedule.” GP4 
Theme A.3: CD disadvantages  
Subtheme A.3.1: Lack of clinical review and/or diagnosis of new disease 
Delays in medical review as a result of CD supply were also reported (CD involves supply of 
a additional supply which may be enough for one month). This subtheme is illustrated below:  
“Lack of chance to undertake prevention care if pill patients not reviewed. It’s usually the time 
for a Pap smear and BP [blood pressure] check. 2. Similar for Statins, monitoring of levels, 
liver function + CK [Creatine kinase] gets delayed/ missed.” GP3 
“….Many people taking Statins have co-morbidities which make medical review with a script 
very important…..” GP5 
“Obviously, if a patient is not seeing a doctor that could be risks such as uncontrolled 
cholesterol levels and failure to do regular Pap smear. I have not encountered any problem 
personally.” GP4 
“Reviews is being missed…” GP3 




“…Delays in identification of new health problems (e.g. angina)…..” GP5 
 Subtheme A.3.2: CD may help patients to avoid the doctor’ visit  
Some patients may use CD to avoid visiting their doctors to decrease the cost. Pharmacists’ 
ability to detect such misuse was also cited. See the comments below: 
“I am not certain whether patients could use multiple pharmacies to get continuing supplies of 
medication without clinical review….” GP5 
“……Do pharmacists know if any pharmacy has dispensed? Not sure. Can the patient do this 
at several places?” GP3 
“If patients able to get enough for some time may not attend review appointments particularly 
if they have to pay Dr’ [doctor] bill.” GP1 
Subtheme A.3.3: Lack of patient history  
 Pharmacists’ ability to verify information obtained from non-regular customers and lack of 
awareness of other medication or appropriateness of the medication were seen 
as disadvantages of the current CD. (However, these concerns are addressed through the 
Pharmaceutical Society of Australia (PSA) guidelines and CD conditions. For example, the 
need to contact the regular pharmacy in case of non-regular customers, and not supplying 
patients who were prescribed the medication for less than 6 months are considered). The 
following comments explain this subtheme: 
“Pharmacists may have difficulties assessing the accuracy of information provided by patients 
(e.g. not for regular pharmacist and last dispensing pharmacy not contactable/ or GP not 
contactable)……” GP5  
“…Lack of awareness of polypharmacy. Lack of awareness of appropriateness of ongoing 
prescription.” GP5 
Subtheme A.3.4: CD does not reflect enough urgency through supply of non-
urgent medication such as Statins  
Statins were not seen as urgently needed medications. Patients who run out of Statins may stop 




The comments below illustrate this. 
“….. I do not think that supply of Statins is an urgent issue which could not wait for a doctor’s 
appointment….” GP5 
“Antihypertensives are more immediate than Statins.” GP2 
Theme A.4: Areas for improvement  
GPs thought CD could be improved through patients having to visit their doctor within a week 
of CD supply. They also recommended that the regular doctor must be informed. GPs also 
suggested the inclusion of more medications under CD. They also recommended limiting the 
CD supply to just enough until the next available appointment, to ensure patients must visit 
their doctor.  
The following subthemes emerged from GPs comments. 
Subtheme A.4.1: Patients must have GP follow-up post CD 
 This subtheme was reported twice by the same GP while answering two questions: 
“I have not encountered any problems with the continued dispensing so am not sure it will be 
improved, but I think generally the patient should attend the doctor within a week after 
dispensing of the script in order to make sure they are up to date with blood tests etc.” GP4 
“…….patient attends the doctor within the following week for a blood check.” GP4 
Subtheme A. 4.2: Informing the GP of medication supply is essential 
This subtheme is illustrated by the following comments: 
 “Better communication with dr’s [doctor’s] surgery as to what has been done.” GP2 
“Notify GP if given?” GP3 
It should be noted this is already among the CD requirements.  
Subtheme A.4.3: Include more medications  





“Antihypertensives (even 7 days as they can get appointment. Heart failure meds 
[medications]. Insulin. Not huge quantities – enough to get by.” GP1 
Additional notes 
Additional note 1: There is a need for CD 
A GP was aware of situations where patients may run out of their medication and unable to 
see their doctor. See the following comment:   
“…We often have patients who ran out of medications (e.g. antidepressants and 
antihypertensives who cannot get an appointment to get a script [prescription] at the time...” 
GP4 
Additional note 2: The regular pharmacist 
A GP had already recommended the use of the regular pharmacy to obtain additional supply 
in urgent situations. See the following comment:  
“… I often tell them if they have a regular pharmacist they can get the medication then book 
an appointment for the script [prescription] within the following week.” GP4 
Additional note 3: GPs interruption through Owing Prescription system. 
GPs may also be interrupted by pharmacists who call them to authorise supply for the 
Owing Prescription (OP) system. This usually occurs if patients who ran out of their 
medications requested a supply from pharmacists without a valid prescription. In this case, the 
pharmacists may phone the prescriber of the last prescription to obtain a verbal prescription 
that must be followed by a paper prescription. This is another source of interruption for GPs. 
See the comment below: 
“Not being rang for urgent scripts.” GP3 
Additional note 4: system abuse 





“[Dispensing] drugs of addiction…” GP2  
Additional note 5: Conflict of interest   
Pharmacists may have financial interest from the CD supply if they independently authorise 
the supply and dispensing of the medication.   
“Pharmacist becomes a prescriber and dispenser – a conflict of interest.” GP5 
6.4.2.2 Category B: Attitudes towards CD expansion 
These were generally positive with GPs supportive of expanding the medications available 
under CD. 
Theme B.1: CD can be expanded to include more important medications 
GPs thought CD may be expanded to include more urgently needed medications and/or 
medications that cannot be safely stopped. The examples provided were: antihypertensives, 
diabetes medications, antidepressants and heart failure drugs, however; they suggested supply 
of small quantities that were only enough until the next appointment with their doctor.  
“….. I believe it could be extended to antihypertensive with proves that the patient attends the 
doctor within the following week for a blood check.” GP4 
 “Anticonvulsants, medications for control of diabetes. The dispensing should only be for 
emergency short term supply, not for longer term management.” GP5  
“….. SSRIs [Selective Serotonin Reuptake Inhibitors] for short supply.” GP3  
6.4.2.3 Category C: Attitudes towards CD extension 
GPs thought current CD restriction regarding the frequency of CD use (once/ 12 months) is 
appropriate. Thus they disagreed with CD extension because of need for the medical review. 
The following theme emerged from their responses.   
Theme C.1: Patients required clinical review before prescription renewal  
The participants stressed the importance of clinical assessment before prescription renewal. 





“No, I think it works well.” GP2 
“No. Patients need review and doses perhaps need changing.” GP3 
“No- the idea of presenting to a GP for script is so that a medical assessment/ review is done 
to ensure treatment is appropriate and that tests and management of co-morbidities is 
arranged.” GP5 
Additionally, one GP mentioned that availability of CD frequency could be dependent on the 
amount supplied under CD: 
“If it’s only a small quantities twice a year.” GP1 
6.4.3 Interview with the GP 
One informal interview was undertaken with a GP during one of the primary investigator’s in-
person visits to GP surgeries. The GP invited the primary investigator to have a conversation 
about the study topic (i.e. CD). The GP stated that she was not aware of CD, and to her 
knowledge none of her patients had been supplied by this method. 
6.5 Discussion 
Although every reasonable effort was made to improve the response rate (see methods 
section), this study is disadvantaged by a very low number of respondents. To the best of our 
knowledge, this study was the first to explore GPs attitudes towards CD. As a method of 
medication supply, CD does not require a valid prescription. Whilst, the AMA has announced 
its opposition to CD,[16] it is not clear whether GPs in general have similar or different views 
about the CD. Results of this study showed that the participants have positive attitudes towards 
the CD. They were aware that some patients may urgently need medication supply without a 
valid prescription. They thought CD may prevent treatment interruption when patients were 
unable to obtain an urgent appointment with their doctor. This is in contrast with the claim that 
CD is a solution for a “problem that does not exist”.[16] In addition, the participants thought 
CD may benefit doctors through minimising urgent requests for appointments, and phone calls 
by pharmacists for prescriptions associated with OP supply. In a previous study, doctors 
expressed concerns about urgent requests for appointments that can lead to ‘squeezing’ of other 
appointment times.[6] 




review and in detection of newly emerging medical issues. This particularly applied if the 
patient was able to utilise CD from different pharmacies without visiting the GP. Therefore, 
they highlighted that the patient must see the doctor after CD supply, preferably within the 
next week.  
It is worth emphasising that according to the current model, patients are not allowed to use CD 
more than once in every 12 months. Therefore if a patient requested supply of a medication 
from their regular pharmacy more than once in that period, the pharmacist would refuse to 
supply based on their dispensing history. Moreover, applying the PSA recommendations 
regarding how to deal with non-regular customers should prevent CD abuse by patients. The 
PSA recommends that “When the consumer is not a regular customer of the pharmacy, the 
pharmacy that has dispensed the medicine most recently and regularly should be consulted for 
the most recent prescriber, an accurate dispensing history and to validate information obtained 
from the consumer.”[43] The latter addresses in part the concern expressed by GPs regarding 
pharmacists’ ability to accurately obtain a patient’s medical history. An incentive for 
pharmacists to ensure patients do not abuse the CD provisions is to avoid claims for 
reimbursement being declined by the Department of Human Services (DHS). “The DHS-
Medicare systems will reject payment for attempted CD supplies made within this 12-month 
period, provided past CD records are held by DHS-Medicare”.[44] 
There was concern by one respondent about conflict of interest that may result from the 
pharmacist being the prescriber and the dispenser. However, the potential for conflict of 
interest is less with CD than other forms of pharmacist prescribing. The PGA stated “ the issue 
of conflict of interest with the pharmacist being both the prescriber and dispenser is addressed 
by the proposed expansion of the existing continued dispensing provisions, rather 
than proposing full independent pharmacist prescribing.”[18]  
GPs thought that there are potential areas for CD improvement. The respondent GPs suggested 
more communication with the prescriber, and that the patient should be reviewed by their 
doctor within a week after CD supply as other ways to improve CD. It seems that if the last 
recommendation was added to the CD requirements, this would address the GPs’ and AMA’s 
major concerns related to the CD system. This may lead to more usage of the CD. For example, 
patients who need their medication and request an urgent appointment with their doctor may 
be instructed, by their doctors, to obtain their regular medications through CD then book 
an appointment within a week.  




may be improved through expanding to other medication classes such as antihypertensive 
medications, diabetic medications,  anticonvulsants  and antidepressants, such as SSRIs. This 
supports the calls of patients for CD to be expanded to include more medication classes.[35, 
45] However, the respondent GPs did not support CD extension to be used more than once in 
a 12 months period. This was in contrast to Statin and OC users who supported a more flexible 
CD system that can be used whenever it is not possible to see the doctor.[35]  
After the informal interview with the GP, the research team suspected that GPs may be 
unaware of the CD potentially due to low uptake of CD by pharmacists. This was confirmed 
by the available publications.[32, 33] Therefore to investigate the low uptake of CD by 
pharmacists the primary investigator conducted informal interviews with pharmacists working 
in three different community pharmacies in the Cannington area. Outcomes of these interviews 
are reported as personal communications below. (See Appendix 6.3 for more details) 
According to one pharmacist, the “optimistic idea of CD was not so practical”. (Personal 
communications). The very limited criteria of CD eligibility has been worsened by the fact 
that many users of Statins and OC (the only CD eligible medication classes) are not eligible to 
use CD unless they were on a concession status (i.e. have a reduced co-payment for 
medications). Moreover, OC users who request a supply with an expired prescription (after a 
year of issue date) “must see their doctor anyway after a year”. (Personal communications) 
Furthermore, the time-consuming nature and paperwork required for CD make other forms of 
urgent supply more appealing and convenient. The pharmacists reported not being faced with 
complaints from GPs about CD after they became aware that CD was a legal process. Whilst, 
all the pharmacists interviewed thought CD expansion is vital to increasing its usability. 
(Personal communications) 
As with any study, this study was not without its limitations. The crucial limitation was the 
low response rate, and the respondents were recruited from only one Australian state (Western 
Australia) which means the study results may not be generalised. We acknowledge that if the 
questionnaire was distributed to a larger sample this would have helped obtaining a richer data 
and probability different views. However, this was not practical due to study budget and time 
constrains. Further, those who did not participate may have had different views to study 
participants, and the fact that low levels of exposure to CD by GPs are likely to have influenced 
the respondents’ comments. In addition, in some cases convenience sampling was used, which 
has its own limitations as a sampling technique (however; this technique did not produce any 




strong positive bias towards pharmacy, however; the responses showed balanced views. In the 
study’s defence, low response rates are not uncommon in surveys involving healthcare 
professionals.[46]  
In regards to the informal interviews which were not recorded, these were of short duration 
and notes were made immediately after the interview, to minimise any memory bias.  
Future research may focus on the practical and financial aspects of adding new requirements 
to CD, such as making it essential to see the GP within a certain time interval after CD supply. 
In other words, how practical they would be to implement will be explored.   
6.6 Conclusions 
GP participants’ views about the CD where generally supportive. There were concerns about 
CD being used by patients to avoid doctors’ appointments and the fact that supply is 
undertaken without clinical review. However, the CD restriction which does not allow patients 
to use CD more than once in every 12 months in part addresses these concerns. They thought 
pharmacists, particularly the patient’s regular pharmacist is capable of providing treatment 
continuity, and that CD offered benefits to GPs in reducing requests for medication-related 
urgent appointments. They also thought that CD could be improved through patients seeing 
their doctor within a week after the CD supply for review. The interviewed pharmacists 
suggested the need for expansion of CD to a broader range of medication to make it more 
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7.1 Overview  
Each of the Chapters 3, 4, 5 and 6 contain their own discussion. Below is a general discussion 
which covers the overall results of this research project.   
7.2 Stakeholders’ attitudes towards the Current CD 
7.2.1 Patients’ attitudes  
This research project involved a telephone survey of Statin and/or OC users (See Chapter 3). 
They indicated strong support for being able to obtain one additional supply of their 
medications through CD when they are unable to see their doctor to obtain a new prescription. 
The majority of the respondents did not have any concerns about CD or thought CD  presented 
any undue risk.[1] This support is consistent with consumers’ health organisations, and public 
support for CD.[2-4] CD supporters put a high value on CD convenience for patients, who are 
unable to obtain a prescription. It also reflects the obvious need for CD.   
Fifty-seven percent of the participants selected ‘that access to pharmacists is easier than to 
doctors” as a reason why there were not concerned about CD, in addition to 55.5% of 
participants who selected ‘it (i.e. CD) saves my time.’[1] In contrast to the difficulty to obtain 
an urgent appointment with doctors, pharmacists are available without an appointment.[5] 
Interestingly, the participants of pharmacist postal survey and the participants in the GPs 
survey both agreed with the convenience of CD and acknowledged the difficulty that may be 
encountered in patients seeing their regular prescriber. As an indication of how patients value 
the convenience of community pharmacy, in the UK patients at risk of the flu paid for 
vaccination at pharmacies even though they were eligible for free vaccination at GPs surgeries 
because that was easier for them.[6] Similarly in Australia, “in many cases, consumers decided 
to have their vaccination [Queensland Pharmacist Immunization Pilot] in the pharmacy despite 
the fact they were eligible under the National Immunisation Program and could have returned 
to their doctor and received the vaccination for free.”[7] 
The majority of Statin and OC users did not see any risk from obtaining their medication 
through the CD. They trusted their pharmacist to supply when it is safe and refer to the doctor 
when it was deemed necessary.[1] Obtaining medication from the regular pharmacist was also 
supported from a participant in the GPs survey, who said “… I often tell them if they have a 
regular pharmacist they can get the medication then book an appointment for the script 




supported CD in the case of regular customers for a range of medication classes. This support 
indicated that they did not see any risk to supply chronic medications without a valid 
prescription.  
On the other hand, there were a few participants (patient survey) who did not support CD. 
Those who were concerned about pharmacists’ lack of access to health records, privacy issues 
and/or they thought CD was not safe without doctors’ supervision.[1] It is worth mentioning 
that some pharmacists in the pharmacist postal survey and the participant GPs were also 
concerned about the lack of access to basic health information such as blood test results. These 
findings are consistent with the previous studies about barriers to expanding pharmacists’ 
roles.[8, 9] The need for pharmacist access to patients’ health records was confirmed by the 
postal survey results where there were clear and significant differences between pharmacist 
practices with regular vs. non-regular customers. The participant pharmacists cited the lack of 
patient history as a reason for not supplying to non-regular customers. According to Services 
for  Australian Rural and Remote Allied Health (SARRAH) “The pharmacist needs to be able 
to access patient medical records via E-health.”[3]  
7.2.2 Pharmacists’ attitudes (Postal, Vignettes and Informal Interviews) 
Results of this project suggested that there were differences between pharmacists’ attitudes 
towards CD before (at the time of the postal survey) and after implementation (when the case 
vignettes and informal interviews were conducted).  
Pre-implementation, the participant pharmacists were highly supportive of the current CD 
model to supply Statins and OCs to regular customers and, to a lesser extent, non-regular 
customers. This may be explained by the mutual trust between the pharmacists and their 
regular customers,[1, 10-12] and pharmacists access to dispensing history of the regular 
customers.  
The pharmacists also specified that CD may alleviate difficulties with the current urgent supply 
methods. For example, the need to contact the prescriber and obtain a new prescription in case 
of OP supply and the insufficient amount available through ES. This supports previous calls 
to enhance the current urgent supply methods.[13, 14]   
While pharmacists saw CD as one step forward, they also identified some drawbacks of the 
current CD. These disadvantages may affect the uptake of CD by community pharmacists. 




they supported the inclusion of other medication classes in place of the currently eligible 
medications. They believed that other medication classes are more urgently needed than 
Statins. They also articulated some concerns about potential abuse of CD by patients who may 
use the CD to avoid doctors’ appointments.[11, 14] Further, they also expressed concerns about 
the lack of access to patients’ health records,[15] and about patients confusion regarding CD 
limitations. In the case of the latter, pharmacists may need to explain to patients why they able 
to obtain some of their medications without a prescription while they still need a prescription 
for other medications.[3] Moreover, pharmacists who participated in this study were concerned 
about doctors’ disapproval of CD. This may depend on how doctors see the CD, they may be 
concerned about shared patient responsibility that may result from CD.[16] They may also see 
it as a financial threat.[14]  
Another factor that may affect pharmacists’ acceptance and use of the CD is the other adopted 
methods of supply, particularly “in advance supply” and the “alternative method”. The “in 
advance supply” is a modified version of the OP system.[1] The standard OP system requires 
that the pharmacist must contact the original prescriber to obtain a verbal authorisation or 
faxed prescription to supply and a follow-up paper prescription that must be posted to the 
pharmacy within a week of supply. However, using “advanced supply”, the pharmacist would 
supply without contacting the GP and trust the patient to bring a prescription from the 
prescriber at a later date. It is more likely that this service is available for selected regular 
customers. For example, those who after several years of interaction with their doctor and their 
pharmacist, obtained the trust of the pharmacist and the ability to bring a new prescription 
from the prescriber. In this case, the “in advance supply” may be more convenient for the 
pharmacist than CD. A similar system of supply was reported by the UK pharmacists (i.e. Loan 
emergency supply).[11, 17] This system is widely used with regular customers. 
The “alternative method” is a two-step method to supply medication, to less trusted customers 
when the pharmacist thinks that the “in advance supply” is a risky practice because of the 
significant probability of not obtaining the anticipated prescription (a follow-up 
prescription).[18] The first step is supplying a limited quantity of the medication as per ES; 
the patient is charged as if it was a private supply. The second step involves supplying the 
remaining amount and refunding the patient who has returned with the follow-up prescription. 
Therefore, pharmacists will choose the most convenient method from five methods: ED, OP, 
“in advance supply”, “alternative model”, or CD. In this regard, it seems that the probability 
of using CD may be low in the following circumstances: (a) for the long-term regular 




was contactable at the time of the request for the OP supply, (c) customers who request other 
Statins/ or OC in addition to other CD ineligible medications (to avoid patient confusion),[19] 
(d) for patients who themselves are concerned about the CD, (e) to non-regular customers 
whom their regular prescriber or regular pharmacy are uncontactable,[19] and (f) for 
medication requests that are considered not urgent by the pharmacist (Statins ,in particular, 
were mentioned by the pharmacists and the GPs as being less urgent than other chronic 
medications). It is worth mentioning that the AMA also cited the absence of urgency of Statins 
when it announced its opposition to CD.[20]  
All of the above factors may contribute to the low uptake of the CD. This was confirmed by 
informal interviews with a small number of community pharmacists who mentioned that 
currently CD is available to a limited number of eligible patients in practice; principally those 
on concession status. They also said that CD is not an option in cases where the cost of the 
medication falls below the standard co-payment of $37.50, i.e. for non-concessional patients. 
Moreover, pharmacists who participated in the case vignettes study reported lack of experience 
and knowledge about the CD. They also expressed concerns about the amount of paperwork 
to conduct the CD, and in some cases even questioned the need for the CD, according to one 
participant, “I avoid it, too much paperwork, patient needs to go to Dr [doctor] eventually 
anyway.” The perception of lack of the need for CD is consistent with AMA claims that CD is 
a solution for a non-existing problem,[21] although this is not consistent with consumer 
sentiments captured through the patients survey.[1] 
Therefore, it can be concluded that while pharmacists initially welcomed CD prior to 
implementation, as did consumers, its uptake by pharmacists has been less enthusiastic. This 
was confirmed by reports of low CD uptake by community pharmacists. According to two 
reports CD was only used for 0.0016% of all medications supplied under PBS during 10 
months (from 1 September 2013 to 30 June 2014). [22, 23]   
7.2.3 General Practitioners’ Attitudes to CD 
Even though the GP survey had a very low response rate, participant GPs were not against CD. 
They acknowledged that there are situations where patients are unable to obtain appointments 
when they run out of medications. One GP reported that she usually advises patients to obtain 
a supply from their regular pharmacy then book an appointment. This supports a finding of a 
previous study by Garth et al.[24] where requests for same day appointments were seen as a 




suggested patients ask the chemist [pharmacist] for an ‘owing-script’ [Owing Prescription OP] 
and then make the next available appointment with the GP.” [24] However as mentioned by 
Garth et al.[24], this is in contrast with the AMA claim “The Bill [Continued Dispensing] is 
effectively fixing a problem that does not exist. GPs currently have arrangements in place to 
see patients who urgently need a consultation to renew prescriptions or get new 
prescriptions.”[21] In addition, the participant GPs reported some potential benefits from the 
CD, for example; CD would minimise the requests for urgent appointments and phone calls 
by pharmacists for the OP supply. This confirms the reported frustrations of GPs regarding 
unpaid efforts to write owing prescriptions and delays resulting from phone calls. [13, 25, 26] 
7.2.4 Summary of stakeholders’ attitudes  
Overall, based on the results of this research it can be concluded that generally the stakeholders 
supported the introduction of the current CD supply mechanism. This is in agreement with the 
key driver for the CD implementation, i.e. a convenient way to obtain medication when getting 
an appointment with the prescriber is not practical. However, all stakeholders who participated 
in this project emphasised the need to modify CD in order to achieve its goals. A discussion of 
these views is presented below. 
7.3 Stakeholders’ attitudes towards a modified version of the 
CD 
7.3.1 CD extension (Increased availability) 
Mixed views were expressed on CD extensions. Whilst the Statin and OC users reported the 
strongest support for CD extension (i.e. to be available more frequently), [27] the limited GPs 
who participated in this study generally disagreed with any change in CD utilisation frequency 
and supported the status quo (i.e. once in any 12 months period). These differences need to 
interpreted with caution given lower number (and hence representation) of GPs. More than 
half (51.1%) of the CD eligible users supported CD availability until it is possible to see the 
doctor.[27] This may reflect the difficulty of obtaining an urgent appointment with their 
doctors. It may also indicate the high frequency of running out of medications. This is 
confirmed by pharmacist postal survey results, where the participants reported facing urgent 
medication requests on a weekly, if not daily basis. However, only 4.4% of pharmacists 
supported CD availability until it is possible for the patient to obtain a renewed prescription. 
This may be because pharmacists were concerned about CD abuse by patients to avoid doctor 




safe and may affect the regular check-ups or could lead to patient abuse of the CD, to avoid 
appointments with their doctors. Continued use of CD was cited as a source of concern for 
GPs in a previous study which evaluated a theoretical model of CD ( i.e. Medication 
Maintenance).[14]  
The participant pharmacists were divided in their views about CD extension. Supporters of the 
current CD utilisation number cited the need for medical review and the potential abuse by 
patients to avoid the regular check-ups, which is consistent with GP views. On the other hand, 
pharmacists who supported more frequent utilisation of the CD model quoted the usual six 
months prescription lifespan allows the probability of running out twice a year. Therefore, it 
seems more appropriate and practical to allow pharmacists to decide on the number of CD 
utilisations on a case by case basis.   
7.3.2  CD expansion (Increased medication coverage) 
All stakeholders agreed on the need to increase CD eligible medications. This reflected the 
main disadvantage of the current CD. In addition to being restricted to only two medication 
classes, the many theoretically eligible customers were not eligible in practice, as explained 
by pharmacists. This finding is consistent with previous calls to expand the CD.[28] This is 
because of concerns about patients’ confusion if they requested both CD eligible and ineligible 
medications.[19] Therefore, patients,[27] pharmacist and GPs agreed with CD expansion to 
include more medications. 
Patients (Statin and OC users) supported, to varying degrees, the inclusion of all medications 
from a list of 14 medication classes presented to them (See Table 3.5). Nonetheless they were 
more supportive for medications without abuse potential.[27] The support to include 
medications with abuse potential was comparable in both patient and pharmacist surveys. 
While a GP was concerned that CD may be used to supply this type of medications, very few 
pharmacists supported the inclusion of these medications. It is worth noting that 48% of 
patients supported dispensing of anti-anxiety medications through the CD. This may reflect an 
awareness that this type of medication has legitimate uses and/or should not be stopped 
abruptly.[27]  
Pharmacists also supported CD expansion through agreement to include the majority of 
medications included in a list of 17 medication classes for regular customers (see Table 4.4). 
However, they supported a narrower range of medications in case of non-regular customers. 




medications for supply under CD than the Statins and OCs. Pharmacies are the most and 
easiest accessible point of healthcare to many patients with chronic disease(s). Patients see the 
pharmacist every time they need their regular medication. Previous studies highlighted the 
central role of pharmacists in chronic disease management. Pharmacists’ involvement 
enhances patient adherence and assists patients in achieving better treatment outcomes.[29-
31] Naik-Panvelkar et al.[32] studied Pharmacy Asthma Management Service, which is a 
“comprehensive patient-focused specialised model of asthma management in primary health 
care” in Australia. Even though that study was limited by recruiting patients who have utilised 
the service which may have biased the results, participants strongly supported the pharmacist 
role and reported increased awareness of their asthma and its medications. They also reported 
that the service had increased their asthma self-management ability. 
Comparing patients with pharmacist attitudes indicated that their support was comparable for 
some medications and different for others. For example, 75.4% of the patients and 73.8% of 
the pharmacists supported inclusion of arthritis medications while 48.2% of the patients and 
27.3% of the pharmacists supported the inclusion of anti-anxiety medications.[27] These 
results suggest that whilst patients were motivated by their need for convenient access to 
medications, pharmacists may be affected by concerns about overuse or abuse of such 
medications. This has been confirmed by pharmacists’ support for dispensing antidepressants 
through the CD method to regular customers, which was less than that of patients with 
depression. It is worth mentioning that this support by pharmacists was stronger than the 
support by patients without depression. This may be explained in part by their awareness of 
clinical advice to avoid premature discontinuation of antidepressants.[27, 33] This 
recommendation may also explain why some GPs suggested SSRI (used as antidepressants) 
could be included within the CD eligible medications. Hoti reported that patients may 
experience behavioural difficulties if they run out of their medication.[13]  
The participant GPs also supported inclusion of more medications that usually need an urgent 
supply such as antihypertensive and diabetic medications. This indicated that doctors are 
supportive of continuity of care for critical treatment, and they were also concerned about 
patient non-adherence to their chronic disease medications.[34]  
7.3.3 Disadvantages of other methods of medication supply      
Identifying drawbacks of the currently available methods of supply namely ES and OP 




pharmacists’ responses to suggested solutions to address the issue of urgent medication 
requests. In these responses, they suggested modifications to the ES and OP methods in 
addition to the repeat system. These modifications, in fact, reflected the disadvantages of these 
methods. The waste production and the very limited quantity of the ES, and difficulty to obtain 
follow-up prescriptions for the OP system were the most commonly reported disadvantages of 
the current urgent supply methods. The participant GPs reported phone calls to authorise OP 
supply as a source of interruption. The commonly reported disadvantages from this study have 
been previously described in the Australian literature.[13, 14] This indicates that these issues 
still need solutions. In this regard, the comments from the pharmacist postal survey suggested 
some areas in the current urgent supply systems that needed to be modified to address the issue 
of medication requests without a valid prescription. The amount of supply available through 
ES was deemed insufficient, and the pharmacists called to increase this amount to one month 
supply or at least until the next available appointment. A call for such a change has been 
reported previously.[13] For the OP system, there were calls for legalisation changes to allow 
the use of faxed or emailed prescriptions. In addition to more cooperation by doctors with the 
OP system, or allowing nurses to renew the prescription based on previous instructions by the 
GP. It is worth mentioning that doctors have shown their frustration with the OP system.[13, 
25, 35] Moreover, more trust in pharmacists through prescribing rights to legally prescribe, 
dependently or independently, when access to the original prescriber or a new prescription 
were impractical. Despite the similarity in basic pharmacy education curriculum between 
Australia and the UK, the Australian pharmacists have not been granted independent 
prescribing rights as have their counterparts in the UK.[36]  
7.4 Case vignette study – Appropriate use of CD 
The fourth aim of this project was to assess pharmacists’ ability to identify the cases where 
CD is not appropriate. To achieve this goal, a case vignette method was used. A group of 30 
pharmacists responded to case vignettes scenarios. In general, the majority of the participants 
identified the inappropriate situations. Surprisingly for one scenario involving a non-regular 
customer, 53.3% of the respondents did not identify that the CD was not appropriate without 
contacting the regular pharmacy (or pharmacy of last dispensing) in the case of non-regular 
customers. This was consistent with the pharmacist postal survey results where 51.4% of the 
respondents agreed to use CD to supply Statins to non-regular customers. It is worth 
mentioning that the PSA guidelines recommended contacting the regular pharmacy of the non-
regular customer to verify any information obtained from the customer.[37] Therefore, the fact 




regular customers may be explained by pharmacists wanting to supply medications through a 
less costly method. For this customer type, the OP is not possible (the original prescriber is 
uncontactable), the “in advance supply” poses a high risk of not obtaining a follow-up 
prescription,[1, 14] and the ES method is costly and it provides insufficient quantity,[13] (ES 
was the least preferred option to supply by case vignettes respondents). In these instances there 
is a higher probability of the pharmacist using the CD method, particularly, if the pharmacist 
is able to contact the regular pharmacy of the consumer. Other factors may affect pharmacists’ 
decision to supply to non-regular customers, such as the customer age and health status, and 
the ability of the consumer to provide sufficient information about their medical and 
medication histories.[38] Pharmacists should only supply if it is safe to do so, and they have 
the skills to identify those cases where a referral to a doctor is necessary.[1]   
Participants in the case vignettes study reported the circumstances where they thought CD is 
inappropriate. These included situations where there was a need for a medical review, if the 
patient was not stable on the medication or in case of recent hospitalisation. This is consistent 
with pharmacist and GP surveys, where participants cited similar concerns about the CD. The 
fear of system abuse by patients was mentioned in every survey in this project. It is worth 
mentioning that pharmacists reported ‘not supply’, as a usual practice when a second request 
for the medication without a prescription was made before any medical review. Additionally, 
the Department of Human Services Medicare systems may help to identify overuse of CD 
(more than once in any 12 months) through refusing of reimbursement claims by 
pharmacists.[19] Nevertheless, abuse of the system, to avoid doctor visits, requires a more 
comprehensive solution that involves both patient education,[39] and full implementation of 
electronic health record.[40]  
The case vignettes study also collected additional pharmacists’ views about the CD. These 
views were collected eight months after CD implementation. Therefore, they provide more 
updated insights about the CD than those of the pharmacist postal survey that was carried out 
before the actual implementation. The majority of case vignette participants who commented 
about their experience with CD said they did not use it, and/or were not aware of CD process 
“Have not done any continued dispensing- extra workload to contact prescriber- better 
alternatives available/ not unhappy with current alternatives” and “Do not quite understand the 
process”. It is worth emphasising that while these views may not represent those who did not 
comment on their experience with CD, it could be concluded that low awareness was not a 
barrier for the majority of pharmacists to identify when CD was appropriate and when it was 




training may be required for those who still do not understand the process. Participants also 
thought CD is an unnecessary method, and they preferred other alternatives. The amount of 
paperwork needed to conduct CD and its limitation may have influenced these views. This 
was reflected by participant’s answers about what would be their preferred course of action. 
On average, only 43.3% of the participants selected the CD method of medication supply as 
their preferred course of action even though CD was appropriate for Scenarios 1, 3 and 4. In 
the pharmacist postal survey, the average support to use CD was 88.5% (89.1 % for Statins 
and 87.8% for OCs). Therefore, the decline in CD support between the postal and the case 
vignettes surveys may be explained that the high expectations of CD before implementation 
had been negatively affected by CD requirements and/or its limitation and/or presence of other 
available supply methods. It has been reported that there has been a low uptake of the CD by 
the community pharmacists.[23] While emphasising that this low uptake may be simply a 
result of the low number of eligible cases to utilise the CD, it could be a result of pharmacists’ 
unwillingness to use the CD method, as a consequence of the reasons mentioned above.  
7.5 Overarching discussion 
Patients, GPs and pharmacists have justified CD implementation. Collectively, they believe 
that CD is a convenient way to obtain medications if urgently needed and no GP appointment 
is available or practical. The patients’ survey results confirmed previous literature findings 
that access to pharmacists is easier as no appointment is required to see a pharmacist in contrast 
to a doctor. Patients reported that they would stop taking their medication until they can see 
their doctor. In this regard, one GP, who was unable to provide an urgent appointment, has 
advised patients to obtain a supply from the regular pharmacist. The pharmacists reported that 
they frequently receive requests to supply without a valid prescription, mostly because it is 
impractical for patients to see the original prescriber. Patients, pharmacists and GPs thought 
CD will prevent treatment interruptions. Whilst pharmacists thought CD will minimise the 
administrative burden to obtain a follow-up prescription after they use ‘in-advance’ supply, 
doctors suggested that CD would remove the need to squeeze their schedule to allow for urgent 
appointments for prescription renewals or being interrupted by phone calls from pharmacists 
seeking OP supply authorisation.  
Participants expressed some concerns about the current CD scheme. Firstly, CD abuse by 
patients to avoid GP visits was the most frequently reported concern by all three stakeholder 
groups. However, the current CD system is only usable once in any 12 months period, which 




pharmacists’ inability to view patients’ medical records and lack of information about patients’ 
history. It seems that lack of patient history would result in more decision to not supply by 
pharmacists to non-regular customers. Thirdly, the current CD system does not include 
medications which require emergency supply and does not cover an appropriate range of 
medications. Pharmacists and GPs thought that Statins do not represent medications with 
urgent need. Those healthcare professionals and the patients thought the current CD is too 
restricted regarding its eligible medications. Finally, pharmacists completing the case vignettes 
study were concerned about CD paperwork and perceived CD as time consuming process. 
Based on these concerns, the stakeholders suggested a number of areas for improvement in the 
current CD.  
The most agreed area of improvement amongst participants was CD expansion to include other 
medication classes. Medications to treat hypertension, asthma, diabetes mellitus (oral 
hypoglycaemics), depression and other drugs were supported for inclusions by patients and 
pharmacists. GPs suggested antihypertensives, anticonvulsants and antidepressants. The other 
area of improvement was CD extension. While the majority of pharmacists and GPs did not 
support a more frequent use of CD rather than the currently allowable frequency of once a year 
(12 months), the patients demanded more frequent CD. It is worth emphasising that while 
patients’ motivation of this support was CD convenience, the healthcare professionals were 
concerned about CD abuse or need for medical review. In this regard, the GPs suggested a post 
CD visit to the prescriber to ensure patient safety. However, it seems that this visit may not 
be necessary because patients’ safety was a priority for pharmacists in both postal and 
case vignettes studies. Safety of the patient or the need for medical review were the most cited 
reasons for non-supply of medication by pharmacists in the case vignettes study.    
7.6  Limitations of this research project 
Limitations of each survey were included in the Discussion sections of Chapters 3, 4, 5 and 6.  
This project has the advantages of being first in this field, and it involved patients and 
pharmacists from across Australia, as well as GPs from Western Australia. It could have been 
strengthened by better response rates to both the pharmacist and GP surveys. However, 
common themes captured through triangulation of data from the four components of the 
research, suggest that it has been successful in identifying stakeholders’ views on the current 
CD system, and provides evidence for the need for its review and potential modification. 




Australian states (for case vignettes and GP surveys). However, similar attitudes are reasonable 
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Results of this project have shown a general support for the current CD model of medication 
supply by the majority of respondents from all the three groups of stakeholders. Patients, in 
particular, followed by the pharmacists supported the current and an expanded versions of the 
CD. We could not reject research hypotheses (H1 and H2) which stated that patients’ concern 
regarding CD are affected by their perception of risk and disease sufferers will be more 
supportive of the inclusion of their medication, respectively. We also could not reject research 
hypotheses (H3, H5 and H6) because we found significance difference between pharmacists’ 
decisions to supply according to customer type (H3), and their support for the use of CD 
according customer type (H5) and pharmacists’ support to include more medication according 
to their demographic variables (H6). However, we could reject hypothesis (H4) which stated 
that pharmacists’ reported practice will not be associated with their demographic variables. 
The participating GPs reported the need for CD when an appointment with the GP is not 
practical. This rejects hypothesis (H8), which stated that GPs will not support CD based on 
the argument raised by the AMA. However, this should be perceived with caution due to the 
very low response rate. All stakeholders agreed that CD has some benefits for patients, 
pharmacists and doctors. The main advantages seen for CD were: it is a convenience method 
to obtain medications when an appointment with a doctor is not feasible, it removes the 
administrative burden to obtain a prescription, and it decreases the demand for urgent 
appointments.   
Based on the results of case vignette study it appeared that pharmacists generally conducted 
CD in accordance with the PSA guidelines. Importantly, they did not use CD method if there 
was a need for a medical review. Pharmacists decisions to use CD were not associated with 
their demographic information (age, gender, years of practice). Thus, hypothesis (H7), which 
stated that these decisions will differ according to pharmacists' demographic variables, could 
not be rejected. Nevertheless, this could have resulted from sample size (30 pharmacists). 
All stakeholders supported CD expansion to include more medications. Among pharmacists 
and patients there was general agreement to support most of the medications suggested by 
the research team with the exception of medications with abuse potential such as opioids. GPs 
also suggested the addition medications that were more urgently need or cannot be abruptly 
stopped such as antihypertensive and antidepressants.   




less supported by pharmacists, and it was not supported by GPs. Based on the reasons cited to 
support/ oppose CD extension, it seems that CD frequency would be more practical if it was 
left to pharmacists’ discretion. 
Pharmacists had different practices of urgent supply according to customer, medication and 
prescription type. While pharmacists reported facing requests for urgent supply on a daily basis 
from regular and non-regular customers, they were partial to supplying medications to their 
regular customers. They also reported that they would be less likely to use CD in the case of 
non-regular compared to regular customers. It is worth mentioning that patients who did not 
have a regular pharmacy reported running out of their medications more frequently than those 
who had a regular pharmacy. Therefore, it seems CD may not be used to supply medication to 
those without a regular pharmacy as much as those with a regular pharmacy. This is a 
significant issue, bearing in mind that interstate travel without medication was among the most 
reported reasons for requests for urgent supply medication.   
The results of this research suggest that the current CD is not a practical method. It does not 
have enough eligible medications and is restricted in its utility, and it is more complex to 
undertake compared with other alternative methods for urgent supply. Therefore, whilst CD is 
safe as long as safeguarded guidelines and medical reviews were maintained, the current CD 
needs to be amended in order to achieve its main goal of allowing medication continuity when 
a new prescription/appointment are unavailable.  
Better communication between doctors, doctors and patients, and doctors and pharmacist were 
all suggested as means of enhancing patients’ adherence to their medications. As an example, 
pharmacists were highly supportive of ‘prescriber annotation’ of prescriptions which would 
allow them to exclude unsuitable patients from CD. Therefore, results of this project indicate 
that many pharmacists support CD as a means to improve access to medications and ensure a 
safe continuation of the treatment when patients are unable to obtain an appointment with their 
doctor. Result also confirm that  pharmacists are aware that not all patients are suitable for the 
CD, and they support better communications with doctors to exclude those patients.  
At the same time, the results of this project suggest that not all pharmacists share the same 
enthusiasm for CD and this may influence the uptake of CD by the pharmacists. In particular, 
those who felt that they are already providing services for which they are not appropriately 
remunerated or who did not see a need for CD. Pharmacists who were satisfied with other 
methods of medication supply were less likely to use it, particularly those who do not see the 




CD. Pharmacists who do not see an urgency for Statin requests may not use it. Pharmacists 
concerned about patients’ confusion of CD may use alternatives to supply Statins and OCs, 
specifically when the patient requests another medication with their Statin or OC.  
While findings of this research may be limited by low response rates in the pharmacist and (in 
particular) GP surveys, it did achieve its aims. The research explored patients’ and pharmacists’ 
attitudes on the CD pre-implementation, and then it explored pharmacists’ and GPs’ attitudes 
post-implementation. In doing so, this research project has identified a change in pharmacists’ 
attitudes as a result CD introduction. The research also has identified issues with current CD 
that need to be addressed in order to make CD a rationale solution to improve urgent access to 
medication.  
This research project has also identified some disadvantages of and improvement areas for 
other currently available methods to supply, namely OP, ES and the repeat system. The issues 
with OP system were stopping patients’ abuse of this system, through applying dispensing 
fees, and allowing the use faxed or emailed prescriptions. The amount of supply with ES 
system is not enough even to allow patients time to see their doctor where the demand for 
appointments is higher than the available service. Hence, there were calls by the pharmacists 
to increase this quantity to be enough for at least one week. Regarding the repeat system, the 
pharmacists have called for non-medical control of the repeat system through allowing nurse 
practitioners to write repeat prescriptions. There were also suggestions to prolong the lifespan 
of the prescription and increase the number of repeats. 
While pharmacists are waiting for changes in the currently available systems, some are using 
an alternative way to satisfy their customers without breaking the law (See Section 4.3.3.6). 
In this alternative method the customer is provided with the minimum applicable quantity of 
the medication and required to pay the full cost (i.e. ES) and then when the customer presents 
a new valid prescription they are provided with the remaining quantity and either pay or are 
refunded any difference between ES and PBS co-payments (i.e. OP).   
As a main conclusion of this project, whilst CD is seen, by stakeholders, as a forward step for 
more convenient urgent access to medications, it has several areas that could be improved. 





8.2 Recommendations  
Based on the findings of this research the following recommendations are made: 
Recommendation 1: Current CD requires a revision 
(See sections: 3.7.9.1, 3.7.9.2, 4.5.4.4, 4.5.4.6, 5.5 and 6.4.2.2) 
Findings from this project suggest that a revision of the current CD model is required to 
enhance its uptake. This revision would need to include eligible medications under CD, 
frequency of CD use, greater pharmacist autonomy, improved communication between 
pharmacists and GPs, and reduced administrative burden. 
Recommendation 2: CD should contain more eligible medications 
(See sections: 3.7.9.1, 3.7.9.2, 4.5.4.4, 4.5.4.6, 5.5 and 6.4.2.2) 
The most appealing modification to the current CD model is the addition of more eligible 
medications. The majority of stakeholders who participated in this project supported CD 
expansion. The high level of stakeholder support for certain chronic medications requires a 
critical review aimed at improving access to these medications. Expansion of CD may be 
achieved by providing regular pharmacists with greater flexibility to continue a broader range 
of medication, whilst referring patients for a medical review when it is deemed necessary based 
on their clinical status. As such, the CD list of eligible medications needs to reflect patients’ 
needs, whilst enabling patients to utilise CD for all their medications, except for a limited few. 
This would minimise pharmacist avoidance of CD for patients who run out of multiple 
medications. Which medications may be included requires further research, however the 
medications supported by this project’s participants may be used as a starting point.    
Recommendation 3: Pharmacists should be given control over the CD utilisation 
frequency  
(See section: 4.5.4.7 ) 
The CD restriction of one supply in any 12 month period is another area for potential 
modification. According to different and mixed opinions collected from stakeholders in this 
study, it seems that one additional supply after the completion of each set of repeats may be 
more suitable. In this case, patients who have five repeats would potentially be able to use CD 
twice a year and patients with 11 repeats would have only one potential CD provision per a 
year. However, this should be used as a guide and pharmacists should be allowed to use/ refuse 




Recommendation 4: The original prescriber should be able to exclude unsuitable patients  
(See section: 4.5.4.9 ) 
It is also suggested that provision be made to allow doctors to exclude patients for whom they 
believe CD is not clinically appropriate. This could be achieved through adding an additional 
checkbox on the prescription to notify the pharmacist that the patient is “Not Eligible” for CD 
on clinical grounds.  
Recommendation 5: Post CD supply visit to the GP 
(See section: 6.4.2.1 ) 
Another amendment, suggested by the participating GPs, was CD utilisers must see their 
doctor within a week of CD supply. This suggestion would allow continuation of treatment 
and would ensure a convenient medical review. It is also an appropriate recommendation for 
patients who had five or more repeats as they are likely not to have visited their doctor for six 
months or more. It is worth mentioning that a visit within one week post CD supply may be 
not practical because of long waiting times as reported in pharmacists’ postal survey.  
Recommendation 6: Current CD requires more clarifications  
(See sections: 4.4.3.1, 4.4.3.2, 4.5.4.7, 5.4.5 and 6.4.2 ) 
Other areas that need improvement are the potential ‘grey’ areas of current CD model. For 
example, CD may only be used when there is an “urgent” need for the medication, and it is 
“impractical” to obtain a prescription. The possible differences between the pharmacist’s 
estimation of what is “urgent” and what is “impractical” need clarification in the guidelines. 
Some pharmacist and GP participants did not think Statins require urgent supply. Moreover, 
in the postal survey, pharmacists reported reasons why patients requested medication supply 
without a valid prescription. There were reasons that needed to be clarified as to whether they 
fitted within “impractical” or not. For example, if the patient is busy at work or has a financial 
reason. Another example if the patient refused to see another doctor to obtain a prescription 
because they prefer to visit their regular doctor. In this case, while it is impractical to obtain a 
prescription from the original doctor, the prescription could be obtained from another medical 
practitioner. In other words, there are situations where patients may make requests based 
on their preference (not to visit the GP to get a new prescription) rather than it being 
impractical to do so. It is worth stating, as previously mentioned in the literature review 




Recommendation 7: Pharmacists should be remunerated for the service  
(See section: 4.5.4.3 ) 
Pharmacist remuneration for CD should be considered. CD is reported to take more time and 
effort than the normal dispensing of original and repeat prescriptions. This is due to the fact 
that in evaluating the appropriateness of CD the pharmacist is required to undertake a 
comprehensive medication review. Therefore, pharmacists should be remunerated for their 
time whether they decide to use CD or refer to a GP. This would remove any conflict of interest 
that may be associated with CD supply. Moreover, pharmacist’s remuneration may be justified 
by the potential role of CD in minimising unnecessary visits to GPs, emergency departments, 
or after-hours clinics.   
Recommendation 8: Better use of community pharmacists’ skills 
(See section: 4.5.4.10 ) 
As indicated by results of this project, pharmacists are the first option for patients to obtain 
medications when they run out and are unable to see their doctor. The pharmacist is being 
trusted by patients and doctors to continue medication supply in urgent cases. Thus, better use 
of the pharmacists may allow avoidance of unnecessary visits to doctors or the use of other 
health services. In this regard, pharmacists may be able to identify the urgency of the medical 
review after CD supply.  
Recommendation 9: Better use of Technology  
(See section: 4.5.4.10 ) 
Additional use of information and communication technology (ICT) may help improve timely 
access to medication for all patients regardless of whether they are regular or not regular 
customers of the pharmacy. For example, email technology through smart mobile phones 
would make communication between pharmacists and doctors easier and less interruptive 
process. Although not all GPs and pharmacists would be interested in this service, it would 
make the communication possible even after-hours or if the doctor was away. Communication 
through the internet would allow pharmacists to access medical records and update the records. 
The technology of SMS (Short Message Service) from dispensing computers may be used to 
remind patients to book an appointment to renew their medication (This service is currently 
used by some pharmacies in Australia). Full implementation of electronic transfer of 
prescriptions is another field where use of technology could improve urgent access to 




pharmacist contacts the original prescriber about a patient requesting a medication without a 
valid prescription, the prescriber needs to write a prescription, and then send it by mail. 
However in case of secure electronic transfer of prescriptions, the prescription would be 
instantly available. This would enable the pharmacist to supply and claim reimbursement from 
the PBS without the frustration of the current OP system. Optimum utilisation of the electronic 
health record would address various stakeholder concerns about information availability to 
pharmacists. 
Recommendation10: Pharmacist training  
(See section: 5.5 ) 
Currently, pharmacists are not required to undergo training to conduct CD. However, in light 
of the results of the case vignette study, it does appear that some pharmacists may require 
training in the provisions and the mechanics of the current CD system.  
8.3 Recommendations for future research 
There is a need to assess whether, in fact, CD has impacted on medication adherence and 
persistence, unplanned hospital admission due to discontinuation of therapy, requests for 
urgent appointments and number of visits to emergency departments ( just to obtain a 
prescription for the ongoing medications). CD’s impact on access to medication in remote and 
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Appendix 6.3 Pharmacists’ perceptions of CD based on informal 
interviews  
After the informal interview with the GP, the research team suspected that GPs may be 
unaware of the CD potentially due to low uptake of CD by pharmacists.[1, 2] Therefore to 
investigate this the primary investigator conducted informal interviews with three pharmacists 
working in three different community pharmacies in Cannington area. 
Pharmacist 1 was aware of CD and some of his oral contraceptives customers used it. He 
provided a number of reasons why there was low utilisation of the CD. Firstly, there is a more 
convenient way to deal with customers seeking medications without a valid prescription, 
namely supplying a small quantity of OC enough for three days or nearest appointment with 
the GP (i.e. ES), then when the customer brings a new prescription they take the rest of the 
pack and obtain a refund (In this model, the patient will obtain one additional repeat without 
out of pocket expense and the pharmacist will avoid the time-consuming CD). However, this 
model may not be used in the case of non-regular customers such as interstate visitors. 
Secondly, OC prescriptions expire one year after the date of issue, which means it is time to 
see the GP before starting a new course. The pharmacist also said if CD was expanded to more 
medication classes then it would be more practical and usable. Asked if GPs ever complained 
about CD, the pharmacist said they had never experienced that.   
Pharmacist 2 was aware of CD, but never used it. The pharmacist thought it required too much 
paper work, and there are other easier alternatives. The pharmacist felt that if CD was 
expanded it would be more practical. The pharmacist was unaware if GPs ever complained 
about CD. 
Pharmacist 3 provided the most comprehensive review of CD. The pharmacist said CD is good 
in theory but not in practice, because most Statin users usually use generic Statins. The 
pharmacist mentioned that these generic Statins are cheaper than the usual co-payment for a 
consumer who is not on a concession (i.e. $37.70). The pharmacist also added for OC users 
they must be a concession card holder to be supplied using the CD method; otherwise CD is 
not practical for them and costs more. The pharmacist said if the customer was a regular 
customer, she usually used the OP method, if not and the patient was CD eligible then she may 
use the CD method. The pharmacist said only a few  Statin and OC medications users are 
aware i.e.: “We need to tell them that they are eligible”. The pharmacist said she used CD less 




before they were aware that it was a legal method of supply. She expressed her opinion that 
CD needs to be expanded to include more medications to be usable but now it restricted to two 
types of medications and in practice only a small number of patients may benefit from the CD 
method.  
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